

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Multicenter randomized comparative trial of balloon pulmonary angioplasty and riociguat in patients with chronic thromboembolic pulmonary hypertension: Rationale and design of the MR BPA study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028831
Article Type:	Protocol
Date Submitted by the Author:	26-Dec-2018
Complete List of Authors:	Kawakami, Takashi; Keio University, School of Medicine, Cardiology Matsubara, Hiromi; Okayama Medical Center Kataoka, Masaharu ; Keio University, School of Medicine Abe, Kohtaro; Kyushu University Kohsaka, Shun; Keio University, School of Medicine Sato, Yasunori ; Department of Preventive Medicine and Public Health, Keio University School of Medicine, Shinke, Toshiro; Showa University Fukuda, Keiichi; Keio University, School of Medicine
Keywords:	chronic thromboembolic pulmonary hypertension, balloon pulmonary angioplasty, riociguat

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 Multicenter randomized comparative trial of balloon pulmonary angioplasty and riociguat in
4 patients with chronic thromboembolic pulmonary hypertension: Rationale and design of the
5
6 MR BPA study
7
8
9

10
11
12
13
14 **Authors:**
15

16
17 Takashi Kawakami^{1*}, Hiromi Matsubara^{2*}, Masaharu Kataoka¹, Kohtaro Abe³, Shun
18
19 Kohsaka¹, Yasunori Sato⁴, Toshiro Shinke⁵, Keiichi Fukuda¹
20
21

22
23 * TK and HM equally contributed in this study.
24
25
26
27

28
29 **Affiliation:**
30
31

32 ¹ Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi,
33
34 Shinjuku-ku, Tokyo, 160-8582, Japan
35
36

37 ² Department of Cardiology, Okayama Medical Center, 1711-1, Tamasu, Kita-ku, Okayama,
38
39 Okayama, 701-1192, Japan
40
41

42 ³ Department of Cardiovascular Medicine, Kyushu University, 3-1-1 Maidashi, Higashi-ku,
43
44 Fukuoka 812-8582, Japan
45
46
47

48 ⁴ Department of Preventive Medicine and Public Health, Keio University School of
49
50 Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
51
52

53 ⁵ Division of Cardiovascular Medicine, Department of Internal Medicine, Showa University
54
55 School of Medicine, 1-5-8 Hatanaodai, Shinagawa-ku, Tokyo, 142-8666 Japan
56
57
58
59
60

1
2
3 **Corresponding author:**
4

5
6 Takashi Kawakami, MD
7

8
9 Department of Cardiology, Keio University School of Medicine, Tokyo, Japan
10

11
12 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
13

14
15
16 Tel: + 81-3-5843-6702, Fax: + 81-3-5363-3875
17

18
19 E-mail: kawakami.1650@gmail.com
20
21
22
23
24

25 **Acknowledgements:** The study was funded by Bayer Yakuhin Ltd.
26
27
28
29
30

31 **Keywords:** Chronic thromboembolic pulmonary hypertension, balloon pulmonary
32
33 angioplasty, riociguat
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction: The management of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) remains a clinical challenge. Medical treatment mainly involving pulmonary vasodilators (e.g. a soluble guanylate cyclase stimulator) is recommended for ameliorating their symptoms. More recently, balloon pulmonary angioplasty (BPA) has developed as alternative treatment modality for inoperable CTEPH. We aim to compare the efficacy and safety of BPA and riociguat, for the treatment of inoperable CTEPH.

Methods and Analysis: The study was designed as a multicenter randomized controlled trial for treatment of inoperable CTEPH. Subjects with inoperable CTEPH will be randomized (1:1) into either BPA or riociguat group, and observed for 12 months after treatment. The primary endpoint will be change in the mean pulmonary arterial pressure from baseline to 12 months. For the primary analysis, the least square mean difference in the change of pulmonary arterial pressure between BPA and riociguat group at 12 months and its 95% confidential interval will be estimated using an analysis of covariance (ANCOVA) model adjusted for allocation factors.

Ethics and Dissemination: This study was approved by the institutional review board of Keio University School of Medicine and each participating institution. Written informed consent will be obtained from all participants. Results of the study will be disseminated at medical conferences and journal publications.

Registration: This study was registered at the University Hospital Medical Information Network Clinical Trial Registry (UMIN-CTR) (UMIN000019549).

Strengths and Limitations of the Study:

- This is the first randomized controlled trial to compare the efficacy and safety of BPA and riociguat in patients with inoperable CTEPH.
- This study evaluates the efficacy and safety of BPA and riociguat at 12 months after the start of the treatment, which is a relatively longer observation period than the usual RCTs.
- This is also the first study to compare the health insurance resource costs between BPA and riociguat.
- This study will be conducted at the expert BPA centers in Japan, and the CTEPH operability will be assessed by experienced PEA surgeon under blind circumstance.
- The limitation of this study is that this is open-label trial, and is expected to recruit a relatively small number of study subjects.

Introduction

Chronic thromboembolic pulmonary hypertension (CTEPH) is an intractable disease in which an organized thrombus causes stenosis or occlusion of the pulmonary artery¹. Unless early diagnosis and appropriate treatment are performed, which causes death due to right-sided heart failure². Pulmonary endarterectomy (PEA) has been established as a method for operable CTEPH³. According to the AHA/ACC and ESC guidelines, PEA is recommended for patients with operable CTEPH as the first line therapy in class of recommendation I and level of evidence C⁴⁻⁵. However, riociguat as soluble guanylate cyclase stimulator is recommended for subjects with inoperable CTEPH⁶⁻⁷, and is the first and only an approved medical treatment for inoperable CTEPH.

In 2014, a soluble guanylate cyclase stimulator (general name: riociguat), which is one of the pulmonary hypertension treatment agents, received insurance reimbursement approval for inoperable or persistent/recurrent CTEPH for the first time. This was based on the findings of a multicenter randomized clinical trial (CHEST-1)⁶ and its extension study (CHEST-2)⁷ indicating the efficacy of riociguat for subjects with inoperable CTEPH. Balloon pulmonary angioplasty (BPA), as catheter-based treatment, has also been reported to be effective for subjects with inoperable CTEPH⁸⁻²⁰.

As described above, the two main treatment options for inoperable CTEPH consist of riociguat or BPA. Although BPA is associated with a certain level of risk of complications such as procedure related pulmonary artery injury, it can provide marked improvement when the treatment finished. On the other hand, riociguat is the most effective pulmonary vasodilator and have low risk of serious adverse events. However, no reports have yet compared the treatment outcomes of these two treatment methods⁸. The present study was planned to compare the efficacy and safety of riociguat with BPA in the treatment of

1
2
3 inoperable CTEPH over the course of 12 months, to potentially aid in optimizing treatment
4 selection and improving treatment outcomes.
5
6
7
8
9

10 **Methods and Analysis**

11
12 **Study Design:** The Multicenter Randomized controlled trial based on Balloon Pulmonary
13 Angioplasty for chronic thromboembolic pulmonary hypertension (MR BPA) study will
14 enroll subjects from January 15, 2016 to October, 31, 2019. The study is designed as a
15 multicenter, prospective, randomized controlled trial. As shown in Figure 1, after acquiring
16 consent, the subjects will undergo right heart catheterization and pulmonary angiography
17 before provisional enrollment. An independent experienced PEA surgeon will determine if
18 these subjects are eligible to undergo PEA under blind circumstance. Those who are judged
19 to have inoperable CTEPH will be assigned into either BPA or riociguat group via an online
20 assignment system and observed for 12 months. The observations will be made at screening,
21 baseline, 0-4 months, 6 months, and 12 months. Table 1 shows the schedule of assessments
22 performed at each visit for each treatment group, including mandatory and optional
23 assessments.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 **Sample size calculation:** Previously, BPA resulted in a reduction in mean pulmonary arterial
44 pressure from 45.4 ± 9.6 to 24.0 ± 6.4 mm Hg in 24 months⁹, while riociguat decreased the
45 pulmonary arterial pressure by 4 ± 7 mm Hg⁷. Based on these studies, the change in mean
46 pulmonary arterial pressure from the start of treatment to 12 months later was assumed to be
47 -15 mmHg for the BPA group and -4 mmHg for the riociguat group, and the standard
48 deviation for each change was assumed to be 14 for the BPA group and 10 for the riociguat
49 group. The minimum sample size required to achieve a significance of 0.05 for a two-sided
50 test with a statistical power of 90% was determined to be 27 subjects for both groups,
51
52
53
54
55
56
57
58
59
60

1
2
3 indicating a total of 54 subjects. With the dropout rate estimated to be 10%, the planned
4
5 enrollment was set at 30 subjects for each group, for a total of 60 subjects.
6
7
8
9

10
11 **Eligibility criteria:** *Inclusion criteria:* Patients meeting the following criteria will be
12
13 included in the study: (a) patients who are diagnosed with CTEPH (based on the diagnostic
14
15 criteria in the 2012 Japanese Circulation Society guidelines²¹ with a WHO functional class II
16
17 or III). (b) male and female aged ≥ 20 years and < 80 years. (c) patients with mean pulmonary
18
19 arterial pressure of ≥ 25 mmHg to < 60 mmHg and pulmonary artery wedge pressure of ≤ 15
20
21 mmHg. (d) patients who undergo appropriate anticoagulant therapy for at least three months
22
23 prior to consent acquisition (if warfarin is used, prothrombin time-international normalized
24
25 ratio should be 1.5 to 3.0). (e) patients who provide written consent form to participate in this
26
27 study after full explanation of the study.
28
29
30

31
32 *Exclusion criteria:* Patients meeting any of the following exclusion criteria will be excluded
33
34 from the trial: (a) patients with a history of BPA. (b) patients who underwent PEA within six
35
36 months prior to consent acquisition. (c) patients who are using unapproved pharmaceutical
37
38 products. (d) patients who used a pulmonary vasodilator within four weeks prior to the right
39
40 heart catheterization after consent acquisition. (e) patients with co-existing etiology of
41
42 pulmonary hypertension other than Group 4 in the Nice Pulmonary Hypertension
43
44 Classification System. (f) patients who are pregnant or breastfeeding. (g) patients who met
45
46 the contraindication for riociguat. (h) patients whose life expectancy is less than two years. (i)
47
48 patients who are considered to be unsuitable for participation by investigators.
49
50
51

52 53 54 55 **Recruitment and consent:**

56
57 When subjects are determined to be able to participate in this study, the informed consent
58
59 document is used to give them a sufficient explanation of this study and their written consent
60

1
2
3 is then obtained. When obtaining consent, it is also explained that data related to pulmonary
4 angiography, right heart catheterization, and chest computed tomography (CT) scan from
5
6 within three months prior to acquiring consent, as well as pulmonary ventilation-perfusion
7
8 scintigraphy prior to acquiring consent, may be used for research purposes.
9
10

11
12 As a general rule, right heart catheterization and pulmonary angiography are performed after
13
14 acquiring consent and investigators determine whether each subject can be definitively
15
16 diagnosed with CTEPH. However, to reduce the burden on the subjects, data from within
17
18 three months prior to consent acquisition for pulmonary angiography, right heart
19
20 catheterization, and CT scan, as well as pulmonary ventilation-perfusion scintigraphy
21
22 obtained in general practice prior to consent acquisition, can also be utilized.
23
24

25
26 Based on the imaging data of the subjects who give their consent, an independent
27
28 experienced PEA surgeon who is not involved in this study will determine operability
29
30 (whether the subjects are eligible to undergo PEA). The standards for this determination of
31
32 operability will be based on the Guidelines for Treatment of Pulmonary Hypertension (2012
33
34 revised version)²¹ and will be anatomically performed.
35
36
37
38
39

40 **Random allocation:** Random assignment will be performed centrally with stratification by
41
42 mean pulmonary arterial pressure (<40 mmHg and \geq 40 mmHg), and research institutions
43
44 (Keio University, Okayama Medical Center, Kyusyu University, and Kobe University) by the
45
46 minimization method with biased coin assignment.
47
48
49
50
51

52 **Endpoints:** Primary endpoint will be the change in mean pulmonary arterial pressure from
53
54 baseline to 12 months. Secondary endpoints will include several clinical and quality of life
55
56 parameters. These are detailed in Table 2.
57
58
59
60

1
2
3 **Data collection:** An electronic clinical testing data collection system, electric data capture
4 system (EDC), will be used for data collection. In cases when the system is unavailable, a
5 case report form, a specialized data collection form, will be used and the data later entered
6 into the EDC. The investigators who will enter information into the EDC system will be
7 responsible for ensuring accuracy and completeness of the information.
8
9

10
11
12
13
14
15
16
17 **Data management and monitoring:** The processes of data collection and management will
18 be performed by third-party entities for data without bias. Data management in this study will
19 be performed by Soiken Inc., Data Management Group (the Data Center). Data Center will
20 prepare a “Procedure Manual for Data Management.” The Data Center’s approval is required
21 prior to sending data related to the subjects in an electronic format. If transmitting data over
22 an unsecured electronic network, the data must be encoded at the source. Linkable
23 anonymization with central registration number will be used to identify the subjects. The
24 investigators will be responsible for appropriately storing the correspondence table prepared
25 by them to identify subjects in accordance with the procedures at the research institution.
26 This correspondence table must be retained for up to five years after the completion of the
27 study or three years after the final publication of the study, whichever comes later. For
28 displaying and publicly disclosing all information related to the study, appropriate measures
29 will be taken, such as encoding or deletion, to ensure that the subjects cannot be identified in
30 accordance with applicable laws and regulations.
31
32

33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49 In this study, the Soiken Inc., Data Management Group will perform monitoring to manage and
50 ensure quality. The monitoring manager will monitor the subjects in accordance with the manual on
51 the monitoring procedure. For data quality management, the principal investigator and Central
52 Committee will confirm the progress of the study, as necessary, through the Soiken Inc., Data
53 Management Group to ensure that the study is being conducted in accordance with the protocol and
54 the Ethical Guidelines for Medical and Health Research Involving Human Subjects (Dec. 22, 2014;
55
56
57
58
59
60

1
2
3 Ministry of Education, Culture, Sports, Science and Technology/Ministry of Health, Labour and
4
5 Welfare).

6
7
8
9
10 **Adverse events:** Occurrence of any untoward medical events experienced by subjects,
11 including the worsening of a pre-existing underlying disease or a complication, will be
12 defined as adverse events. However, the worsening of efficacy evaluation indices will not be
13 defined as an adverse event. Any concomitant symptoms or clinically significant abnormal
14 fluctuations in test results will be investigated to determine whether there is a cause-and-
15 effect relationship with BPA or riociguat and findings will be documented in the EDC
16 system. As a general rule, adverse events will be followed up until normalization or recovery
17 occurs to a level at which it is not considered to be an adverse event or in case of an
18 irreversible adverse event (cerebral infarction, myocardial infarction etc.), until symptoms
19 stabilize or no longer change.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 **Statistical Analysis:**

37
38 The analyses of the primary and secondary efficacy endpoints will be performed using the
39 full analysis set, which will include all patients who underwent randomization and received at
40 least one dose of a study drug and had at least one assessment after baseline. Safety analysis
41 will be conducted in the safety analysis population.
42
43
44
45
46

47 For the baseline variables, summary statistics will be constructed using frequencies and
48 proportions for categorical data, and means and standard deviations for continuous variables.
49 Patient characteristics will be compared using Pearson's chi-square test or Fisher's exact test
50 for categorical endpoints, and Student's t-test for continuous variables, as appropriate.
51
52
53
54
55

56 For the primary analysis, the least square mean difference in the change of pulmonary
57 arterial pressure between groups at 12 months and its 95% confidential interval will be
58
59
60

1
2
3 estimated using an analysis of covariance (ANCOVA) model adjusted for allocation factors.

4
5 The secondary analysis will be performed in the same manner as the primary analysis.

6
7 Adverse events will be evaluated during the safety analysis. The frequencies of adverse
8
9 events will be compared using Fisher's exact test. All comparisons are planned, and all p -values
10
11 will be two sided. P -values <0.05 will be considered statistically significant. All statistical analyses
12
13 will be performed using SAS software version 9.4 (SAS Institute, Cary, NC, USA). The statistical
14
15 analysis plan will be developed by the principal investigator and the biostatistician before completion
16
17 of patient recruitment and data fixation.
18
19
20
21
22

23 24 **Discussion**

25
26 Early diagnosis and appropriate treatment for CTEPH are essential to prevent death due to
27
28 right-sided heart failure. Riociguat as a pulmonary vasodilator is recommended for treatment
29
30 of inoperable CTEPH¹. As a result, riociguat is now covered by the Japanese health insurance
31
32 system. The two main treatment options for inoperable CTEPH consist of riociguat or BPA, a
33
34 form of catheter-based treatment. The present study was therefore planned to compare the
35
36 efficacy and safety of riociguat with BPA in the treatment of inoperable CTEPH. This study
37
38 will also compare healthcare costs for each of the therapies. Results from such a randomized
39
40 trial will be important for optimizing the treatment selection and improving treatment
41
42 outcomes.
43
44
45
46
47
48

49 **Ethics and Dissemination:** This study was approved by the institutional review board of
50
51 Keio University School of Medicine and each participating institution and will be conducted
52
53 in accordance with the Declaration of Helsinki, Ethical Guidelines for Medical and Health
54
55 Research Involving Human Subjects issued by the Ministry of Health, Labor and Welfare in
56
57 Japan, and other current legal regulations in Japan. Written informed consent will be obtained
58
59
60

1
2
3 from all participants after a full explanation of this study. Results of the study will be
4
5 disseminated at medical conferences and journal publications.
6
7
8
9

10 **References**

11
12 1) Chronic Thromboembolic Pulmonary Hypertension: Pearls and Pitfalls of Diagnosis.

13
14 Memon HA, Lin CH, Guha A. *Methodist Debaquey Cardiovasc J.* 2016 12(4): 199-204.
15
16

17
18
19 2) Improved survival in medically treated chronic thromboembolic pulmonary hypertension.

20
21 Nishimura R, Tanabe N, Sugiura T, et al. *Circ J.* 2013; 77(8): 2110– 7.
22
23

24
25
26 3) Combined pulmonary endarterectomy and balloon pulmonary angioplasty in patients with
27
28 chronic thromboembolic pulmonary hypertension. Wiedenroth CB, Liebetrau C, Breithecker

29
30 A, Guth S, Lautze HJ, Ortmann E, Arlt M, Krombach GA, Bandorski D, Hamm CW,

31
32 Möllmann H, Mayer E. *J Heart Lung Transplant.* 2016 May;35(5):591-6.
33
34

35
36
37 4) Guidelines on diagnosis and treatment of pulmonary hypertension: the Task Force on

38
39 Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology

40
41 and of the European Respiratory Society. Galie` N, Hoeper MM, Humbert M, Torbicki A,

42
43 Vachery JL, Barbera JA, et al. *Eur Heart J.* 2009;30:2493–537.
44
45

46
47
48 5) ACCF/AHA, ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a

49
50 report of the American College of Cardiology Foundation Task Force on Expert Consensus

51
52 Documents and the American Heart Association: developed in collaboration with the

53
54 American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary
55
56
57
58
59
60

1
2
3 Hypertension Association. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW,
4
5 Lindner JR, et al. *Circulation*. 2009;119:2250–94
6
7
8
9

10 6) Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.

11
12 Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E,
13
14 Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C; CHEST-1 Study
15
16 Group. *N Engl J Med*. 2013 Jul 25;369(4):319-29.
17
18
19

20
21 7) Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-
22
23 term extension study (CHEST-2).

24
25 Simonneau G, D'Armini AM, Ghofrani HA, Grimminger F, Hoeper MM, Jansa P, Kim NH,
26
27 Wang C, Wilkins MR, Fritsch A, Davie N, Colorado P, Mayer E
28
29
30
31 *Eur Respir J* 45:1293-1302
32
33
34

35 8) Percutaneous transluminal pulmonary angioplasty for the treatment of chronic
36
37 thromboembolic pulmonary hypertension.

38
39
40 Kataoka M, Inami T, Hayashida K, Shimura N, Ishiguro H, Abe T, Tamura Y, Ando M,
41
42 Fukuda K, Yoshino H, Satoh T.
43
44
45 *Circ Cardiovasc Interv*. 2012 Dec;5(6):756-62.
46
47
48

49 9) Refined balloon pulmonary angioplasty for inoperable patients with chronic
50
51 thromboembolic pulmonary hypertension.

52
53 Mizoguchi H, Ogawa A, Munemasa M, Mikouchi H, Ito H, Matsubara H.
54
55
56 *Circ Cardiovasc Interv*. 2012 Dec;5(6):748-55.
57
58
59
60

1
2
3 10) Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic
4
5 pulmonary hypertension.

6
7 Andreassen AK, Ragnarsson A, Gude E, Geiran O, Andersen R.

8
9
10 Heart. 2013 Oct;99(19):1415-20.
11
12

13
14
15 11) Right ventricular reverse remodelling after balloon pulmonary angioplasty.

16
17 Fukui S, Ogo T, Morita Y, Tsuji A, Tateishi E, Ozaki K, Sanda Y, Fukuda T, Yasuda S,
18
19 Ogawa H, Nakanishi N.

20
21 Eur Respir J. 2014 May;43(5):1394-402.
22
23

24
25
26 12) Balloon pulmonary angioplasty: an additional treatment option to improve the prognosis
27
28 of patients with chronic thromboembolic pulmonary hypertension.

29
30 Taniguchi Y, Miyagawa K, Nakayama K, Kinutani H, Shinke T, Okada K, Okita Y, Hirata
31
32 KI, Emoto N.

33
34
35 EuroIntervention. 2014 Aug;10(4):518-25.
36
37

38
39
40 13) Significance of echocardiographic assessment for right ventricular function after balloon
41
42 pulmonary angioplasty in patients with chronic thromboembolic induced pulmonary
43
44 hypertension.

45
46
47 Tsugu T, Murata M, Kawakami T, Yasuda R, Tokuda H, Minakata Y, Tamura Y, Kataoka M,
48
49 Hayashida K, Tsuruta H, Maekawa Y, Inoue S, Fukuda K.

50
51 Am J Cardiol. 2015 Jan 15;115(2):256-61.
52
53

54
55
56 14) Percutaneous transluminal pulmonary angioplasty for the treatment of chronic
57
58 thromboembolic pulmonary hypertension: Challenges and future directions.
59
60

1
2
3 Dimopoulos K, Kempny A, Alonso-Gonzalez R, Wort SJ

4
5 Int J Cardiol. 2015 May 6;187:401-3.
6
7
8
9

10 15) Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension:
11 Results of a Multicenter Registry.
12

13
14 Ogawa A, Satoh T, Fukuda T, Sugimura K, Fukumoto Y, Emoto N, Yamada N, Yao A, Ando

15
16 M, Ogino H, Tanabe N, Tsujino I, Hanaoka M, Minatoya K, Ito H, Matsubara H.

17
18 Circ Cardiovasc Qual Outcomes 10: e004029
19
20
21
22

23
24 16) Midterm Effect of Balloon Pulmonary Angioplasty on Hemodynamics and Subclinical
25 Myocardial Damage in Chronic Thromboembolic Pulmonary Hypertension.
26

27
28 Kimura M, Kohno T, Kawakami T, Kataoka M, Tsugu T, Akita K, Isobe S, Itabashi Y,

29
30 Maekawa Y, Murata M, Fukuda K.
31

32
33 Can J Cardiol 33:463-470
34
35
36
37

38 17) Comprehensive evaluation of the effectiveness and safety of balloon pulmonary
39 angioplasty for inoperable chronic thrombo-embolic pulmonary hypertension: long-term
40 effects and procedure-related complications.
41
42

43
44 Aoki T, Sugimura K, Tatebe S, Miura M, Yamamoto S, Yaoita N, Suzuki H, Sato H, Koza K,

45
46 Konno R, Miyata S, Nochioka K, Satoh K, Shimokawa H.
47

48
49 Eur Heart J 38:3152-3159
50
51
52

53 18) Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic
54 pulmonary hypertension: the initial German experience.
55
56
57
58
59
60

1
2
3 Olsson KM, Wiedenroth CB, Kamp JC, Breithecker A, Fuge J, Krombach GA, Haas M,
4 Hamm C, Kramm T, Guth S, Ghofrani HA, Hinrichs JB, Cebotari S, Meyer K, Hoeper MM,
5 Mayer E, Liebetrau C, Meyer BC.
6
7

8
9
10 Eur Respir J 49:1602409
11
12

13
14
15 19) Novel Angiographic Classification of Each Vascular Lesion in Chronic Thromboembolic
16
17 Pulmonary Hypertension Based on Selective Angiogram and Results of Balloon Pulmonary
18
19 Angioplasty.
20

21 Kawakami T, Ogawa A, Miyaji K, Mizoguchi H, Shimokawahara H, Naito T, Oka T, Yunoki
22
23 K, Munemasa M, Matsubara H.
24

25
26 Circ Cardiovasc Interv 9:e003318
27
28

29
30
31 20) Efficacy and safety of balloon pulmonary angioplasty for chronic thromboembolic
32
33 pulmonary hypertension guided by cone-beam computed tomography and electrocardiogram-
34
35 gated area detector computed tomography.
36

37 Ogo T, Fukuda T, Tsuji A, Fukui S, Ueda J, Sanda Y, Morita Y, Asano R, Konagai N,
38
39 Yasuda S.
40

41
42 Eur J Radiol 89:270-276
43
44

45
46
47 21) Guidelines for Treatment of Pulmonary Hypertension (JCS2012).
48

49 Nakanishi N, Ando M, Ueda H, Ogino H, Saji T, Shiomi T, Tatsumi K, Date H, Nishimura
50
51 M, Fukushima N, Fukumoto Y, Momomura S, Yamada N, Yoshida S.
52

53
54 available at http://www.j-circ.or.jp/guideline/pdf/JCS2012_nakanishi_h.pdf. last accessed at
55
56 September 5th, 2018 (in Japanese)
57
58
59
60

Author's Contributions:

TK and HM equally contributed in this study. TK and HM contributed to the conception and design of the study, drafted the protocol, and supervised the revision. MK, KA, SK, YS and TS provided intellectual input into improving the study design and revising the protocol. KF contributed to and supervised the conception and design of the study. All authors read and approved the final manuscript.

Funding statement:

This study was financially supported by Bayer Yakuhin, Ltd.

Competing interests statement:

SK has received honoraria for scientific lectures from Bayer Yakuhin, Ltd. KF has received scholarship grants from Bayer Yakuhin, Ltd. and MSD K.K. The other authors declare no conflict of interest.

Figure and Table Legends

Figure 1. Study outline and randomization schematic. After consent, and CTEPH diagnosis is confirmed, subjects will be randomized into either BPA or riociguat group for 12 months, and observation measurements taken at screening, baseline, 0-4, 6 and 12 months.

Table 1. Schedule of assessments for subjects enrolled into the study.

Table 2. Secondary endpoints that will be measured and/or compared at baseline and at 12 months.

Table 1: Schedule of assessments for subjects enrolled into the study.

Observation items	Screening	Baseline	observation period		
	~0M	0M	0~4M	6M+1M	12M+2M
Subjects' attributes	○	○	—	—	—
6-minute walk distance	—	○	—	○	○
Borg dyspnea index	—	○	—	○	○
WHO functional class	—	○	—	○	○
Right heart catheterization	○	—	—	○	○
Pulmonary angiography	○	—	—	—	—
Pulmonary function testing	—	○	—	○	○
Blood gas test ^(a)	—	○	—	○	○
Vital signs ^(a)	—	○	—	○	○
Echocardiography (cardiac ultrasound)	—	○	—	○	○
Chest X-ray	—	○	○ ^(b)	○	○
Chest CT scan	○	—	○ ^(b)	○	○
Oxygen therapy usage status	—	○	—	○	○
Adverse event onset ^(c)	—	—	—	← ○ →	
Clinical worsening and time to clinical	—	—	—	← ○ →	

worsening (TTCW) ^(c)					
Quality of Life parameters (EQ5D)	—	○	—	○	○
Health insurance	—	—	←	○	→
BPA status ^(d)	—	—	○	—	—
Medication adherence ^(e)	—	—	←	○	→

(a) Recommended to be implemented during right heart catheterization

(b) Required if BPA is performed

(c) Onset of adverse events and indices related to clinical worsening will be observed, as necessary, throughout the clinical study period

(d) Observation items for Group A (BPA group)

(e) Observation items for Group B (riociguat group)

Table 2: Secondary endpoints that will be studied and or compared at baseline and at 12 months.

Endpoint	
Change in 6-minute walk distance	
Change in Borg dyspnea index	
Change in hemodynamic variables	Includes pulmonary vascular resistance, mean right arterial pressure, cardiac output etc.
Change in WHO functional class	
Change in plasma brain natriuretic peptide levels	
Change in SaO ₂ and PaO ₂	
Change in usage volume of oxygen therapy	Includes commencing oxygen therapy due to the exacerbation of a primary disease or dosage change.
Change in pulmonary function test	
Change in echocardiography test parameter	
Frequency and severity of pulmonary artery injury	Assessed by chest X-ray and chest CT scan.
Frequency of Adverse Events	Bloody sputum/hemoptysis/pulmonary hemorrhage (vascular perforation, vascular dissection, vascular rupture, etc.), pneumothorax, hypotension, pulmonary congestion/pulmonary edema, late-onset lung disturbance, heart failure, pneumonia, headache, dizziness, peripheral edema, nausea/vomiting,

retching, diarrhea, nasopharyngitis, upper respiratory inflammation, respiratory distress, coughing, fainting.

Clinical worsening during the All-cause mortality, heart/lung transplant, salvage observation period and time to clinical PEA due to worsening of primary disease, new or worsening repeated implementation of BPA due to the worsening of a primary disease, hospitalization, new initiation of pulmonary vasodilators, worsening of 30% or greater from baseline in the 6-minute walk distance, persistent worsening in the WHO functional class from baseline due to the worsening of a primary disease.

Change in Quality of Life parameters

(EQ5D)

Health insurance resource costs




Figure 1. Study outline and randomization schematic. After consent, and CTEPH diagnosis is confirmed, subjects will be randomized into either BPA or riociguat group for 12 months, and observation measurements taken at screening, baseline, 0-4, 6 and 12 months.

1
2
3
4
5
6
7
8
9
10 Multicenter Randomized controlled trial based on Balloon Pulmonary Angioplasty
11 for chronic thromboembolic pulmonary hypertension (MR BPA study)
12
13
14
15
16
17
18
19
20
21

22 **Protocol**

23
24
25
26
27
28
29
30
31
32

33 Principal Investigator: Keiichi Fukuda
34 Professor at the Department of Cardiology, Keio University School of Medicine
35 〒160-8582 35 Shinanomachi, Shinjuku-ku, Tokyo
36 Tel 03-3353-1211
37
38
39

40 Study execution period: January 2016–March 2021
41
42
43
44

45 Ver. 1.0 created: June 16, 2015

46 Ver. 2.0 created: November 17, 2015

47 Ver. 2.1 created: January 4, 2016

48 Ver. 3.0 created: March 25, 2016

49 Ver. 4.0 created: September 23, 2016

50 Ver. 5.0 created: October 16, 2017
51
52
53
54
55
56
57
58
59
60

Table of Contents

1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		
12	1. PROTOCOL OUTLINE AND SCHEMATIC	5
13	1.1. Protocol Outline	5
14	1.2. Schematic	8
15	2. DEFINITIONS OF TERMS	9
16	3. STUDY BACKGROUND AND SIGNIFICANCE	11
17	4. STUDY PURPOSE	12
18	5. STUDY DESIGN AND PLANNED ENROLLMENT OF SUBJECTS	12
19	5.1. Study Design	12
20	5.2. Planned Enrollment of Subjects	12
21	6. STUDY AGENT	12
22	7. STUDY SUBJECTS	13
23	7.1. Inclusion Criteria	13
24	7.2. Exclusion Criteria	13
25	8. ENDPOINTS	14
26	8.1. Primary Endpoint	14
27	8.2. Secondary Endpoints	14
28	9.1. Study Outline	16
29	9.2. Study Execution Period	16
30	9.4. Prohibited Concomitant Drugs	17
31	10. STUDY PROCEDURES	17
32	10.1. Acquisition of Consent	17
33	10.2. Screening, Provisional Enrollment	18
34	10.3. Determination of Operability	18
35	10.4. Actual Enrollment and Allocation	19
36	10.5. Treatment and Observation	20
37	11. OBSERVATION ITEMS AND SCHEDULE	21
38	11.1. Observation Items	21
39	11.2. Observation Schedule (one month is defined as 30 days).	24
40	12. ADVERSE EVENTS	25
41	12.1. Handling of Adverse Events	25
42	12.2. Response to Adverse Events	25
43	12.3. Recording of Adverse Events and Follow-up	25
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

1		
2		
3		
4		
5		
6	12.3.1 Classification of Adverse Events	26
7	12.3.2 Classification of Concomitant Symptoms.....	26
8	12.3.3 Cause-and-Effect Relationship with BPA or Riociguat	26
9	12.3.4 Classification of Outcomes	26
10	12.3.5 Other Classifications	27
11	12.4. SAEs and Unexpected SAEs	27
12	12.5. Reporting (Immediate Reporting) of and Response to SAEs	27
13	12.6. Provision of New Information to Study Subjects	28
14	13. TERMINATING SUBJECT PARTICIPATION OR DROPOUT	28
15	14. DATA MANAGEMENT	29
16	14.1. Data Management.....	29
17	14.2. Handling of Data for the Determination of Operability.....	30
18	14.3. Handling of Subject Data.....	30
19	14.4. Handling of EQ5D (QOL) Data	30
20	14.5. Creation of Data Sets	30
21	15. MONITORING	31
22	15.1. Monitoring.....	31
23	15.2. Source Document Verification (SDV).....	31
24	16. PLANNED ENROLLMENT OF SUBJECTS AND RATIONALE.....	32
25	16.1. Planned Enrollment of Subjects.....	32
26	16.2. Rationale for Planned Enrollment of Subjects.....	32
27	17. STATISTICAL ANALYSIS	32
28	17.1. Allocation Factor	32
29	17.2. General Approach for Analysis.....	33
30	17.3. Subject Background Analysis	33
31	17.4. Primary Endpoint Analysis	33
32	17.5. Secondary Endpoint Analysis	34
33	17.6. Interim Analysis.....	34
34	18. PROTOCOL APPROVAL, STUDY INITIATION, AND PROTOCOL CHANGES	
35	34
36	18.1. Protocol Approval	34
37	18.2. Study Initiation.....	35
38	18.3. Protocol Changes	35
39	19. STUDY CLOSURE AND PREMATURE TERMINATION.....	36
40	19.1. Study Closure	36
41	19.2. Premature Study Termination.....	36
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

1		
2		
3		
4		
5		
6	20. HUMAN RIGHTS AND INFORMED CONSENT OF SUBJECTS	36
7	20.1. Protection of Subjects and Rules Requiring Observance	36
8	20.2. Informed Consent	37
9	20.3. Handling of Personal Information	38
10		
11	21. SUBJECT BURDENS, POTENTIAL RISKS AND BENEFITS, MEASURES TO	
12	MINIMIZE BURDENS AND RISKS, AND COMPREHENSIVE EVALUATION	39
13	21.1. Subject Burdens and Potential Risks	39
14	21.2. Potential Benefits	40
15	21.3. Measures to Minimize Burdens and Risks	40
16	21.4. Comprehensive Evaluation	40
17		
18	22. RESPONDING TO REQUESTS FOR CONSULTATIONS FROM SUBJECTS	
19	AND RELATED PARTIES	41
20		
21	23. PROTOCOL FOR REPORTING TO HEADS OF RESEARCH INSTITUTIONS	
22	(CONTENT AND METHOD)	41
23		
24	24. SPECIMEN AND DATA STORAGE AND DISPOSAL METHODS	42
25		
26	25. METHODS OF DISCLOSURE OF STUDY-RELATED INFORMATION	42
27		
28	26. STUDY FUNDING AND CONFLICTS OF INTEREST	43
29	26.1. Funding Provider	43
30	26.2. Conflicts of Interest	43
31		
32	27. RULES REQUIRING OBSERVANCE	43
33		
34	28. ORGANIZATIONAL STRUCTURE OF THE CLINICAL STUDY	43
35	28.1. Principal Investigator	43
36	28.2. Central Committee	44
37	28.3. Collaborating Research institutions *In Japanese alphabetical order ..	45
38	28.4. Physician to Determine Operability	46
39	28.5. Data and Safety Monitoring Board (DSMB)	46
40	28.6. Clinical Event Committee (CEC)	46
41	28.7. Data Handling Committee	47
42	28.8. Biostatistician	47
43	28.9. Core Laboratory (CT, CXR)	47
44	28.10. Core Laboratory (Echocardiography)	47
45	28.11. Research Support Center (Data Center)	48
46		
47	29. REFERENCES	48
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

1. PROTOCOL OUTLINE AND SCHEMATIC


1.1. Protocol Outline

Title	Multicenter Randomized controlled trial based on Balloon Pulmonary Angioplasty for chronic thromboembolic pulmonary hypertension (MR BPA study)
Purpose	To compare the efficacy and safety of riociguat with balloon pulmonary angioplasty (BPA) in the treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) over the course of 12 months, to potentially aid in optimizing treatment selection and improving treatment outcomes
Study Design	Multicenter, prospective, randomized, controlled, open-label, two-arm, trial Subjects with inoperable CTEPH will be randomized (1:1) into either BPA (group A) or riociguat (group B), and observed for 12 months after treatment.
Inclusion Criteria	Patients meeting the following criteria will be included in the study. (a) patients who are diagnosed with CTEPH (based on the diagnostic criteria in the 2012 Japanese Circulation Society guidelines with a WHO functional class II or III). (b) male and female aged ≥ 20 years and < 80 years. (c) patients with mean pulmonary arterial pressure of ≥ 25 mmHg to < 60 mmHg and pulmonary artery wedge pressure of ≤ 15 mmHg. (d) patients who undergo appropriate anticoagulant therapy for at least three months prior to consent acquisition (if warfarin is used, prothrombin time-international normalized ratio should be 1.5 to 3.0). (e) patients who provide written consent form to participate in this study after full explanation of the study.
Exclusion Criteria	Patients meeting any of the following exclusion criteria will be excluded from the trial. (a) patients with a history of BPA. (b) patients who underwent PEA within six months prior to consent acquisition.

	<p>(c) patients who are using unapproved pharmaceutical products.</p> <p>(d) patients who used a pulmonary vasodilator within four weeks prior to the right heart catheterization after consent acquisition.</p> <p>(e) patients with co-existing etiology of pulmonary hypertension other than Group 4 in the Nice Pulmonary Hypertension Classification System.</p> <p>(f) patients who are pregnant or breastfeeding.</p> <p>(g) patients who met the contraindication for riociguat.</p> <p>(h) patients whose life expectancy is less than two years.</p> <p>(i) patients who are considered to be unsuitable for participation by investigators.</p>
Primary Endpoint	Change in the mean pulmonary arterial pressure from baseline to 12 months
Secondary Endpoints	<p>① Changes in the six-minute walk distance from baseline to 12 months</p> <p>② Changes in the Borg dyspnea index from baseline to 12 months</p> <p>③ Changes in hemodynamic variables, including pulmonary vascular resistance (PVR), mean right arterial pressure, and cardiac output] from baseline to 12 months</p> <p>④ Changes in the WHO functional class</p> <p>⑤ Changes in plasma brain natriuretic peptide (BNP) levels from baseline to 12 months</p> <p>⑥ Changes in arterial oxygen saturation (SaO₂) and oxygen partial pressure (PaO₂) from baseline to 12 months</p> <p>⑦ Changes in the usage volume of oxygen therapy from baseline to 12 months, including commencing oxygen therapy due to the exacerbation of a primary disease or dosage change.</p> <p>⑧ Changes in pulmonary function test parameters from baseline to 12 months</p> <p>⑨ Changes in echocardiography test parameters from baseline to 12 months</p> <p>⑩ Frequency and severity of pulmonary artery injury</p>

	<p>assessed by chest X-ray and chest computed tomography (CT) scan</p> <p>⑪ Frequency of adverse events</p> <p>⑫ Clinical worsening during the observation period and time to clinical worsening (TTCW)</p> <p>⑬ Change in Quality of Life (QOL) parameters (EQ5D) from baseline to 12 months</p> <p>⑭ Health insurance resource costs over 12 months</p>
Study execution period and observation points	<p>Enrollment period: January 15, 2016, to October 31, 2019 (45 months)</p> <p>Study period: January 15, 2016, to March 31, 2021* (62 months)</p> <p>Observation period: 12 months (+2 months)</p> <p>Observation measurement: Screening, baseline, 0 to 4 months, 6 months (+1 month), 12 months (+2 months) (five observation measurements in total)</p> <p>*A period of five months is provided after the completion of subject observation to allow for the preparation of statistical and analytical data</p>
Planned Enrollment of Subjects	Inoperable CTEPH: 60 subjects

1.2. Schematic



2. DEFINITIONS OF TERMS

Term	Definition
Subjects	Individuals who participate in the study (includes those who were asked to participate)
Responsible investigators	Physicians who are engaged in implementing the study and preside over duties related to this study at their affiliated research institution
Investigators	Attending physicians, the responsible investigators, and other people related to study implementation
Research institution	Medical institution at which the study is implemented. Exclude institution that receive a consignment to engage in part of the duties related to the study (Soiken Inc.)
Collaborating research institution	Refers to research institutions at which the study is jointly conducted in accordance with the protocol; includes institutions at which specimens and data are newly obtained from subjects for the study and then provided to other research institutions
Intervention	Actions that limit the presence or extent of factors that affect various health-related phenomena for research purposes
Institutional Review Board	Refers to a council body established to examine whether a study can be implemented or continued or other necessary matters related to the study from ethical and scientific viewpoints
Linkable anonymizing	A method of anonymization in which a correspondence table of symbols or numbers newly added to each individual's data is stored so that subjects can be identified if necessary
BPA	Balloon Pulmonary Angioplasty
BNP	Brain Natriuretic Peptide
CTEPH	Chronic Thromboembolic Pulmonary Hypertension
CRF	Case Report Form: a specialized data collection form for this study
EDC	Electric Data Capture System: an electronic clinical testing data collection system
EQ5D	EuroQol 5 Dimension: a comprehensive evaluation scale composed of five items; it was developed to measure health-related Quality of Life (QOL)
Inoperable	Not eligible for surgery

Operable	Eligible for surgery
PEA	Pulmonary Endarterectomy
QOL	Quality of Life
SDV	Source Data Verification: direct viewing of source materials
SAE	Serious Adverse Event: includes unexpected SAEs. In this study, any kind of SAE requires emergency reporting (Chapter 12.5).

For peer review only

3. STUDY BACKGROUND AND SIGNIFICANCE

Chronic thromboembolic pulmonary hypertension (CTEPH) is an intractable disease in which an organized thrombus causes stenosis or occlusion of the pulmonary artery. Unless early diagnosis and appropriate treatment are performed, which causes death due to right-sided heart failure. Pulmonary endarterectomy (PEA) has been established as a method for operable CTEPH. According to the AHA/ACC and ESC guidelines, PEA is recommended for patients with operable CTEPH as the first line therapy in class of recommendation I and level of evidence C. However, riociguat as soluble guanylate cyclase stimulator is recommended for subjects with inoperable CTEPH, and is the first and only an approved medical treatment for inoperable CTEPH.

In 2014, a soluble guanylate cyclase stimulator (general name: riociguat), which is one of the pulmonary hypertension treatment agents, received insurance reimbursement approval for inoperable CTEPH for the first time; this was based on the findings of a multicenter randomized clinical trial (CHEST-1) indicating the efficacy of riociguat for subjects with inoperable CTEPH¹⁾. Balloon pulmonary angioplasty (BPA), as a catheter-based treatment, has also been reported to be effective for subjects with inoperable CTEPH^{2)- 8)}.

As described above, the two main treatment options for inoperable CTEPH consist of riociguat and BPA. Although BPA is associated with a certain level of risk of complications such as procedure related pulmonary artery injury, it can provide marked improvement when the treatment finished. On the other hand, riociguat is the most effective pulmonary vasodilator and have low risk of serious adverse events (SAEs). However, no reports have yet compared the treatment outcomes of these two methods⁸⁾.

We planned the present study to compare the efficacy and safety of riociguat with BPA in the treatment of inoperable CTEPH over the course of 12 months, to potentially aid in optimizing treatment selection and improving treatment outcomes.

4. STUDY PURPOSE

To compare the efficacy and safety of riociguat with BPA in the treatment of inoperable CTEPH over the course of 12 months, to potentially aid in optimizing treatment selection and improving treatment outcomes

5. STUDY DESIGN AND PLANNED ENROLLMENT OF SUBJECTS

5.1. Study Design

This will be a multicenter, prospective, randomized, controlled, open-label, two-arm, trial.

Subjects with inoperable CTEPH will be randomized (1:1) into either BPA (group A) or riociguat (group B), and observed for 12 months after treatment.

5.2. Planned Enrollment of Subjects

The enrollment of 60 subjects with inoperable CTEPH (30 subjects × 2 groups) is planned.

Group A: BPA group (30 subjects)

Group B: Riociguat group (30 subjects)

*The rationale for the sample size is as described in "16. PLANNED ENROLLMENT OF SUBJECTS AND RATIONALE."

6. STUDY AGENT

General name: Riociguat

Brand name: Adempas® tablets (0.5 mg, 1.0 mg, and 2.5 mg) (riociguat tablets)

Manufactured and sold by: Bayer Yakuhin, Ltd.

BREEZE TOWER 2-4-9, Umeda, Kita-ku, Osaka 530-0001

Contraindications*:

- (1) Those with a history of hypersensitivity to an ingredient in this drug
- (2) Women who are or may be pregnant
- (3) Those with severe hepatic dysfunction (Child-Pugh class C)
- (4) Those with severe renal dysfunction (creatinine clearance below 15 mL/min) or subjects receiving dialysis
- (5) Those being administered a nitric acid agent or nitrogen monoxide (NO) donor (nitroglycerin, amyl nitrite, isosorbide dinitrate, nicorandil, etc.)
- (6) Those being administered a phosphodiesterase (PDE) type 5 inhibitor

- 1
2
3
4
5
6 (7) Those being administered an azole-based antifungal agent (e.g.,
7 itraconazole and voriconazole) or an HIV protease inhibitor (e.g., ritonavir,
8 lopinavir/ritonavir, indinavir, atazanavir, and saquinavir)
9

10
11 *Package insert revised in February 2015 (2nd version)
12
13
14

15 **7. STUDY SUBJECTS**

16
17 This study will investigate the advanced methods of treatment of CTEPH subjects.
18 Due to the small number of CTEPH subjects being treated in Japan, care is taken
19 to encourage the enrollment of as many subjects as possible. However, in
20 consideration of subject safety, high-risk subjects are excluded. In addition, to
21 more thoroughly examine subject eligibility requirements for treatment strategies,
22 the judgment of a third party (physician to determine operability) is incorporated.
23
24
25
26
27
28
29

30 **7.1. Inclusion Criteria**

31 Patients meeting the following criteria will be included in the study.

- 32
33 (a) patients who are diagnosed with CTEPH (based on the diagnostic criteria in the
34 2012 Japanese Circulation Society guidelines with a WHO functional class II or
35 III).
36
37 (b) male and female aged ≥ 20 years and < 80 years.
38
39 (c) patients with mean pulmonary arterial pressure of ≥ 25 mmHg to < 60 mmHg
40 and pulmonary artery wedge pressure of ≤ 15 mmHg.
41
42 (d) patients who undergo appropriate anticoagulant therapy for at least three
43 months prior to consent acquisition (if warfarin is used, prothrombin
44 time-international normalized ratio should be 1.5 to 3.0).
45
46 (e) patients who provide written consent form to participate in this study after full
47 explanation of the study.
48
49

50 **7.2. Exclusion Criteria**

51 Patients meeting any of the following exclusion criteria will be excluded from the
52 trial.
53

- 54
55 (a) patients with a history of BPA.
56
57 (b) patients who underwent PEA within six months prior to consent acquisition.
58
59 (c) patients who are using unapproved pharmaceutical products.
60

- 1
2
3
4
5
6 (d) patients who used a pulmonary vasodilator within four weeks prior to the right
7 heart catheterization after consent acquisition.
8
9 (e) patients with co-existing etiology of pulmonary hypertension other than Group
10 4 in the Nice Pulmonary Hypertension Classification System.
11
12 (f) patients who are pregnant or breastfeeding.
13
14 (g) patients who met the contraindication for riociguat.
15
16 (h) patients whose life expectancy is less than two years.
17
18 (i) patients who are considered to be unsuitable for participation by investigators.

19 **8. ENDPOINTS**

20 **8.1. Primary Endpoint**

21 Change in the mean pulmonary arterial pressure from baseline to 12 months later

22 **8.2. Secondary Endpoints**

- 23
24
25
26
27 ① Changes in the six-minute walk distance (6MWD) from baseline to 12 months
28
29 ② Changes in the Borg dyspnea index from baseline to 12 months
30
31 ③ Changes in hemodynamic variables, including pulmonary vascular resistance
32 (PVR), mean right arterial pressure, and cardiac output] from baseline to 12
33 months
34
35 ④ Changes in the WHO functional class
36
37 ⑤ Changes in plasma brain natriuretic peptide (BNP) levels from baseline to 12
38 months
39
40 ⑥ Changes in arterial oxygen saturation (SaO₂) and oxygen partial pressure
41 (PaO₂) from baseline to 12 months
42
43 ⑦ Changes in the usage volume of oxygen therapy from baseline to 12 months,
44 including commencing oxygen therapy due to the exacerbation of an primary
45 disease or dosage change
46
47 ⑧ Changes in pulmonary function test parameters from baseline to after 12
48 months
49
50 ⑨ Changes in echocardiography test parameters from baseline to after 12 months
51
52 ⑩ Frequency and severity of pulmonary artery injury assessed by chest X-ray and
53 chest computed tomography (CT) scan
54
55 ⑪ Frequency of adverse events
56 Bloody sputum/hemoptysis/pulmonary hemorrhage (vascular perforation,
57 vascular dissection, vascular rupture, etc.), pneumothorax, hypotension,
58
59
60

1
2
3
4
5
6 pulmonary congestion/pulmonary edema, late-onset lung disturbance, heart
7 failure, pneumonia, headache, dizziness, peripheral edema, nausea/vomiting,
8 retching, diarrhea, nasopharyngitis, upper respiratory inflammation, respiratory
9 distress, coughing, fainting, etc.

10
11
12 ⑫ Clinical worsening during the observation period and time to clinical worsening
13 (TTCW)

14 ⑫-1 The following events are considered to indicate clinical worsening and are
15 calculated as TTCW.

16
17 ⑬ -2 Each clinical worsening item should be entered into the electric data capture
18 system (EDC) only at initial onset.

19 ⑫-3 As a general rule, follow-up observations should be continued.

20
21 List of TTCW events:

- 22 ● All-cause mortality
- 23 ● Heart-lung transplantation
- 24 ● Salvage PEA due to the worsening of a primary disease
- 25 ● New or repeated implementation of BPA due to the worsening of a primary
26 disease*

27
28 *Repeated implementation refers to performing BPA again (or
29 additionally) on a subject in the BPA group due to worsening of a primary
30 disease four months after the reference date or after all BPA sessions
31 have been completed.

- 32 ● Hospitalization due to the worsening of a primary disease
- 33 ● New initiation of pulmonary vasodilators due to the worsening of a primary
34 disease
35 (e.g., soluble guanylate cyclase stimulator, endothelin receptor antagonist,
36 PDE type 5 inhibitor, and prostaglandin I₂)
- 37 ● Worsening of 30% or greater from baseline in the 6MWD due to a primary
38 disease
- 39 ● Persistent worsening in the WHO functional class from baseline due to the
40 worsening of a primary disease*

41
42 *For subjects whose condition worsened as shown below according to the
43 WHO functional class, as a general rule, confirm this a second time 14
44 days later (interview by telephone allowed) and check that the worsening
45 is persistent.

- 46 ➤ Class II to class III
- 47 ➤ Class II to class IV

➤ Class III to class IV


- ⑭ Change in Quality of Life (QOL) parameters (EQ5D) from baseline to 12 months
- ⑮ Health insurance resource costs over 12 months

9. STUDY METHODS

9.1. Study Outline

After acquiring consent, the subjects will undergo right heart catheterization and pulmonary angiography before provisional enrollment. An independent experienced PEA surgeon will determine if these subjects are eligible to undergo PEA under blind circumstance. Those who are judged to have inoperable CTEPH will be assigned into group A (BPA group) or group B (riociguat group) via an online assignment system, and observed for 12 months (Figure 1).

Figure 1: Study outline



9.2. Study Execution Period

Enrollment period: January 15, 2016, to October 31, 2019 (45 months)

Study period: January 15, 2016, to March 31, 2021* (62 months)

Observation period: 12 months (+2 months)

Observation measurement: Screening, baseline, 0 to 4 months, 6 months (+1 month), 12 months (+2 months) (five observation measurements in total)

*A period of five months is provided after the completion of subject observation to allow for the preparation of statistical and analytical data.

9.3. Study Reference Dates

Following actual enrollment, the initial BPA implementation date will be the study reference date (observation point base calculation date) for group A (BPA group) and the riociguat administration start date will be the study reference date for group B (riociguat group).

9.4. Prohibited Concomitant Drugs

The following drugs may not be used during the observation period. However, if any of the following drugs are initiated during the observation period, the drug name, directions, and dosage should be input into the EDC and follow-up observation should be performed as much as possible. If a pulmonary vasodilator is used due to the worsening of a primary disease, calculate this as TTCW.

1. Pulmonary vasodilators

Soluble guanylate cyclase stimulator, endothelin receptor antagonist, PDE type 5 inhibitor, and prostaglandin I₂

2. Others

- Nitric acid agent or nitrogen monoxide donor (nitroglycerin, isosorbide dinitrate, etc.)
- PDE type 5 inhibitors (sildenafil, vardenafil, tadalafil, etc.)
- Azole-based antifungal agents (itraconazole, voriconazole, etc.)
- HIV protease inhibitor (ritonavir, indinavir, atazanavir, saquinavir, etc.)

10. STUDY PROCEDURES

10.1. Acquisition of Consent

When subjects are determined able to participate in this study, the informed consent document is used to give them a sufficient explanation of this study and their written consent is then obtained. When obtaining consent, it is also explained that data related to pulmonary angiography, right heart catheterization, and chest CT scan from within three months prior to acquiring consent, as well as pulmonary ventilation-perfusion scintigraphy prior to acquiring consent, may be

1
2
3
4
5
6 used for research purposes. See “20.2 Informed Consent” for details on the
7 methods of acquiring consent.
8
9

10 **10.2. Screening, Provisional Enrollment**

11 As a general rule, right heart catheterization and pulmonary angiography are
12 performed after acquiring consent and investigators determine whether each
13 subject can be definitively diagnosed with CTEPH. However, to reduce the burden
14 on the subjects, data from within three months prior to consent acquisition for
15 pulmonary angiography, right heart catheterization, and chest CT scan, as well as
16 pulmonary ventilation-perfusion scintigraphy obtained in general practice prior to
17 consent acquisition, can also be utilized. This information will be included on the
18 informed consent document. Then, the subjects diagnosed with CTEPH are
19 provisionally enrolled in the EDC after determining their eligibility based on the
20 inclusion and exclusion criteria. During this assessment process, the subjects are
21 assigned a number (central registration number) to identify them.
22
23
24
25
26
27
28
29

30 **10.3. Determination of Operability**

31 Based on the imaging data of the subjects who give their consent, an independent
32 experienced PEA surgeon who is not involved in this study (physician to determine
33 operability) will determine operability (whether the subjects are eligible to
34 undergo PEA). The standards for this determination of operability will be based on
35 the Guidelines for Treatment of Pulmonary Hypertension (2012 revised version)
36 and will be anatomically performed.
37
38
39

40 The physician to determine operability in this study must meet one of the
41 following criteria:
42
43

- 44 ● Has performed PEA on more than 20 subjects per year in the year before
45 starting to determine the eligibility of subjects in this study to undergo
46 surgery
47
- 48 ● Has performed PEA on over 40 subjects in the three years prior to starting to
49 determine the eligibility of subjects in this study to undergo surgery
50
51

52
53 The determination of operability will be based on the above guidelines, as well as
54 on the technical feasibility of surgery, taking the following into account:
55
56
57

- 58 ● Ability to surgically reach the organized thrombus
59
60

- Conformity of a surgically reachable vascular occlusion site and PVR

The above guidelines should be used to determine whether the subject is operable or inoperable based on pulmonary angiography imaging test results.

See the next section for specific procedures.

Procedures for Determining Operability

- ① The investigators will submit the subjects' imaging data, attributes, and right heart catheterization data to the Data Center. Linkable anonymization with central registration number will be used to identify the subjects.
- ② The Data Center confirms the receipt of imaging data and forwards it to the surgeon to determine operability.
- ③ The surgeon determines operability based on subjects' imaging data, attributes, and right heart catheterization data sent from the Data Center in accordance with the Guidelines for Treatment of Pulmonary Hypertension (2012 revised version). In addition, the surgeon takes into account the two considerations previously described (whether the organized thrombus causes stenosis or occlusion of the pulmonary artery)

Based on these factors, a determination is made on subject suitability to undergo surgery (determination of operability). The surgeon determining operability will then promptly report the results to the Data Center. The data used for determination are as follows:

(Data to be submitted)

- Subjects' attributes
- Pulmonary angiography
- Right heart catheterization
- Chest CT scan

*If possible, the following data will also be submitted:

- Pulmonary ventilation-perfusion scintigraphy

10.4. Actual Enrollment and Allocation

- ① The Data Center will receive the results of the determination from the surgeon determining operability and will then officially enroll subjects using an online system in accordance with these results.
 - 1) Subjects determined to have inoperable CTEPH will be enrolled and allocated into groups A or B.

- 1
2
3
4
5
6 ② The Data Center will report the results of operability determinations and
7 allocation to study groups (actual enrollment) to the investigators.
8
9

10 As a general rule, the period until actual enrollment will be within 12 weeks after
11 obtaining informed consent.
12
13

14 **10.5. Treatment and Observation**

15 The investigators will perform the following treatment in accordance with the
16 allocation results and begin observation:
17
18

19 ① Treatment

20 Group A: BPA group

- 21
22
23 ● BPA is performed after allocation to this group (initial date of implementation
24 will be the reference date).
25
26 ● Based on preoperative right heart catheterization and pulmonary angiography,
27 the degree of pulmonary hypertension severity is assessed and the pulmonary
28 lesion is morphologically evaluated. Diuretics are used to regulate a high right
29 atrial pressure. When the pulse cardiac output is low, measures are taken,
30 such as administering dobutamine, prior to surgery. When performing BPA, a
31 long sheath will be inserted into the main trunk of the pulmonary artery using
32 a 0.014-inch guidewire. The first choice is the right internal jugular vein
33 approach; however, depending on the state of the internal jugular vein, the
34 femoral vein approach may be considered by the surgeon. Diagnostic imaging
35 devices (e.g., intravascular ultrasound or optical coherence tomography) may
36 be used to confirm lesion shape, range, blood vessel diameter, etc. Depending
37 on the lesion type, the pulmonary blood vessel is expanded with a balloon
38 catheter. After BPA, a Swan-Ganz catheter is placed, if necessary, and chest
39 CT and X-ray scan must be taken within 24 h after treatment to confirm the
40 presence/absence and extent of postoperative lung impairment. Sequential
41 images will be taken with the slice thickness set at 2 mm or below.
42
43 ● As a general rule, BPA will be completed within four months of the reference
44 date.
45
46
47
48
49
50
51
52
53

54 Group B: Riociguat group

- 55
56 ● After allocation to this group, riociguat treatment will be initiated (the initial
57 administration day will be the reference date).
58
59
60

- 1
2
3
4
5
6 ● Riociguat will be initially administered three times per day at 1.0 mg per dose.
7 Using systolic blood pressure (95 mmHg or higher) as a guide, the dose will
8 be increased by 0.5 mg for each subject every two weeks with a thrice-daily
9 administration of 2.5 mg/dose set as the maximum dosage. Dosage
10 adjustment, including the maintenance dosage, is based on the judgment of
11 the responsible investigators and investigators. Dosage adjustment will be
12 completed within four months of the reference date.
13
14
15
16

17
18 ② Observation

- 19 ● The observation period is 12 months (+2 months). A total of five observations
20 are made at five points: 1) screening, 2) baseline, 3) 0 to 4 months, 4) 6
21 months (+1 month), and 5) 12 months (+2 months). One month is
22 considered to be 30 days.
23
24 ● In group B, if the study agent is discontinued or treatment with another
25 pulmonary vasodilator is started, the investigators should report this by
26 inputting the date and reason for discontinuation into the EDC system.
27 However, for the purpose of safety analysis, the observation will be continued
28 for as long as possible.
29
30
31
32
33

34 **11. OBSERVATION ITEMS AND SCHEDULE**

35 **11.1. Observation Items**

36 ① Common items

37 1) Subject attributes

38 Age, sex, height, BMI, weight, primary disease, medical history, complications,
39 risk factors (Associated Medical Conditions), right heart catheterization after
40 consent acquisition, information regarding drug usage (e.g., pulmonary
41 vasodilators, anticoagulants, etc. used in the past), reason for the
42 determination of operability/inoperability, and history of CTEPH treatment.
43
44
45
46
47
48

49 2) 6MWD

50 *Arterial oxygen saturation and pulse rate are measured. If oxygen inhalation
51 is performed during the test, the oxygen inhalation volume will be measured.
52

53 3) Borg dyspnea index

54 4) WHO functional class

55 5) Right heart catheterization

56 Thermodilution is recommended. The Fick method is also allowed (performed
57
58
59
60

under room temperature and in the dorsal position).

- Right atrial pressure (mean), pulmonary arterial pressure (mean systolic and diastolic phase), pulmonary artery wedge pressure (mean), cardiac output, heart rate, cardiac index, PVR, mixed venous oxygen saturation, and hemoglobin level

6) Pulmonary angiography

7) Pulmonary ventilation-perfusion scintigraphy (optional)

8) Pulmonary function tests

VC, %VC, FVC, %FVC, FEV1, %FEV1, FEV1%, RV, %RV, TLC, %TLC, DLCO, %DLCO, DLCO/VA, %DLCO/VA, VA, %VA, Peak flow, MMF, %MMF, V75, %V75, V50, %V50, V25, %V25, V50/V25

9) Echocardiography (cardiac ultrasound)

10) Blood tests (recommended to be performed during right heart catheterization, performed under room temperature in the dorsal position)

Plasma BNP, Cr, CCr, eGFR, SaO₂, pH, PaO₂, PaCO₂, HCO₃⁻, BE, A-aDO₂

11) Measuring vital signs (recommended prior to performing right heart catheterization under room temperature and in the dorsal position), blood pressure, and pulse rates

12) Chest X-ray (CXR) scan *Must be measured after BPA.

13) Chest CT (CT) scan *Must be measured after BPA.

14) Oxygen therapy usage status

Oxygen inhalation volume during resting and exertion is expressed as mean oxygen inhalation volume.

*If there is worsening of the primary disease resulting in the initiation of oxygen therapy or a change in the oxygen dosage, this should be reported as an adverse event.

*If SpO₂ is ≥95% or higher during resting or ≥90% during exertion and at night, this will be used as the basis for increasing or decreasing oxygen dosage.

15) Occurrence of adverse events

16) Clinical worsening during the observational period and TTCW

17) QOL parameters (EQ5D)

18) Health insurance expenses

The starting points for subjects' health insurance expenses (medical costs) will be (a) the first day when BPA is performed (hospitalization day if hospitalized for initial treatment) in the BPA group and (b) riociguat administration start date in the riociguat group. Data will be collected for 12 months from the start point.

1
2
3
4
5
6
7 ② Group A: Observation items only in the BPA group
8 •Whether BPA was performed at months 0–4
9

10
11
12 ③ Group B: Observation items only in the riociguat group
13 •Adherence to the study agent.

14 Confirm whether the subjects are taking the study agent at each observation
15 point during the observational period via interviews conducted by the
16 investigators.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

11.2. Observation Schedule (one month is defined as 30 days).

Observation items	Screening	Baseline	Follow-up		
	~0M	0 M	0~4M	6M +1M	12M +2M
Subjects' attributes	○	○	—	—	—
6MWD	—	○	—	○	○
Borg dyspnea index	—	○	—	○	○
WHO functional class	—	○	—	○	○
Right heart catheterization	○	—	—	○	○
Pulmonary angiography	○	—	—	—	—
Pulmonary function testing	—	○	—	○	○
Blood tests ⁽¹⁾		○	—	○	○
Vital signs ⁽¹⁾		○	—	○	○
Echocardiography (cardiac ultrasound)	—	○	—	○	○
Chest X-ray		○	○ ⁽²⁾	○	○
Chest CT scan	○	—	○ ⁽²⁾	○	○
Pulmonary ventilation-perfusion scintigraphy	△	—	—	—	—
Oxygen therapy usage status	—	○	—	○	○
Adverse event onset ⁽³⁾	—	—	← ○ →		
Clinical worsening and TTCW ⁽³⁾	—	—	← ○ →		
QOL parameters (EQ5D)	—	○	—	○	○
Health insurance resource costs	—	—	← ○ →		
BPA implementation status ⁽⁴⁾	—	—	○	—	—
Subjects' medication adherence ⁽⁵⁾	—	—	← ○ →		

○...Required △...Optional

(1) Recommended to be implemented during right heart catheterization

(2) Required if BPA is performed

(3) Onset of adverse events and indices related to clinical worsening will be observed, as necessary, throughout the clinical study period

(4) Observation items for Group A (BPA group)

(5) Observation items for Group B (riociguat group)

12. ADVERSE EVENTS

12.1. Handling of Adverse Events

During the study period, the occurrence of any untoward medical events experienced by subjects, including the worsening of a pre-existing underlying disease, will be defined as adverse events. If complications worsen after starting the study, this will also be defined as an adverse event. However, the worsening of efficacy evaluation indices will not be treated as an adverse event.

If any concomitant symptoms or clinically significant abnormal fluctuations in test results are observed, a subject's disease condition, medical history, concomitant medications, and temporal relationship between medication and onset will be investigated. The investigators at each medical facility will subsequently determine whether there is a cause-and-effect relationship with BPA or riociguat and findings will be documented into the EDC system.

12.2. Response to Adverse Events

If a subject experiences an adverse event during the study period, the investigators will immediately take the appropriate medical action. In accordance with the procedures of each participating research institution, they will also generate a report to the responsible investigator and the head of the institution and enter the necessary information into the subject's medical record and the EDC system.

12.3. Recording of Adverse Events and Follow-up

If an adverse event occurs, in accordance with the classifications described below in section 12.3.1, symptoms or the clinical condition; objective findings; day of onset; extent and severity; whether medical treatment was provided and, if so, what treatment; outcome that was determined and day this was determined; and the relationship of adverse events to this study as well as the reasons for the occurrence of the adverse event should be entered into the subject's medical record and the EDC system. As a general rule, adverse events will be followed up until normalization or recovery occurs to a level at which it is not considered to be an adverse event or if damage (cerebral infarction, myocardial infarction etc.) causes an irreversible adverse event until symptoms stabilize or no longer change.

1
2
3
4
5
6 However, this is not required if the responsible investigator or investigator
7 determines that there has been recovery or if it has been determined that there is
8 no clear cause-and-effect relationship. The reasons for this determination will be
9 entered into the EDC system.
10
11

12 13 **12.3.1 Classification of Adverse Events**

- 14 ① Mild: Does not disrupt the activities of daily living of subjects
- 15 ② Moderate: Impairs subjects' activities of daily living, but they can still engage in
16 these activities if they endure a significant amount of discomfort.
- 17 ③ Severe: Greatly impedes subjects' activities of daily living

18 19 20 21 **12.3.2 Classification of Concomitant Symptoms**

- 22 ① Mild: Subjects can continue to participate with no treatment
- 23 ② Moderate: Subject participation can be continued if some form of treatment is
24 administered
- 25 ③ Severe: Subject participation is or should be terminated

26 27 28 29 30 31 **12.3.3 Cause-and-Effect Relationship with BPA or Riociguat**

32 The cause-and-effect relationship will be determined based on the following
33 criteria: assessing a subject's clinical condition, temporal relationship with
34 treatment, and other potential associations. Adverse events which were judged to
35 be (1) or (3) will be considered to be "adverse events in which a relationship with
36 BPA or riociguat cannot be denied." Those judged as (2) will be considered to be
37 "adverse events for which a relationship with this study can be denied."
38
39

- 40 ① Related, ② Unrelated, and ③ Unknown

41 42 43 44 45 **12.3.4 Classification of Outcomes**

- 46 ① Recovery: Normalization or recovery to a level at which it is no longer
47 considered to be an adverse event
- 48 ② Improvement: Not normalized, but symptoms have improved
- 49 ③ Recovery (with after effects): Recovery, but residual dysfunction that impairs
50 activities of daily living
- 51 ④ Non-recovery: Not recovered at this point
- 52 ⑤ Unknown: Outcome is unknown as subjects have stopped visiting the hospital
- 53 ⑥ Death

12.3.5 Other Classifications

- Status of riociguat (1: continuation, 2: discontinuation)
- Repeat BPA (1: yes, 2: no)
- Were appropriate actions required? (1: yes, 2: no)

12.4. SAEs and Unexpected SAEs

Regardless of the cause-and-effect relationship with the clinical study drug, this section pertains to undesirable or unintended signs, symptoms and disorders that occur in subjects, as well as SAEs that meet the criteria described in “Ethical Guidelines for Medical and Health Research Involving Human Subjects (Dec. 22, 2014; Ministry of Education, Culture, Sports, Science and Technology/Ministry of Health, Labour and Welfare; Chapter 1, Part 2).” Among SAEs, those that are not described in the clinical study protocol, drug agent package insert, or pharmaceutical interview form or those that are documented but for which properties or severity differs from the documentation will be treated as “unexpected SAEs.”

Regardless of the cause-and-effect relationship with BPA or riociguat, if an SAE or unexpected SAE occurs during the study period, the investigators or responsible investigators will immediately offer appropriate treatment to the subject.

[SAEs]

- 1) SAEs resulting in death
- 2) Life-threatening SAEs
- 3) SAEs requiring hospitalization or extended hospitalization for treatment
- 4) SAEs causing permanent or marked impairment/dysfunction
- 5) SAEs causing a congenital anomaly in the offspring

12.5. Reporting (Immediate Reporting) of and Response to SAEs

- If an adverse event (SAE or unexpected SAE) requiring immediate reporting occurs during the study period, regardless of the cause-and-effect relationship with BPA or riociguat, the investigators must take necessary measures in accordance with the “Ethical Guidelines for Medical and Health Research Involving Human Subjects (Dec. 22, 2014; Ministry of Education, Culture, Sports, Science and Technology/Ministry of Health, Labour and Welfare)” and established procedures at the research institution: providing an explanation to the subjects and reporting the matter to the appropriate head of the institution with authority or to the Institutional Review Board. If this was an unexpected

1
2
3
4
5
6 SAE in which a cause-and-effect relationship with BPA or riociguat cannot be
7 denied, it must be promptly reported to the Minister for Health, Labour and
8 Welfare in accordance with procedure at the research institution
9

- 10 ● Within 24 h of learning about an adverse event, investigators must report this
11 to the Research Support Center. The Research Support Center will immediately
12 gather relevant information and submit a report to the principal investigator and
13 Safety Monitoring Committee. Similarly, the Research Support Center will report
14 this to the responsible investigators at the collaborating research institutions.
15
- 16 ● The principal investigator will consult with the Central Committee and the Safety
17 Monitoring Committee and determine whether to continue the study or make
18 any changes to the protocol. This will be reported to the collaborating research
19 institutions, and necessary measures will immediately be taken. Moreover, if the
20 principal investigator considers the event to be highly urgent, the principal
21 investigator will take necessary measures without waiting for an evaluation by
22 the Central Committee or the Safety Monitoring Committee.
23
24
25
26
27
28
29

30 **12.6. Provision of New Information to Study Subjects**

31 If investigators become aware of new information related to this clinical study, the
32 investigators will provide follow-up explanations to subjects and, if necessary,
33 revise the informed consent document/consent form.
34
35
36
37

38 **13. TERMINATING SUBJECT PARTICIPATION OR DROPOUT**

39
40 If, for the reasons listed below, the investigators determine that a subject can no
41 longer continue to participate in the study, necessary measures such as
42 discontinuing administration of the study drug will be immediately taken. Data on
43 the subject will be handled as data of a "study termination case." The date, time
44 point in the study, reason for termination, and the subject's course of the disease
45 will be entered into the EDC system. Necessary tests will also be performed upon
46 termination. The efficacy and safety of the subject's treatment will be evaluated
47 at this point. Moreover, even if the subject's participation is terminated, excluding
48 cases in which a request is made to withdraw informed consent, items to be
49 evaluated will be followed up as much as possible for the purpose of analyzing
50 safety. If informed consent was withdrawn, no data on the subject, including data
51 that has already been collected, except for data related to study termination, such
52 as the termination date or reason, will be used for analysis.
53
54
55
56
57
58
59
60

1
2
3
4
5
6 If it becomes difficult to follow-up subjects, their data will be treated as a “dropout
7 case.”

8
9 Subjects who use contraindicated drugs will be handled as “study termination
10 cases,” although follow-up observations will be continued.
11
12

- 13
14 ① If the subject or their legal representative declines to participate in the study or
15 requests the withdrawal of consent
16
17 ② If the investigators determine that continuing the study would harm the health
18 of the subject
19
20 ③ If riociguat needs to be discontinued for some reason or administration is
21 banned
22
23 ④ If pregnancy is detected or breastfeeding has started
24
25 ⑤ If the study itself is discontinued
26
27 ⑥ If, for any reason, the investigators consider it appropriate to terminate study
28 participation
29

30 **14. DATA MANAGEMENT**

31 **14.1. Data Management**

32
33 The processes of data collection and management will be performed by
34 third-party entities for data without bias. Data management in this study will be
35 performed by Soiken Inc., Data Management Group (Data Center). Before
36 performing data management, the Data Center will prepare a “Procedure Manual
37 for Data Management.”
38

39
40 Linkable anonymization with central number registration will be used to identify
41 the subjects. The investigators will be responsible for appropriately storing the
42 correspondence table prepared by them to identify subjects in accordance with
43 the procedures at the research institution. This correspondence table must be
44 retained for up to five years after the completion of the study or three years after
45 the final publication of the study, whichever comes later.
46
47

48
49 For displaying and publicly disclosing all information related to the study,
50 appropriate measures will be taken, such as encoding or deletion, to ensure that
51 the subjects cannot be identified in accordance with applicable laws and
52 regulations.
53

54
55 The Data Center’s approval is required prior to sending data related to the
56 subjects in an electronic format. If transmitting data over an unsecured electronic
57
58
59
60

1
2
3
4
5
6 network, the data must be encoded at the source.
7
8

9 **14.2. Handling of Data for the Determination of Operability**

10 The investigators will store data necessary for determining the operability of the
11 subjects on paper and electronic media (such as CD-R disks) without including any
12 personal information and present it to the Data Center. The Data Center will save
13 a backup of the data and present it to the surgeon determining operability.
14 Feedback will be given to the investigators via the Data Center on whether the
15 subject is suitable for undergoing surgery.
16
17
18
19

20 **14.3. Handling of Subject Data**

21 In this study, the EDC system will be used to collect clinical data. The clinical data
22 for each subject will be accurately entered into the EDC system in accordance with
23 the protocol of the investigators at the research institutions. The investigators who
24 will enter required information for the study into the EDC system will be
25 responsible for ensuring accuracy and completeness of the information.
26
27
28
29

30 If data that have already been submitted require revision, a "Fixed Data Change
31 Request" or query is generated. When accessing the EDC system, each
32 investigator must have a login ID and password.
33

34 Moreover, when direct input into the EDC system is difficult for reasons such as
35 the IT environment of the EDC system at the research institution, a case report
36 form (CRF) should be used. In this case, the CRF should also be submitted by the
37 investigators to the Data Center.
38
39

40 The CT, CXR, and echocardiography data submitted to the Data Center for storage
41 from each research institution should not contain personal information of the
42 subject. The Data Center then forwards the data to the Core Laboratory.
43
44
45

46 **14.4. Handling of EQ5D (QOL) Data**

47 As a general rule, the QOL scores assessing the psychological state of the subjects
48 are directly mailed by the subjects to the Data Center using a specialized QOL
49 questionnaire (EQ5D). If subjects find it difficult to mail the questionnaire, the
50 investigators will collect sealed questionnaires, which prevent the responses of the
51 subjects from being seen, for submission to the Data Center. The Data Center
52 enters the data into the EDC system and database for storage.
53
54
55
56
57
58
59
60

14.5. Creation of Data Sets

The Data Center will store all data collected for this study in an independent database. The Data Center will convert the data to fixed data in accordance with the standards determined by the Data Handling Committee before data fixation. The following three data sets will be created prior to analysis:

- ① Creation of the full analysis set (FAS) for analysis
- ② Creation of the per protocol set (PPS) for analysis
- ③ Creation of the Safety Evaluation Analysis data set

15. MONITORING

15.1. Monitoring

In this study, the Soiken Inc., Data Management Group will perform monitoring to manage and ensure quality. The monitoring manager will monitor the subjects in accordance with the manual on the monitoring procedure. For data quality management, the principal investigator and Central Committee will confirm the progress of the study, as necessary, through the Soiken Inc., Data Management Group to ensure that the study is being conducted in accordance with the protocol and the Ethical Guidelines for Medical and Health Research Involving Human Subjects (Dec. 22, 2014; Ministry of Education, Culture, Sports, Science and Technology/Ministry of Health, Labour and Welfare). Appropriate measures will be taken to prevent any deviation from the protocol and from regulatory and human subject guidelines. The monitoring manager will regularly generate monitoring reports for submission to the Central Committee.

The collaborating research institutions will manage and maintain the following information to respond to the requests from the monitoring in this study or the Institutional Review Board.

- (1) Source documents for EDC creation or CRF entry
 - *Medical records, nursing records, test data, medication records, etc.
- (2) Informed consent records showing that the subject consented to participate in this study

15.2. Source Document Verification (SDV)

When necessary, the monitoring manager will directly view records related to the study for SDV and confirm that the study is being appropriately implemented as

well as the reliability of the data. Head and responsible investigator in research institutions and collaborating research institutions will ensure that the direct viewing of records related to the study can be done in response to requests from the monitoring manager. The person performing SDV must do so under the following conditions: 1) permission has been received for this study from the head of the research institution and approval has been obtained from the Institutional Review Board and 2) SDV is conducted in accordance with procedure of the research site after confirming that appropriate consent has been received from the subjects.

16. PLANNED ENROLLMENT OF SUBJECTS AND RATIONALE

16.1. Planned Enrollment of Subjects

Total of 60 inoperable CTEPH subjects

Group A: BPA group: 30 subjects

Group B: Riociguat group: 30 subjects

16.2. Rationale for Planned Enrollment of Subjects

Previously, BPA resulted in a reduction in mean pulmonary arterial pressure from 45.4 ± 9.6 to 24.0 ± 6.4 mm Hg in 24 months³), while riociguat decreased the pulmonary arterial pressure by 4 ± 7 mm Hg¹). Based on these studies, the change in mean pulmonary arterial pressure from the start of treatment to 12 months later was assumed to be -15 mmHg in the BPA group and -4 mmHg in the riociguat group, and the standard deviation for each change was assumed to be 14 for the BPA group and 10 for the riociguat group. The minimum sample size required to achieve a significance of 0.05 for a two-sided test with a statistical power at 90% is determined to be 27 subjects for both groups, indicating a total of 54 subjects. With the dropout rate estimated to be 10%, the planned enrollment was set at 30 subjects for both groups, for a total of 60 subjects.

17. STATISTICAL ANALYSIS

17.1. Allocation Factor

In aligning important subject background attributes between the two groups, the mean pulmonary arterial pressure and research institution will be used as allocation factors. Random assignment will be performed centrally with

1
2
3
4
5
6 stratification by mean pulmonary arterial pressure (<40 mmHg and ≥40 mmHg)
7 and research institutions (Keio University, Okayama Medical Center, Kyusyu
8 University, and Kobe University) by the minimization method with biased coin
9 assignment.
10
11
12

13 **17.2. General Approach for Analysis**

14 The analyses of the primary and secondary efficacy endpoints will be performed
15 using the full analysis set, which will include all patients who underwent
16 randomization and received at least one dose of a study drug and had at least one
17 assessment after baseline. Safety analysis will be conducted in the safety analysis
18 population. All p-values will be two sided. P-values <0.05 will be considered
19 statistically significant. All statistical analyses will be performed using SAS
20 software version 9.4 (SAS Institute, Cary, NC, USA). The statistical analysis plan
21 will be developed by the principal investigator and the biostatistician before
22 completion of patient recruitment and data fixation.
23
24
25
26
27
28
29

30 **17.3. Subject Background Analysis**

31 Subject background data distribution and summary statistics will be calculated for
32 both groups. The frequency distribution and proportion of nominal variables will
33 be shown for both groups. The summary statistics (number of subjects, mean
34 value, standard deviation, minimum value, median value, and maximum value) of
35 the continuous variables will be calculated per group. For the comparison between
36 the groups, Fisher's exact test will be used for nominal variables to determine
37 whether the proportions for one variable are different among those of the other
38 variable. For continuous variables, Student's *t*-test will be used.
39
40
41
42
43
44

45 **17.4. Primary Endpoint Analysis**

46 The primary endpoint for efficacy will be the change in the mean pulmonary
47 arterial pressure from the baseline to 12 months. Comparisons will be made
48 between the two groups. Comparisons will be made by testing the null hypothesis
49 that the change will be equal in both groups. Using analysis of covariance with
50 both groups as the fixed effect and the allocation adjustment factor (mean
51 pulmonary arterial pressure before starting the study and the research institute)
52 as the covariance, the null hypothesis that the degree of change in the mean
53 pulmonary arterial pressure is identical between the two groups will be tested.
54
55
56
57
58
59
60

1
2
3
4
5
6 value, standard deviation, minimum value, median value, and maximum value)
7 will also be calculated.

8
9 For sensitivity analysis, changes in the mean pulmonary arterial pressure over
10 time in both groups will be presented. With an unstructured correlation structure,
11 chronologically measured data will be analyzed using the mixed effects model for
12 repeated measures. In this case, the fixed-effect factors consist of treatment
13 effects, effect timing, and correlation between treatment and timing. The
14 random-effect factors are subjects who were nested with the group effect.
15 However, if the correlation structure is unstructured and the calculation results
16 cannot be converged, composite symmetry will be used.
17
18
19
20
21

22 **17.5. Secondary Endpoint Analysis**

23 For each secondary endpoint, the measurement values, change, and summary
24 statistics (number of subjects, mean value, standard deviation, minimum value,
25 median value, and maximum value) will be calculated at each measurement point
26 and compared between the two groups. The chi-square test or Fisher's exact test
27 will be used for nominal values and Student's *t*-test or Wilcoxon sum rank test will
28 be used for continuous variables. In terms of safety, lists of all adverse events will
29 be made for both groups. If necessary, inter-group comparisons will be conducted
30 using Fisher's exact test. Lists will also be made of clinical worsening seen during
31 the observation period in the two groups. If necessary, K-M plots will be prepared
32 for each instance of clinical worsening, and inter-group comparisons will be
33 performed using the log-rank test. The hazard ratio will be estimated with Cox
34 regression.
35
36
37
38
39
40
41
42

43 **17.6. Interim Analysis**

44 No interim analysis will be conducted in this study.
45
46
47

48 **18. PROTOCOL APPROVAL, STUDY INITIATION, AND PROTOCOL**

49 **CHANGES**

50 **18.1. Protocol Approval**

51 In preparing the protocol for this clinical study, a rough draft will be created by
52 the Central Committee. During this process, members of the committee must
53 agree to the aims of this study and prepare the protocol so that the study can be
54
55
56
57
58
59
60

1
2
3
4
5
6 smoothly executed. Following this step, a medical statistician and the Central
7 Committee will examine the protocol. Once it has been approved by the principal
8 investigator, the document will be considered as the official protocol. This protocol
9 will be followed when conducting this study after receiving approval from the
10 Institutional Review Board of the research institution (medical facility) to which
11 the principal investigator belongs. See "18.3 Protocol Changes" regarding any
12 changes to be made to the protocol after approval has been received.

13
14
15
16 Even at a collaborating research institution, the protocol, as well as other
17 necessary materials, must be approved by the head and the Institutional Review
18 Board of the collaborating research institution prior to participating in the study
19
20 When approval has been received from the Institutional Review Board of the
21 collaborating research institution, a copy of the approval document will be sent to
22 the Research Support Center for storage. Annual updates of the screening and
23 approval by the Institutional Review Board regarding the protocol of this study will
24 be conducted in accordance with the regulations at each research institution.
25
26
27
28
29

30 **18.2. Study Initiation**

31 This study will be initiated with the permission of the head of each research
32 institution after approval has been received from the Institutional Review Board.
33
34

35 **18.3. Protocol Changes**

36
37 If necessary, the principal investigator will determine whether changes to the
38 protocol are required.
39

40 If a change to the protocol is necessary, the principal investigator will amend* or
41 revise** the protocol after discussion with the Central Committee. After
42 amendment/revision, a report will be promptly made to the responsible
43 investigators in the collaborating research institutions so that appropriate steps to
44 implement this change can be initiated at the collaborating research institutions.
45
46

47 *A change to an item that could increase the risk to subjects or is related to the
48 primary endpoint
49

50 **A change to an item that will not increase the risk to subjects and will not affect
51 the primary endpoint
52
53

54
55 If a change is made to the protocol after the study is initiated, the Research
56 Support Center will inform the collaborating research institutions of this change. If
57 any major changes are made to the protocol, the clinical study may not be
58
59
60

1
2
3
4
5
6 restarted at the collaborating research institutions until approval has been
7 received from the head and Institutional Review Board or an equivalent committee
8 or organization of the collaborating research institution.
9
10
11
12

13 **19. STUDY CLOSURE AND PREMATURE TERMINATION**

14 **19.1. Study Closure**

15
16 Once this study has been completed, the principal investigator will report on the
17 closure of the study to the responsible investigators at each collaborating research
18 institution. The responsible investigators will then report on the closure of the
19 study to the head and Institutional Review Board of the collaborating research
20 institution.
21
22
23
24
25

26 **19.2. Premature Study Termination**

- 27
28 1) If the principal investigator determines that it is difficult to continue the study
29 for an unavoidable reason, such as one of the reasons shown below, a
30 discussion will be held with the Central Committee to decide whether the study
31 can be continued. If a decision is made that it would be inappropriate to
32 continue with the study, the principal investigator will communicate the
33 premature termination, reasons, and how to respond to the needs of the
34 subjects as quickly as possible to the responsible investigators in all
35 collaborating research institutions and implement any necessary measures.
36
37 ① If serious information related to the quality, safety, or efficacy of the study drug
38 or medical material involved in the study is received
39
40 ② If there is difficulty in recruiting subjects and achieving the enrollment target
41 number is difficult
42
43 ③ If the purpose of the study is achieved before reaching the planned enrollment
44 number or the end of the planned study period
45
46 ④ If a directive such as a change to the protocol is received and it is determined
47 to be difficult to accept this change
48
49 ⑤ If an event occurs that is judged to markedly detract from the appropriateness
50 of implementing the study or the reliability of the study results
51
52 2) If the responsible investigators in the collaborating research institutions report
53 this in writing to the head of the collaborating research institution or
54 Institutional Review Board and the study is swiftly terminated prematurely,
55
56
57
58
59
60

appropriate measures, such as contacting the subjects, will be taken.

20. HUMAN RIGHTS AND INFORMED CONSENT OF SUBJECTS

20.1. Protection of Subjects and Rules Requiring Observance

All subjects involved in this study must obey the WMA Declaration of Helsinki (revised in 2013) and the Ethical Guidelines for Medical and Health Research Involving Human Subjects (Dec. 22, 2014; Ministry of Education, Culture, Sports, Science and Technology/Ministry of Health, Labour and Welfare) as well as all applicable laws and regulations.

20.2. Informed Consent

When participating in this study, the investigators must offer explanations regarding the objectives of the study using informed consent document and consent form approved by the Institutional Review Board and obtain written consent based on sufficient subject understanding. If it is difficult to obtain informed consent from the subjects, they cannot be enrolled in the study as consent cannot be obtained via a proxy. To prevent potential subjects from being subjected to any disadvantages, the following points will be included in the informed consent document: (1) that participation in this study is based on their free will, (2) that consent can be withdrawn after it is provided, and (3) that care will be taken to prevent subjects from suffering any disadvantages as a result of discontinuing their participation. This should prevent any limitations from being placed on the subjects' rights to self-determination in choosing medical treatment. As this study will not exceed the range of normal medical treatment, this will not be mentioned on the form; however, if special instructions are received from the Institutional Review Board or medical facility director regarding the methodology or details of obtaining informed consent from the subjects, this limitation is not applicable.

The investigator who provides the explanation to a potential subject will create two copies of the consent forms with their signature or name, date, and seal. One copy will be given to the subject, while an original copy will be kept with the subject's medical records at the research institution. The consent forms will be appropriately stored at the research institution for five years after the study has been completed or three years after the final publication of this study, whichever comes later.

1
2
3
4
5
6 If a subject chooses to revoke his/her consent during the study, all existing data
7 provided by the subject for this study will be destroyed.
8
9

10 Items recorded on the informed consent document:

- 11 ① The study title and language that states that implementation has been
12 approved by the head of the research institution
- 13 ② The research institution title and responsible investigator's name
- 14 ③ The study purpose and significance
- 15 ④ The study methods including the purpose of obtaining specimens and
16 information from the subjects and the study schedule
- 17 ⑤ Reasons the subject is being selected
- 18 ⑥ Period of study participation, the points that subjects must adhere to during the
19 study, and cautionary notes
- 20 ⑦ Burden and predicted risks and benefits for the subjects
- 21 ⑧ That consent can be revoked by the subject at any time even after consenting
22 to study participation or continuation (if there are situations in which it is
23 difficult to execute the measures in accordance with the revocation of consent,
24 these situations and reasons should be described)
- 25 ⑨ No disadvantages will be suffered by the subject by not consenting to study
26 participation or continuation or by revoking consent
- 27 ⑩ Methods of disclosure of information related to the study
- 28 ⑪ In response to a request by a subject, the protocol and materials related to the
29 study methods can be obtained and viewed as long as this does not impede the
30 protection of other subjects' personal information or the assurance of this
31 study's originality (include the methods of acquisition/viewing)
- 32 ⑫ Handling of personal information (anonymization)
- 33 ⑬ Methods of specimen/information storage and disposal
- 34 ⑭ The study's funding source, conflicts of interest related to the study facilities,
35 and conflicts of interest related to the investigators (e.g., personal profits)
- 36 ⑮ Response to consultations from subjects and other related parties and
37 communication channels for inquiries
- 38 ⑯ Existence of compensation for any health damage that occurs as a result of the
39 study and details of such compensation
- 40 ⑰ While protecting subject confidentiality, people engaged in monitoring and the
41 Institutional Review Board will be able to view the specimens and data provided
42 by the subjects as necessary
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3
4
5
6 ⑱ The research results will be made public after processing them in an
7 appropriate manner so that the subjects cannot be identified
8
9 ⑲ Entitlement to intellectual property and patent rights
10
11 ⑳ Economic burden or any rewards to the participants and the details
12

13 **20.3. Handling of Personal Information**

14 All people involved in this study must obey all relevant laws, such as the “Act on
15 the Protection of Personal Information,” pertaining to all personal information
16 obtained from the subjects and will not divulge any of this information without a
17 valid reason. The same restriction applies even after parties involved in the study
18 have left their post. When handling any source materials or consent forms related
19 to this study, sufficient care must be taken to protect the confidentiality of the
20 subjects. People not associated with the research institution must not be involved
21 in the entering of information into the EDC system that could identify the subjects
22 (e.g., names, addresses, phone numbers, or medical record numbers) or the
23 recording of such information in CRFs or QOL score questionnaires.
24

25 When the Data Center makes inquiries to the research institutions, central record
26 numbers are used. The investigators should use a subject differentiation
27 management table (correspondence table) to identify the subject. The
28 investigators should carefully and appropriately store the correspondence table at
29 the research institute for five years after the study has been completed or three
30 years after the final publication of this study is released, whichever comes later.
31 The person responsible for managing personal information at each research
32 institution is the responsible investigator.
33

34 While it is planned that the results obtained in this study will be presented at
35 academic conferences and in medical journals, sufficient care will be taken to not
36 include any information that could identify the subjects (e.g., subjects’ names).
37 Data from subjects obtained in this study will not be used for non-research
38 purposes.
39
40
41
42
43
44
45
46
47
48
49

50 **21. SUBJECT BURDENS, POTENTIAL RISKS AND BENEFITS,**

51 **MEASURES TO MINIMIZE BURDENS AND RISKS, AND**

52 **COMPREHENSIVE EVALUATION**

53
54
55

56 **21.1. Subject Burdens and Potential Risks**

57 As all treatments in this study are covered by national health insurance, the
58
59
60

1
2
3
4
5
6 subjects will be subjected to a cost burden within the range of national health
7 insurance applicability. Moreover, because most tests in this study are the same
8 tests and treatment used in routine medical practice, there are no particular risks.
9 As riociguat and BPA are currently routinely conducted for inoperable CTEPH
10 subjects, no particular disadvantages are associated with this study, and it
11 appears that the level of risk will not exceed that of normal medical treatment.
12 The associated tests other than the QOL score questionnaires (EQ5D) of the
13 subjects are all conducted in general clinical practice and will not cause any special
14 burden to the subject.
15
16
17
18
19

20 **21.2. Potential Benefits**

21
22 As the subjects will receive the same treatment as that offered in routine clinical
23 treatment, they will not receive any particular treatment benefits. However, the
24 responsible investigators (investigators) will provide a 5,000 Quo card to each
25 subject for their cooperation at baseline and at each observation point (a total of
26 two times) during the 12 months.
27
28
29
30

31 **21.3. Measures to Minimize Burdens and Risks**

32
33 In this study, from the standpoint of protecting the subjects, the investigators as
34 well as the surgeon determining operability will judge the treatment strategy for
35 each subject to ensure the most appropriate treatment. The test items were
36 reduced as much as possible to reduce the burden on the subjects.
37
38

39 As this study will be conducted using approved existing drugs and all treatments
40 will be the general treatments performed in routine clinical practice, as a general
41 rule, no special compensation will be offered for health damage caused by the
42 study drug. Any damages will be treated in an identical manner as health damage
43 or a medical accident that occurs during the course of routine clinical treatment.
44 Any such compensation will be offered in accordance with the Relief System for
45 Victims of Side Effects of a Drug of the Pharmaceuticals and Medical Devices
46 Agency, the Product Liability Act, and completed operations liability insurance.
47

48 However, the principal investigator will represent the investigators and apply for
49 clinical study insurance offered by an insurance company in case of any health
50 damage not related to treatment that occurs as a result of the study design.
51

52 The investigators will carefully observe the subjects' symptoms and conditions and
53 strive to reduce all burdens and risks, including discomfort and fatigue associated
54 with testing during observations with measures, including breaks.
55
56
57
58
59
60

21.4. Comprehensive Evaluation

This study will place little burden on the subjects, and there are no foreseen risks exceeding those observed in routine clinical practice. Although there will be no direct benefits for the subjects, this study may contribute to improving the disease pathophysiology and further developing the field of medicine.

22. RESPONDING TO REQUESTS FOR CONSULTATIONS FROM SUBJECTS AND RELATED PARTIES

If consultation requests regarding this study are received from subjects or other related parties, the investigators will respond rapidly and with sincerity. If the investigators find it difficult to respond, the responsible investigator should consult the principal investigator, Central Committee, or Research Support Center, after which rapid measures will be taken based on an investigation on determining how to respond. If necessary, the responsible investigators should also report on consultations with the subjects or related parties to collaborating research institutions and responsible investigators through the Research Support Center.

23. PROTOCOL FOR REPORTING TO HEADS OF RESEARCH INSTITUTIONS (CONTENT AND METHOD)

In accordance with the rules of the affiliated research institution, the investigators should directly report to the head of the research institution or through the Institutional Review Board for the following points mentioned below. Based on the content of such a report, the principal investigator will hold discussions with the Central Committee and the Safety Monitoring Committee and consider measures (e.g., premature termination of the study) as necessary.

- Progress of the study and findings related to efficacy and safety obtained at the time reporting
- Occurrence of any SAEs or unexpected SAEs
- Receipt of any serious complaints from the subjects or other events that could impede the continuation of the study
- Occurrence of any serious risks from the standpoint of respecting the subjects' human rights or implementation the study
- Any facts, information, or risks that detract from the appropriateness of implementing the study or the reliability of study results

- Changes to the protocol
- Report on study closure
- Any other instructions from the head of the research institution or Institutional Review Board

24. SPECIMEN AND DATA STORAGE AND DISPOSAL METHODS

The responsible investigators and investigators must appropriately store all necessary documents related to the implementation of the study [application form copies, written notifications from the heads of the research institutions, application and report copies, subject management table (correspondence table), consent forms, and other documents or records required to ensure the reliability of data] in a locked cabinet for five years after it is reported that the study has been completed or three years after the final publication of this study is released, whichever comes later. Following this period, the data must be destroyed in accordance with the procedure at the research institution.

The Data Center must also store necessary information and data sets related to this study in an electronic format. Data present after the storage period must be destroyed after implementing necessary measures to ensure that they cannot be recovered. No particular specimens need to be stored for this study. Blood samples and other data will be destroyed in accordance with the procedures of the research institution after the results are converted to raw data. As a general rule, data collected during this study cannot be used for research that has a completely different purpose. If the data are to be used in a new study, a new application must be made to the Institutional Review Board of the said research institution.

25. METHODS OF DISCLOSURE OF STUDY-RELATED INFORMATION

Before the first subject is enrolled in this study, the details of the protocol must be registered on a public registration system (University Hospital Medical Information Network) and made public. The responsible investigators must implement updates, as necessary, because of changes in the protocol or the progress of the study; furthermore, they must register the results of the study without delay once it has been completed. The responsible investigators will make the results of this study public at a relevant academic society or in a report. Results should only be published after taking necessary measures to protect the human rights of the

1
2
3
4
5
6 subjects and related parties, as well as the rights and interests of those involved
7 in implementing the study. Upon the final publication of the results, a report must
8 be made to the head of the research institution without delay.
9

10 11 12 **26. STUDY FUNDING AND CONFLICTS OF INTEREST**

13 14 **26.1. Funding Provider**

15 This study will be funded by the company shown below in the form of research
16 outsourcing contract.
17

18
19
20 Bayer Yakuhin, Ltd.

21 BREEZE TOWER 2-4-9, Umeda, Kita-ku, Osaka 530-0001
22
23

24 25 **26.2. Conflicts of Interest**

26 The implementation or results of this study will not be affected by any related
27 parties or the funding provider. The study protocol, its implementation, and
28 details will be determined by the principal investigator. The funding provider will
29 not be involved in data analysis in any way, and no data will be provided to the
30 funding provider. The funding provider may utilize the results of this study,
31 including those related to safety; however, any funds not used in the research will
32 be quickly returned to the funding provider after study closure.
33

34 In accordance with the regulations at the collaborating research institution, parties
35 involved in this study will report on any necessary items to the Conflict of Interest
36 Committee established at each research institution for screening prior to approval.
37
38
39
40
41

42 43 **27. RULES REQUIRING OBSERVANCE**

44
45 This study will be conducted in accordance with the WMA Declaration of Helsinki
46 (revised in October 2013) and the Ethical Guidelines for Medical and Health
47 Research Involving Human Subjects (Dec. 22, 2014; Ministry of Education,
48 Culture, Sports, Science and Technology/Ministry of Health, Labour and Welfare).
49 The principal investigator and all other people involved in the study will protect
50 the confidentiality of the subjects during the implementation of this study.
51
52
53
54
55
56
57
58
59
60

28. ORGANIZATIONAL STRUCTURE OF THE CLINICAL STUDY

28.1. Principal Investigator

Keiichi Fukuda (Professor, Department of Cardiology, Keio University School of Medicine)

28.2. Central Committee

The Central Committee will supervise this study from the medical, scientific, and ethical viewpoints and co-ordinate with the collaborating research institutions and other parties involved in the implementation of this study. Any clerical functions based on decisions made by the Central Committee will be conducted by the Research Support Center. Regular reports must also be submitted to the Research Support Center, which will be supervised. In addition, on implementing this study, the Central Committee will record study details (e.g., test items) and prepare a rough draft for the protocol, including relevant laws that need to be followed.

- ① Prepare the protocol for this study and subsequently review as necessary.
- ② Act as the organizing unit of this study by determining its progress and understanding problems and solutions.
- ③ If feedback is received that there is a problem related to safety and that countermeasures should be taken, the appropriate methods and implementing countermeasures should be investigated.
- ④ Confirm the progress of this study as necessary and contact the collaborating research institutions in this study as necessary.
- ⑤ Work with medical statisticians and decide on methods for statistical analysis.
- ⑥ Determine the procedures and details related to this study that can be made public and editing material after determining which items will be made public.
- ⑦ Supervise external support companies.

Chairperson:

Keiichi Fukuda (Professor, Department of Cardiology, Keio University School of Medicine)

Members:

Hiroshi Matsubara (Director, Department of Cardiology, Okayama Medical Center)

Shun Kohsaka (Lecturer, Department of Cardiology, Keio University School of Medicine)

1
2
3
4
5
6 Masaharu Kataoka (Specially appointed lecturer, Department of Cardiology, Keio
7 University School of Medicine)
8
9 Takashi Kawakami (Specially appointed lecturer, Department of Cardiology, Keio
10 University School of Medicine)
11
12

13 **28.3. Collaborating Research institutions** *In Japanese alphabetical order

14 Department of Cardiovascular Medicine, Graduate (Responsible investigator:
15 School of Medical Sciences, Kyushu University Hiroyuki Tsutsui)
16
17 Department of Cardiology, Keio University School of (Responsible investigator:
18 Medicine Keiichi Fukuda)
19
20 Division of Cardiovascular Medicine/Department of (Responsible investigator:
21 Internal Medicine, Graduate School of Medicine, Kobe Kenichi Hirata)
22 University
23
24 Department of Cardiology, Okayama Medical Center (Responsible investigator:
25 Hiromi Matsubara)
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

28.4. Physician to Determine Operability

This physician will determine the eligibility of the subjects sent from the collaborating research sites via the Data Center and then inform each study site of the assessment.

Motomi Ando (Head of Department of Cardiac Surgery, Cardiovascular Center, Daiyukai General Hospital)

28.5. Data and Safety Monitoring Board (DSMB)

This independent organization is composed of three members who will not participate in this study. Based on information regarding adverse events etc., this organization will offer appropriate advice and recommendations to the principal investigator in order to protect the interests of subjects, ensure their safety, and maintain the ethical and scientific validity of implementing the study. It will monitor safety. The principal investigator will take necessary measures in accordance with any reports received from the DSMB.

Chairperson:

Hiroshi Ito (Professor, Division of Biophysiological Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University)

Members:

Hitoshi Ogino (Professor and Chairperson, Department of Cardiovascular Surgery, School of Medicine, Tokyo Medical University)

Toru Satoh (Professor, Division of Cardiology, Department of Medicine, Kyorin University Hospital)

28.6. Clinical Event Committee (CEC)

This committee is composed of three people who are not participating in this study: one cardiologist and two pulmonary cardiologists. The CEC ensures the scientific validity of the study by blindly evaluating whether important events presented by the responsible investigators at each collaborating research institution meet the standards of the protocol and maintains consistency and objectivity in the evaluation of events.

Chairperson:

Nobuhiro Tanabe (Specially appointed lecturer, Department of Respiriology, Graduate School of Medicine, Chiba University)

Members:

Fumio Sakamaki (Professor, Division of Respiratory Medicine, Department of Internal Medicine, School of Medicine, Tokai University)

Ken Kozuma (Professor, Department of Medicine, School of Medicine, Teikyo University)

28.7. Data Handling Committee

The Data Handling Committee blindly evaluates data that have deviated from the protocol and missing data prior to analysis and determines how all data will be handled. The members include the members of the Central Committee as well as the statistical analysis manager.

28.8. Biostatistician

The biostatistician will perform medical statistical discussions and analyses for this study and offer advice.

Biostatistician:

Yasunori Sato (Associate Professor, Department of Preventive Medicine and Public Health, Keio University School of Medicine)

28.9. Core Laboratory (CT, CXR)

Chest CT scan and CXR data should be submitted to the Core Laboratory and analyzed. Measurement results will be presented to Soiken Inc. (Data Center) using central registration numbers.

Core Laboratory (CT, CXR) managers:

Masahiro Jinzaki (Professor, Department of Diagnostic Radiology, Keio University School of Medicine)

Yoshitake Yamada (Assistant professor, Department of Diagnostic Radiology, Keio University School of Medicine)

28.10. Core Laboratory (Echocardiography)

Echocardiography (cardiac ultrasound) data will be presented to the Core Laboratory and analyzed. Measurement results will be presented to Soiken Inc. (Data Center) using central registration numbers.

Core Laboratory (Echocardiography) Manager:

Mitsushige Murata (Full-time lecturer, Department of Laboratory Diagnosis, Keio University School of Medicine)

28.11. Research Support Center (Data Center)

To implement this study, some duties will be outsourced to a Contract Research Organization. The Research Support Center will be responsible for executing the duties of overseeing this study in accordance with the instructions of the Central Committee. The Research Support Center will also conduct research office duties (e.g., computer allocation during registration) as well as monitor and handle data for each independent department.

Clinical Research Support Division, Soiken Inc.

4F, NBF Ogawa-machi Bldg. 1-3-1 Kanda Ogawa-machi, Chiyoda-ku, Tokyo 101-0052

29. REFERENCES

1) Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.

Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C; CHEST-1 Study Group.

N Engl J Med. 2013 Jul 25;369(4):319-29.

2) Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension.

Kataoka M, Inami T, Hayashida K, Shimura N, Ishiguro H, Abe T, Tamura Y, Ando M,

Fukuda K, Yoshino H, Satoh T.

Circ Cardiovasc Interv. 2012 Dec;5(6):756-62.

3) Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension.

Mizoguchi H, Ogawa A, Munemasa M, Mikouchi H, Ito H, Matsubara H.

Circ Cardiovasc Interv. 2012 Dec;5(6):748-55.

1
2
3
4
5
6
7 4) Balloon pulmonary angioplasty in patients with inoperable chronic
8 thromboembolic pulmonary hypertension.

9
10 Andreassen AK, Ragnarsson A, Gude E, Geiran O, Andersen R.
11 Heart. 2013 Oct;99(19):1415-20.
12

13
14 5) Right ventricular reverse remodelling after balloon pulmonary angioplasty.

15 Fukui S, Ogo T, Morita Y, Tsuji A, Tateishi E, Ozaki K, Sanda Y, Fukuda T, Yasuda
16 S,
17 Ogawa H, Nakanishi N.
18 Eur Respir J. 2014 May;43(5):1394-402.
19
20
21
22

23
24 6) Balloon pulmonary angioplasty: an additional treatment option to improve the
25 prognosis of patients with chronic thromboembolic pulmonary hypertension.

26 Taniguchi Y, Miyagawa K, Nakayama K, Kinutani H, Shinke T, Okada K, Okita Y,
27 Hirata KI, Emoto N.
28 EuroIntervention. 2014 Aug;10(4):518-25.
29
30
31

32
33 7) Significance of echocardiographic assessment for right ventricular function after
34 balloon pulmonary angioplasty in patients with chronic thromboembolic induced
35 pulmonary hypertension.

36 Tsugu T, Murata M, Kawakami T, Yasuda R, Tokuda H, Minakata Y, Tamura Y,
37 Kataoka M, Hayashida K, Tsuruta H, Maekawa Y, Inoue S, Fukuda K.
38 Am J Cardiol. 2015 Jan 15;115(2):256-61.
39
40
41
42

43
44 8) Percutaneous transluminal pulmonary angioplasty for the treatment of chronic
45 thromboembolic pulmonary hypertension: Challenges and future directions.

46 Dimopoulos K, Kempny A, Alonso-Gonzalez R, Wort SJ
47 Int J Cardiol. 2015 May 6;187:401-3.
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Multicenter randomized controlled trial of balloon pulmonary angioplasty and riociguat in patients with chronic thromboembolic pulmonary hypertension: Protocol for the MR BPA study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028831.R1
Article Type:	Protocol
Date Submitted by the Author:	31-May-2019
Complete List of Authors:	Kawakami, Takashi; Keio University, School of Medicine, Cardiology Matsubara, Hiromi; Okayama Medical Center Abe, Kohtaro; Kyushu University Kataoka, Masaharu ; Keio University, School of Medicine Kohsaka, Shun; Keio University, School of Medicine Sato, Yasunori ; Department of Preventive Medicine and Public Health, Keio University School of Medicine, Shinke, Toshiro; Showa University Fukuda, Keiichi; Keio University, School of Medicine
Primary Subject Heading:	Surgery
Secondary Subject Heading:	Cardiovascular medicine, Surgery
Keywords:	chronic thromboembolic pulmonary hypertension, balloon pulmonary angioplasty, riociguat

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 Multicenter randomized controlled trial of balloon pulmonary angioplasty and riociguat in
4 patients with chronic thromboembolic pulmonary hypertension: Protocol for the MR BPA
5
6
7
8 study
9
10
11
12
13

14 **Authors:**

15
16
17 Takashi Kawakami^{1*}, Hiromi Matsubara^{2*}, Kohtaro Abe³, Masaharu Kataoka¹, Shun
18
19 Kohsaka¹, Yasunori Sato⁴, Toshiro Shinke⁵, Keiichi Fukuda¹
20
21

22
23 * TK and HM equally contributed in this study.
24
25
26
27
28

29 **Affiliation:**

30
31
32 ¹ Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi,
33
34 Shinjuku-ku, Tokyo, 160-8582, Japan
35
36

37
38 ² Department of Cardiology, Okayama Medical Center, 1711-1, Tamasu, Kita-ku, Okayama,
39
40 Okayama, 701-1192, Japan
41
42

43
44 ³ Department of Cardiovascular Medicine, Kyushu University, 3-1-1 Maidashi, Higashi-ku,
45
46 Fukuoka 812-8582, Japan
47
48

49
50 ⁴ Department of Preventive Medicine and Public Health, Keio University School of
51
52 Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
53
54

55
56 ⁵ Division of Cardiovascular Medicine, Department of Internal Medicine, Showa University
57
58 School of Medicine, 1-5-8 Hatanaodai, Shinagawa-ku, Tokyo, 142-8666 Japan
59
60

1
2
3 **Corresponding author:**
4

5
6 Takashi Kawakami, MD
7

8
9 Department of Cardiology, Keio University School of Medicine, Tokyo, Japan
10

11
12 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
13

14
15
16 Tel: + 81-3-5843-6702, Fax: + 81-3-5363-3875
17

18
19 E-mail: kawakami.1650@gmail.com
20
21
22
23
24

25 **Acknowledgements:** The study was funded by Bayer Yakuhin Ltd.
26
27
28
29
30

31 **Keywords:** Chronic thromboembolic pulmonary hypertension, balloon pulmonary
32
33 angioplasty, riociguat
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction: The management of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) remains a clinical challenge. Medical treatment mainly involving pulmonary vasodilators (e.g. a soluble guanylate cyclase stimulator) is recommended for ameliorating their symptoms. More recently, balloon pulmonary angioplasty (BPA) has developed as alternative treatment modality for inoperable CTEPH. We aim to compare the efficacy and safety of BPA and riociguat, for the treatment of inoperable CTEPH.

Methods and Analysis: The study was designed as a multicenter randomized controlled trial for treatment of inoperable CTEPH. Subjects with inoperable CTEPH will be randomized (1:1) into either BPA or riociguat group, and observed for 12 months after treatment. The primary endpoint will be change in the mean pulmonary arterial pressure from baseline to 12 months. For the primary analysis, the least square mean difference in the change of pulmonary arterial pressure between BPA and riociguat group at 12 months and its 95% confidential interval will be estimated using an analysis of covariance (ANCOVA) model adjusted for allocation factors.

Ethics and Dissemination: This study was approved by the institutional review board of Keio University School of Medicine and each participating institution. Written informed consent will be obtained from all participants. Results of the study will be disseminated at medical conferences and journal publications.

Registration: This study was registered at the University Hospital Medical Information Network Clinical Trial Registry (UMIN-CTR) (UMIN000019549).

Strengths and Limitations of the Study:

- This is the first randomized controlled trial to compare the efficacy and safety of BPA and riociguat in patients with inoperable CTEPH.
- This study evaluates the efficacy and safety of BPA and riociguat for relatively longer observation period (12 months).
- This is also the first study to compare the health insurance resource costs between BPA and riociguat.
- The limitation of this study is that this is open-label trial.
- Another limitation of this study is that this study will recruit a relatively small number of study subjects.

Introduction

Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by which an organized thrombus causes stenosis and/or occlusion of the pulmonary arteries¹. Unless early diagnosis and appropriate treatment are performed, which causes death due to right-sided heart failure². Pulmonary endarterectomy (PEA) has been established as a curative treatment for operable CTEPH^{3,4}. According to the AHA/ACC⁵, ESC/ERS⁶, and JCS/JPCPHS⁷ guidelines, PEA is recommended for patients with operable CTEPH as the first line therapy in class of recommendation I and level of evidence C.

In 2014, a soluble guanylate cyclase stimulator (general name: riociguat), which is the pulmonary vasodilator, received insurance reimbursement approval for inoperable or persistent/recurrent CTEPH for the first time. This was based on the findings of a multicenter randomized clinical trial (CHEST-1)⁸ and its extension study (CHEST-2)⁹ indicating the efficacy of riociguat for subjects with inoperable CTEPH. Balloon pulmonary angioplasty (BPA), as catheter-based treatment, has also been reported to be effective for subjects with inoperable CTEPH¹⁰⁻²².

As described above, the two treatment modalities for inoperable CTEPH are riociguat and BPA. Riociguat and BPA are recommended for inoperable CTEPH patients in class of recommendation I and level of evidence B, and class of recommendation IIb and level of evidence C, respectively in 2015 ESC/ESR guidelines⁶ and in class of recommendation I and level of evidence B, and class of recommendation I and level of evidence C, respectively in 2017 JCS/JPCPHS guidelines⁷. Although BPA is associated with a certain level of risk of complications such as procedure related pulmonary artery injury, it can provide marked improvement when the treatment finished. On the other hand, riociguat is the most effective pulmonary vasodilator and have low risk of serious adverse events. Although it has been reported that sequential treatment with riociguat and BPA for inoperable CTEPH patients

1
2
3 significantly improved the mean pulmonary arterial pressure and pulmonary vascular
4 resistance²³, no reports have yet directly compared the treatment outcomes of these two
5
6 treatment methods. A randomized controlled trial to compare riociguat and BPA (RACE
7
8 study) is ongoing in France²⁴, which has been started at the almost same time with this
9
10 study²⁵. The present study was planned to compare the efficacy and safety of riociguat with
11
12 BPA in the treatment of inoperable CTEPH over the course of 12 months, to potentially aid
13
14 in optimizing treatment selection and improving treatment outcomes.
15
16
17
18
19
20
21

22 **Methods and Analysis**

23
24 **Study Design:** The Multicenter Randomized controlled trial based on Balloon Pulmonary
25
26 Angioplasty for chronic thromboembolic pulmonary hypertension (MR BPA) study will
27
28 enroll subjects from January 15, 2016 to October, 31, 2019. The study is designed as a
29
30 multicenter, prospective, randomized controlled trial. As shown in Figure 1, the subjects will
31
32 undergo right heart catheterization and pulmonary angiography before provisional
33
34 enrollment. An independent experienced PEA surgeon will determine if these subjects are
35
36 eligible to undergo PEA under blind circumstance. Those who are judged to have inoperable
37
38 CTEPH will be assigned into either BPA or riociguat group via an online assignment system
39
40 and observed for 12 months. In the BPA group, the degree of pulmonary hypertension
41
42 severity and the pulmonary lesion is morphologically evaluated by preoperative right heart
43
44 catheterization and pulmonary angiography. BPA is then conducted depending on the lesion
45
46 type. In general, BPA will be completed within 4 months after the initial BPA procedure. In
47
48 the riociguat group, riociguat will be initially administered three times per day at 1.0 mg per
49
50 dose. Using systolic blood pressure (95 mmHg or higher) as a guide, the dose will be
51
52 increased by 0.5 mg for each subject every two weeks with a thrice-daily administration of
53
54 2.5 mg/dose set as the maximum dosage. Dosage adjustment will be completed within 4
55
56
57
58
59
60

1
2
3 months after the first administration of riociguat, and the administration of riociguat will be
4 continued for total 12 months. The observations will be made at screening, baseline, 0-4
5 months, 6 months, and 12 months. Table 1 shows the schedule of assessments performed at
6 each visit for each treatment group, including mandatory and optional assessments.
7
8
9
10
11
12
13
14

15 **Sample size calculation:** Previously, BPA resulted in a reduction in mean pulmonary arterial
16 pressure from 45.4 ± 9.6 to 24.0 ± 6.4 mmHg in 24 months¹¹, while riociguat decreased the
17 pulmonary arterial pressure by 4 ± 7 mmHg⁹. Based on these studies, the change in mean
18 pulmonary arterial pressure from the start of treatment to 12 months later was assumed to be
19 -15 mmHg for the BPA group and -4 mmHg for the riociguat group, and the standard
20 deviation for each change was assumed to be 14 for the BPA group and 10 for the riociguat
21 group. The minimum sample size required to achieve a significance of 0.05 for a two-sided
22 test with a statistical power of 90% was determined to be 27 subjects for both groups,
23 indicating a total of 54 subjects. With the dropout rate estimated to be 10%, the planned
24 enrollment was set at 30 subjects for each group, for a total of 60 subjects.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 **Eligibility criteria:** *Inclusion criteria:* Patients meeting the following criteria will be
43 included in the study: (a) patients who are diagnosed with CTEPH (based on the diagnostic
44 criteria in the 2012 Japanese Circulation Society guidelines²⁴ with a WHO functional class II
45 or III). (b) male and female aged ≥ 20 years and < 80 years. (c) patients with mean pulmonary
46 arterial pressure of ≥ 25 mmHg to < 60 mmHg and pulmonary artery wedge pressure of ≤ 15
47 mmHg. (d) patients who undergo appropriate anticoagulant therapy for at least three months
48 prior to consent acquisition (if warfarin is used, prothrombin time-international normalized
49 ratio should be 1.5 to 3.0). (e) patients who provide written consent form to participate in this
50 study after full explanation of the study.
51
52
53
54
55
56
57
58
59
60

1
2
3 *Exclusion criteria:* Patients meeting any of the following exclusion criteria will be excluded
4 from the trial: (a) patients with a history of BPA. (b) patients who underwent PEA within six
5 months prior to consent acquisition. (c) patients who are using unapproved pharmaceutical
6 products. (d) patients who used a pulmonary vasodilator within four weeks prior to the right
7 heart catheterization after consent acquisition. (e) patients with co-existing etiology of
8 pulmonary hypertension other than Group 4 in the Nice Pulmonary Hypertension
9 Classification System. (f) patients who are pregnant or breastfeeding. (g) patients who met
10 the contraindication for riociguat. (h) patients whose life expectancy is less than two years. (i)
11 patients who are considered to be unsuitable for participation by investigators.
12
13
14
15
16
17
18
19
20
21
22
23
24
25

26 **Recruitment and consent:**

27
28 When subjects are determined to be able to participate in this study, the informed consent
29 document is used to give them a sufficient explanation of this study and their written consent
30 is then obtained. When obtaining consent, it is also explained that data related to pulmonary
31 angiography, right heart catheterization, and chest computed tomography (CT) scan from
32 within three months prior to acquiring consent, as well as pulmonary ventilation-perfusion
33 scintigraphy prior to acquiring consent, may be used for research purposes.
34
35
36
37
38
39
40
41

42 As a general rule, right heart catheterization and pulmonary angiography are performed after
43 acquiring consent and investigators determine whether each subject can be definitively
44 diagnosed with CTEPH. However, to reduce the burden on the subjects, data from within
45 three months prior to consent acquisition for pulmonary angiography, right heart
46 catheterization, and CT scan, as well as pulmonary ventilation-perfusion scintigraphy
47 obtained in general practice prior to consent acquisition, can also be utilized.
48
49
50
51
52
53
54

55 Based on the imaging data of the subjects who give their consent, an independent
56 experienced PEA surgeon who is not involved in this study will determine operability
57
58
59
60

1
2
3 (whether the subjects are eligible to undergo PEA). The standards for this determination of
4 operability will be based on the Guidelines for Treatment of Pulmonary Hypertension (2012
5 revised version)²⁶ and will be anatomically performed.
6
7
8
9

10
11
12 **Random allocation:** Random assignment will be performed centrally with stratification by
13 mean pulmonary arterial pressure (<40 mmHg and ≥40 mmHg), and research institutions
14 (Keio University, Okayama Medical Center, Kyusyu University, and Kobe University) by the
15 minimization method with biased coin assignment.
16
17
18
19
20
21
22

23
24
25 **Endpoints:** Primary endpoint will be the change in mean pulmonary arterial pressure from
26 baseline to 12 months. Secondary endpoints will include several clinical and quality of life
27 parameters. These are detailed in Table 2.
28
29
30
31
32
33

34 **Data collection:** An electronic clinical testing data collection system, electric data capture
35 system (EDC), will be used for data collection. In cases when the system is unavailable, a
36 case report form, a specialized data collection form, will be used and the data later entered
37 into the EDC. The investigators who will enter information into the EDC system will be
38 responsible for ensuring accuracy and completeness of the information.
39
40
41
42
43
44
45
46
47

48 **Data management and monitoring:** The processes of data collection and management will
49 be performed by third-party entities for data without bias. Data management in this study will
50 be performed by Soiken Inc., Data Management Group (the Data Center). Data Center will
51 prepare a “Procedure Manual for Data Management.” The Data Center’s approval is required
52 prior to sending data related to the subjects in an electronic format. If transmitting data over
53 an unsecured electronic network, the data must be encoded at the source. Linkable
54
55
56
57
58
59
60

1
2
3 anonymization with central registration number will be used to identify the subjects. The
4
5 investigators will be responsible for appropriately storing the correspondence table prepared
6
7 by them to identify subjects in accordance with the procedures at the research institution.
8
9

10 This correspondence table must be retained for up to five years after the completion of the
11
12 study or three years after the final publication of the study, whichever comes later. For
13
14 displaying and publicly disclosing all information related to the study, appropriate measures
15
16 will be taken, such as encoding or deletion, to ensure that the subjects cannot be identified in
17
18 accordance with applicable laws and regulations.
19
20

21 In this study, the Soiken Inc., Data Management Group will perform monitoring to manage
22
23 and ensure quality. The monitoring manager will monitor the subjects in accordance with the
24
25 manual on the monitoring procedure. For data quality management, the principal investigator
26
27 and Central Committee will confirm the progress of the study, as necessary, through the
28
29 Soiken Inc., Data Management Group to ensure that the study is being conducted in
30
31 accordance with the protocol and the Ethical Guidelines for Medical and Health Research
32
33 Involving Human Subjects (Dec. 22, 2014; Ministry of Education, Culture, Sports, Science
34
35 and Technology/Ministry of Health, Labour and Welfare).
36
37
38
39
40
41
42

43 **Adverse events:** Occurrence of any untoward medical events experienced by subjects,
44
45 including the worsening of a pre-existing underlying disease or a complication, will be
46
47 defined as adverse events. However, the worsening of efficacy evaluation indices will not be
48
49 defined as an adverse event. Any concomitant symptoms or clinically significant abnormal
50
51 fluctuations in test results will be investigated to determine whether there is a cause-and-
52
53 effect relationship with BPA or riociguat and findings will be documented in the EDC
54
55 system. As a general rule, adverse events will be followed up until normalization or recovery
56
57 occurs to a level at which it is not considered to be an adverse event or in case of an
58
59
60

1
2
3 irreversible adverse event (cerebral infarction, myocardial infarction etc.), until symptoms
4 stabilize or no longer change.
5
6
7
8
9

10 **Statistical Analysis:**

11
12 The analyses of the primary and secondary efficacy endpoints will be performed using the
13 full analysis set, which will include all patients who underwent randomization and received at
14 least one dose of a study drug and had at least one assessment after baseline. Safety analysis
15 will be conducted in the safety analysis population.
16
17
18
19

20
21 For the baseline variables, summary statistics will be constructed using frequencies and
22 proportions for categorical data, and means and standard deviations for continuous variables.
23
24 Patient characteristics will be compared using Pearson's chi-square test or Fisher's exact test
25 for categorical endpoints, and Student's t-test for continuous variables, as appropriate.
26
27
28
29

30
31 For the primary analysis, the least square mean difference in the change of pulmonary
32 arterial pressure between groups at 12 months and its 95% confidential interval will be
33 estimated using an analysis of covariance (ANCOVA) model adjusted for allocation factors.
34
35
36

37 The secondary analysis will be performed in the same manner as the primary analysis.

38
39 Adverse events will be evaluated during the safety analysis. The frequencies of adverse
40 events will be compared using Fisher's exact test. All comparisons are planned, and all *p*-
41 values will be two sided. *P*-values <0.05 will be considered statistically significant. All
42 statistical analyses will be performed using SAS software version 9.4 (SAS Institute, Cary,
43 NC, USA). The statistical analysis plan will be developed by the principal investigator and
44 the biostatistician before completion of patient recruitment and data fixation.
45
46
47
48
49
50
51
52
53
54
55
56

57 **Patient and Public Involvement**

58
59 No patient involved.
60

Discussion

Guidelines for diagnosis and treatment for CTEPH in Western countries^{5, 6} and Japan^{7, 26} recommend riociguat and BPA for inoperable CTEPH patients. However, no reports have yet directly compared the treatment outcomes of these two treatment methods. Sequential treatment with riociguat and BPA for inoperable CTEPH patients significantly improved the mean pulmonary arterial pressure and pulmonary vascular resistance, suggesting more benefits of BPA²³. Direct comparison of riociguat and BPA by a randomized controlled trial is also ongoing in France²⁴. The present study was therefore planned to compare the efficacy and safety of riociguat with BPA in the treatment of inoperable CTEPH, and has started at almost same time with the RACE study (both started from January, 2016)²⁵. Results from such randomized trials will be important for optimizing the treatment selection and improving treatment outcomes in inoperable CTEPH.

This study will complete BPA treatment in 4 months. This treatment period is almost as same as that under real-world condition in Japan. Also, this study will evaluate longer-term efficacy and safety of riociguat and BPA for 12 months after the start of the treatment.

Furthermore, recent systematic review showed that the treatment outcomes of BPA were greater in Japan than those in Western countries^{4, 27}. This study will be conducted in expert CTEPH centers in Japan. Therefore, this study will compare the treatment efficacy and safety of riociguat and the highest-quality BPA in Japan. In addition, the operability of PEA is determined under blind circumstance by an independent experienced PEA surgeon who belongs to independent institute. This will avoid bias on the subject enrollment. Furthermore, this study will also compare health insurance resource costs and patient-reported quality of life parameters for each of the therapies. These may contribute to optimize treatment strategy or further to amend treatment guidelines for inoperable CTEPH. These are the strengths of

1
2
3 this study. On the other hands, this study has several limitations. One limitation is that this is
4 open-label trial. Because there is no distinct criterion for BPA implementation in each lesion,
5 bias for BPA surgeons cannot be completely avoided. However, since this study will compare
6 medical treatment and surgical intervention, it is difficult to use placebo or to mask patients
7 and/or physicians. Another limitation is that relatively small number of patients will be
8 enrolled in this study (30 subjects for each group, for a total of 60 subjects).
9
10
11
12
13
14
15
16
17
18

19 **Ethics and Dissemination:** This study was approved by the institutional review board of
20 Keio University School of Medicine and each participating institution and will be conducted
21 in accordance with the Declaration of Helsinki, Ethical Guidelines for Medical and Health
22 Research Involving Human Subjects issued by the Ministry of Health, Labor and Welfare in
23 Japan, and other current legal regulations in Japan. Written informed consent will be obtained
24 from all participants after a full explanation of this study. Results of the study will be
25 disseminated at medical conferences and journal publications.
26
27
28
29
30
31
32
33
34
35
36
37

38 **References**

- 39
40 1) Memon HA, Lin CH, Guha A (2016) Chronic Thromboembolic Pulmonary
41 Hypertension: Pearls and Pitfalls of Diagnosis. *Methodist Debakey Cardiovasc J.*
42 12:199-204
43
44
45
46 2) Nishimura R, Tanabe N, Sugiura T, Shigeta A, Jujo T, Sekine A, Sakao S, Kasahara Y,
47 Tatsumi K (2013) Improved survival in medically treated chronic thromboembolic
48 pulmonary hypertension. *Circ J.* 77:2110-2117
49
50
51
52
53 3) Madani MM (2016) Surgical Treatment of Chronic Thromboembolic Pulmonary
54 Hypertension: Pulmonary Thromboendarterectomy. *Methodist Debakey Cardiovasc J.*
55 12:213-218
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 4) Kim NH, Delcroix M, Jais X, Madani MM, Matsubara H, Mayer E, Ogo T, Tapson VF, Ghofrani HA, Jenkins DP (2019) Chronic thromboembolic pulmonary hypertension. *Eur Respir J.* 53:1801915
 - 5) McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, Moliterno DJ, Mukherjee D, Pohost GM, Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. *Circulation.* 119:2250-2294
 - 6) Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M (2016) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J.* 37:67-119
 - 7) Fukuda K, Date H, Doi S, Fukumoto Y, Fukushima N, Hatano M, Ito H, Kuwana M, Matsubara H, Momomura SI, Nishimura M, Ogino H, Satoh T, Shimokawa H,

- 1
2
3 Yamauchi-Takahara K, Tatsumi K, Ishibashi-Ueda H, Yamada N, Yoshida S, Abe K,
4
5 Ogawa A, Ogo T, Kasai T, Kataoka M, Kawakami T, Kogaki S, Nakamura M,
6
7 Nakayama T, Nishizaki M, Sugimura K, Tanabe N, Tsujino I, Yao A, Akasaka T, Ando
8
9 M, Kimura T, Kuriyama T, Nakanishi N, Nakanishi T, Tsutsui H (2019) Guidelines for
10
11 the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017). *Circ J.* 83:842-
12
13 945
14
15
16
17 8) Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E,
18
19 Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C; CHEST-1
20
21 Study Group (2013) Riociguat for the treatment of chronic thromboembolic pulmonary
22
23 hypertension. *N Engl J Med.* 369:319-329
24
25
26
27 9) Simonneau G, D'Armini AM, Ghofrani HA, Grimminger F, Hoeper MM, Jansa P, Kim
28
29 NH, Wang C, Wilkins MR, Fritsch A, Davie N, Colorado P, Mayer E (2015) Riociguat
30
31 for the treatment of chronic thromboembolic pulmonary hypertension: a long-term
32
33 extension study (CHEST-2). *Eur Respir J.* 45:1293-1302
34
35
36
37 10) Kataoka M, Inami T, Hayashida K, Shimura N, Ishiguro H, Abe T, Tamura Y, Ando M,
38
39 Fukuda K, Yoshino H, Satoh T (2012) Percutaneous transluminal pulmonary
40
41 angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. *Circ*
42
43 *Cardiovasc Interv.* 5:756-762
44
45
46
47 11) Mizoguchi H, Ogawa A, Munemasa M, Mikouchi H, Ito H, Matsubara H (2012)
48
49 Refined balloon pulmonary angioplasty for inoperable patients with chronic
50
51 thromboembolic pulmonary hypertension. *Circ Cardiovasc Interv.* 5:748-755
52
53
54
55 12) Andreassen AK, Ragnarsson A, Gude E, Geiran O, Andersen R (2013) Balloon
56
57 pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary
58
59 hypertension. *Heart.* 99:1415-1420
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 13) Fukui S, Ogo T, Morita Y, Tsuji A, Tateishi E, Ozaki K, Sanda Y, Fukuda T, Yasuda S, Ogawa H, Nakanishi N (2014) Right ventricular reverse remodelling after balloon pulmonary angioplasty. *Eur Respir J.* 43:1394-1402
 - 14) Taniguchi Y, Miyagawa K, Nakayama K, Kinutani H, Shinke T, Okada K, Okita Y, Hirata KI, Emoto N (2014) Balloon pulmonary angioplasty: an additional treatment option to improve the prognosis of patients with chronic thromboembolic pulmonary hypertension. *EuroIntervention.* 10:518-525
 - 15) Tsugu T, Murata M, Kawakami T, Yasuda R, Tokuda H, Minakata Y, Tamura Y, Kataoka M, Hayashida K, Tsuruta H, Maekawa Y, Inoue S, Fukuda K (2015) Significance of echocardiographic assessment for right ventricular function after balloon pulmonary angioplasty in patients with chronic thromboembolic induced pulmonary hypertension. *Am J Cardiol.* 115:256-261
 - 16) Dimopoulos K, Kempny A, Alonso-Gonzalez R, Wort SJ (2015) Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension: Challenges and future directions. *Int J Cardiol.* 187:401-403
 - 17) Ogawa A, Satoh T, Fukuda T, Sugimura K, Fukumoto Y, Emoto N, Yamada N, Yao A, Ando M, Ogino H, Tanabe N, Tsujino I, Hanaoka M, Minatoya K, Ito H, Matsubara H (2017) Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Results of a Multicenter Registry. *Circ Cardiovasc Qual Outcomes.* 10:e004029
 - 18) Kimura M, Kohno T, Kawakami T, Kataoka M, Tsugu T, Akita K, Isobe S, Itabashi Y, Maekawa Y, Murata M, Fukuda K (2017) Midterm Effect of Balloon Pulmonary Angioplasty on Hemodynamics and Subclinical Myocardial Damage in Chronic Thromboembolic Pulmonary Hypertension. *Can J Cardiol.* 33:463-470

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 19) Aoki T, Sugimura K, Tatebe S, Miura M, Yamamoto S, Yaoita N, Suzuki H, Sato H, Kozu K, Konno R, Miyata S, Nochioka K, Satoh K, Shimokawa H (2017) Comprehensive evaluation of the effectiveness and safety of balloon pulmonary angioplasty for inoperable chronic thrombo-embolic pulmonary hypertension: long-term effects and procedure-related complications. *Eur Heart J.* 38:3152-3159
- 20) Olsson KM, Wiedenroth CB, Kamp JC, Breithecker A, Fuge J, Krombach GA, Haas M, Hamm C, Kramm T, Guth S, Ghofrani HA, Hinrichs JB, Cebotari S, Meyer K, Hoepfer MM, Mayer E, Liebetrau C, Meyer BC (2017) Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. *Eur Respir J.* 49:1602409
- 21) Kawakami T, Ogawa A, Miyaji K, Mizoguchi H, Shimokawahara H, Naito T, Oka T, Yunoki K, Munemasa M, Matsubara H (2016) Novel Angiographic Classification of Each Vascular Lesion in Chronic Thromboembolic Pulmonary Hypertension Based on Selective Angiogram and Results of Balloon Pulmonary Angioplasty. *Circ Cardiovasc Interv.* 9:e003318
- 22) Ogo T, Fukuda T, Tsuji A, Fukui S, Ueda J, Sanda Y, Morita Y, Asano R, Konagai N, Yasuda S (2017) Efficacy and safety of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension guided by cone-beam computed tomography and electrocardiogram-gated area detector computed tomography. *Eur J Radiol.* 89:270-276
- 23) Wiedenroth CB, Ghofrani HA, Adameit MSD, Breithecker A, Haas M, Kriechbaum S, Rieth A, Hamm CW, Mayer E, Guth S, Liebetrau C (2018) Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. *Pulm Circ.* 8:2045894018783996

- 1
2
3 24) Riociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic
4 thromboEmbolic Pulmonary Hypertension (RACE). ClinicalTrials.gov identifier
5 NCT02634203. available at <https://clinicaltrials.gov/ct2/show/NCT02634203>. last
6 accessed at May 21st, 2019
7
8
9
10
11
12 25) Multicenter Randomized controlled trial based on Balloon Pulmonary Angioplasty for
13 chronic thromboembolic pulmonary hypertension (MR BPA study). UMIN-CTR ID:
14 UMIN000019549. available at [https://upload.umin.ac.jp/cgi-open-](https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022608)
15 [bin/ctr_e/ctr_view.cgi?recptno=R000022608](https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022608). last accessed at May 21st, 2019
16
17
18
19
20
21 26) Nakanishi N, Ando M, Ueda H, Ogino H, Saji T, Shiomi T, Tatsumi K, Date H,
22 Nishimura M, Fukushima N, Fukumoto Y, Momomura S, Yamada N, Yoshida S (2012)
23 Guidelines for Treatment of Pulmonary Hypertension (JCS2012). available at
24 http://www.j-circ.or.jp/guideline/pdf/JCS2012_nakanishi_h.pdf. last accessed at
25 September 5th, 2018 (in Japanese)
26
27
28
29
30
31
32 27) Tanabe N, Kawakami T, Satoh T, Matsubara H, Nakanishi N, Ogino H, Tamura Y,
33 Tsujino I, Ogawa A, Sakao S, Nishizaki M, Ishida K, Ichimura Y, Yoshida M, Tatsumi
34 K (2018) Balloon pulmonary angioplasty for chronic thromboembolic pulmonary
35 hypertension: A systematic review. *Respir Investig*. 56:332-341
36
37
38
39
40
41
42
43
44

Author's Contributions:

45
46 TK and HM equally contributed in this study. TK and HM contributed to the conception and
47 design of the study, drafted the protocol, and supervised the revision. MK, KA, SK, YS and
48
49 TS provided intellectual input into improving the study design and revising the protocol. KF
50
51 contributed to and supervised the conception and design of the study. All authors read and
52
53 approved the final manuscript.
54
55
56
57
58
59
60

1
2
3 **Funding statement:**
4

5
6 This study was financially supported by Bayer Yakuhin, Ltd.
7
8
9
10

11
12 **Competing interests statement:**
13

14
15
16 SK has received honoraria for scientific lectures from Bayer Yakuhin, Ltd. KF has received
17
18 scholarship grants from Bayer Yakuhin, Ltd. and MSD K.K. The other authors declare no
19
20 conflict of interest.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure and Table Legends

Figure 1. Study outline and randomization schematic. After consent, and CTEPH diagnosis is confirmed, subjects will be randomized into either BPA or riociguat group for 12 months, and observation measurements taken at screening, baseline, 0-4, 6 and 12 months.

Table 1. Schedule of assessments for subjects enrolled into the study.

Table 2. Secondary endpoints that will be measured and/or compared at baseline and at 12 months.

Table 1: Schedule of assessments for subjects enrolled into the study.

Observation items	Screening	Baseline	observation period		
	~0M	0M	0~4M	6M+1M	12M+2M
Subjects' attributes	○	○	—	—	—
6-minute walk distance	—	○	—	○	○
Borg dyspnea index	—	○	—	○	○
WHO functional class	—	○	—	○	○
Right heart catheterization	○	—	—	○	○
Pulmonary angiography	○	—	—	—	—
Pulmonary function testing	—	○	—	○	○
Blood gas test ^(a)	—	○	—	○	○
Vital signs ^(a)	—	○	—	○	○
Echocardiography (cardiac ultrasound)	—	○	—	○	○
Chest X-ray	—	○	○ ^(b)	○	○
Chest CT scan	○	—	○ ^(b)	○	○
Oxygen therapy usage status	—	○	—	○	○
Adverse event onset ^(c)	—	—	—	← ○ →	
Clinical worsening and time to clinical	—	—	—	← ○ →	

worsening (TTCW) ^(c)					
Quality of Life parameters (EQ5D)	—	○	—	○	○
Health insurance	—	—	←	○	→
BPA status ^(d)	—	—	○	—	—
Medication adherence ^(e)	—	—	←	○	→

(a) Recommended to be implemented during right heart catheterization

(b) Required if BPA is performed

(c) Onset of adverse events and indices related to clinical worsening will be observed, as necessary, throughout the clinical study period

(d) Observation items for Group A (BPA group)

(e) Observation items for Group B (riociguat group)

Table 2: Secondary endpoints that will be studied and or compared at baseline and at 12 months.

Endpoint	
Change in 6-minute walk distance	
Change in Borg dyspnea index	
Change in hemodynamic variables	Includes pulmonary vascular resistance, mean right arterial pressure, cardiac output etc.
Change in WHO functional class	
Change in plasma brain natriuretic peptide levels	
Change in SaO ₂ and PaO ₂	
Change in usage volume of oxygen therapy	Includes commencing oxygen therapy due to the exacerbation of a primary disease or dosage change.
Change in pulmonary function test	
Change in echocardiography test parameter	
Frequency and severity of pulmonary artery injury	Assessed by chest X-ray and chest CT scan.
Frequency of Adverse Events	Bloody sputum/hemoptysis/pulmonary hemorrhage (vascular perforation, vascular dissection, vascular rupture, etc.), pneumothorax, hypotension, pulmonary congestion/pulmonary edema, late-onset lung disturbance, heart failure, pneumonia, headache, dizziness, peripheral edema, nausea/vomiting,

retching, diarrhea, nasopharyngitis, upper respiratory inflammation, respiratory distress, coughing, fainting.

Clinical worsening during the All-cause mortality, heart/lung transplant, salvage observation period and time to clinical PEA due to worsening of primary disease, new or worsening repeated implementation of BPA due to the worsening of a primary disease, hospitalization, new initiation of pulmonary vasodilators, worsening of 30% or greater from baseline in the 6-minute walk distance, persistent worsening in the WHO functional class from baseline due to the worsening of a primary disease.

Change in Quality of Life parameters

(EQ5D)

Health insurance resource costs




Figure 1. Study outline and randomization schematic. After consent, and CTEPH diagnosis is confirmed, subjects will be randomized into either BPA or riociguat group for 12 months, and observation measurements taken at screening, baseline, 0-4, 6 and 12 months.



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/Item	Item No.	Description	Page in protocol	Page in protocol paper
Administrative information				
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1, 5	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	42	3
	2b	All items from the World Health Organization Trial Registration Data Set	42	3
Protocol version	3	Date and version identifier	1	
Funding	4	Sources and types of financial, material, and other support	43	2, 17
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1, 43-47	1
	5b	Name and contact information for the trial sponsor	1	2
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	43	
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	44-47	
Introduction				
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	11	3, 5
	6b	Explanation for choice of comparators	11	3, 5
Objectives	7	Specific objectives or hypotheses	5, 11-12	3, 5-6
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	5, 12	6
Methods: Participants, interventions, and outcomes				
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	45	1
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	5-6, 13-14	7
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	12, 16-24	6
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	28-29, 36	
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	23-24	20
	11d	Relevant concomitant care and interventions that are permitted	17	

1					
2					
3			or prohibited during the trial		
4	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	6-7, 14-16	8, 21-22
5					
6					
7					
8					
9					
10	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	16-24	6-8, 19-20
11					
12					
13	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	31	6-7
14					
15	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	17-20	7-8
16					
17					
18	Methods: Assignment of interventions (for controlled trials)				
19	Allocation:				
20	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	19-20	6-8
21					
22					
23					
24					
25	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	16, 19-20	8
26					
27					
28	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	16, 19-20	8
29					
30	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	18-19	6
31					
32					
33					
34		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	18-19	6
35					
36					
37	Methods: Data collection, management, and analysis				
38	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	20-24	6-8, 19-20
39					
40					
41					
42					
43					
44		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	28-29	
45					
46					
47					
48	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	29-31	9
49					
50					
51					
52					
53	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	32-34	10-11
54					
55		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	32-34	10-11
56					
57		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple	30-31	10-11
58					
59					
60					

1				
2				
3			imputation)	
4	Methods: Monitoring			
5	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	46
6				
7				
8				
9				
10		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	34
11				
12				
13	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	25-28 10
14				
15				
16	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	N/A N/A
17				
18				
19	Ethics and dissemination			
20	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	34-35 11-12
21				
22	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	35
23				
24				
25	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	36-39 7-8
26				
27		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A N/A
28				
29	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	38-39
30				
31				
32	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	43 17
33				
34	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	29-31 9
35				
36				
37	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	40
38				
39	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	42 11-12
40				
41		31b	Authorship eligibility guidelines and any intended use of professional writers	N/A N/A
42				
43		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	N/A N/A
44				
45	Appendices			
46	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	37-38
47				
48	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A N/A
49				

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "Attribution-NonCommercial-NoDerivs 3.0 Unported" license.

BMJ Open

Multicenter randomized controlled trial of balloon pulmonary angioplasty and riociguat in patients with chronic thromboembolic pulmonary hypertension: Protocol for the MR BPA study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028831.R2
Article Type:	Protocol
Date Submitted by the Author:	10-Oct-2019
Complete List of Authors:	Kawakami, Takashi; Keio University, School of Medicine, Cardiology Matsubara, Hiromi; Okayama Medical Center Abe, Kohtaro; Kyushu University Kataoka, Masaharu ; Keio University, School of Medicine Kohsaka, Shun; Keio University, School of Medicine Sato, Yasunori ; Department of Preventive Medicine and Public Health, Keio University School of Medicine, Shinke, Toshiro; Showa University Fukuda, Keiichi; Keio University, School of Medicine
Primary Subject Heading:	Surgery
Secondary Subject Heading:	Cardiovascular medicine, Surgery
Keywords:	chronic thromboembolic pulmonary hypertension, balloon pulmonary angioplasty, riociguat

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 Multicenter randomized controlled trial of balloon pulmonary angioplasty and riociguat in
4 patients with chronic thromboembolic pulmonary hypertension: Protocol for the MR BPA
5
6
7
8 study
9

10
11
12
13
14 **Authors:**
15

16
17 Takashi Kawakami^{1*}, Hiromi Matsubara^{2*}, Kohtaro Abe³, Masaharu Kataoka¹, Shun
18
19 Kohsaka¹, Yasunori Sato⁴, Toshiro Shinke⁵, Keiichi Fukuda¹
20
21

22
23 *These authors contribute equally to the study.
24
25
26
27
28

29 ¹Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi,
30
31 Shinjuku-ku, Tokyo, 160-8582, Japan
32

33
34 ²Department of Cardiology, Okayama Medical Center, 1711-1, Tamasu, Kita-ku, Okayama,
35
36 Okayama, 701-1192, Japan
37
38

39
40 ³Department of Cardiovascular Medicine, Kyushu University, 3-1-1 Maidashi, Higashi-ku,
41
42 Fukuoka 812-8582, Japan
43
44

45
46 ⁴Department of Preventive Medicine and Public Health, Keio University School of Medicine,
47
48 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
49

50
51 ⁵Division of Cardiovascular Medicine, Department of Internal Medicine, Showa University
52
53 School of Medicine, 1-5-8 Hatanaodai, Shinagawa-ku, Tokyo, 142-8666 Japan
54
55
56
57
58

59 **Corresponding Author:**
60

1
2
3 Takashi Kawakami, MD
4

5
6 Department of Cardiology, Keio University School of Medicine, Tokyo, Japan
7

8
9 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
10

11
12 Tel: + 81-3-5843-6702, Fax: + 81-3-5363-3875
13

14
15 E-mail: kawakami.1650@gmail.com
16
17

18
19
20
21
22 **Acknowledgements:** The study was funded by Bayer Yakuhin Ltd.
23
24

25
26
27
28 **Keywords:** Chronic thromboembolic pulmonary hypertension, balloon pulmonary
29
30 angioplasty, riociguat
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction: Management of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) remains a clinical challenge. Currently, medical treatment involving pulmonary vasodilators (such as soluble guanylate-cyclase stimulators) is recommended, primarily for ameliorating symptoms. More recently, balloon pulmonary angioplasty (BPA) has been developed as alternative treatment for inoperable CTEPH. The present study aimed to compare the efficacy and safety of BPA and riociguat (a soluble guanylate-cyclase stimulator) as treatments for inoperable CTEPH.

Methods and analysis: The present study is a multicenter randomized controlled trial. Subjects with inoperable CTEPH will be randomized (1:1) into either a BPA or riociguat group, and observed for 12 months after initiation of treatment. The primary endpoint will be the change in mean pulmonary arterial pressure from baseline to 12 months after initiation of treatment. For primary analysis, we will estimate the least square-means difference and 95% confidential interval for the change of pulmonary arterial pressure between the groups at 12 months using analysis of covariance adjusted for allocation factors.

Ethics and dissemination: This study and its protocols were approved by the institutional review board of Keio University School of Medicine and each participating institution. Written informed consent will be obtained from all participants. Results will be disseminated at medical conferences and in journal publications.

Registration: This study is registered at the University Hospital Medical Information Network Clinical Trial Registry (UMIN-CTR) (UMIN000019549).

Strengths and limitations of the study:

- This is a randomized controlled trial comparing the efficacy and safety of BPA and riociguat in patients with inoperable CTEPH.
- This study evaluates the efficacy and safety of BPA and riociguat over a relatively long period (12 months).
- This is the first study to compare health insurance resource costs between BPA and riociguat.
- A limitation of this study is the open-label trial design.
- Another limitation of is that this study will recruit a relatively small number of subjects.

Introduction

Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by stenosis and/or occlusion of pulmonary arteries caused by organized thrombi¹. Early diagnosis and appropriate treatment are critical, as the condition is associated with a high rate of mortality due to right-sided heart failure². Pulmonary endarterectomy (PEA) is an established curative treatment for operable CTEPH^{3,4}. According to the American Heart Association/American College of Cardiology (AHA/ACC)⁵, European Society of Cardiology/European Respiratory Society (ESC/ERS)⁶, and Japanese Circulation Society/the Japanese Pulmonary Circulation and Pulmonary Hypertension Society (JCS/JPCPHS)⁷ guidelines, PEA is recommended for patients with operable CTEPH as the first-line therapy in the case of recommendation class I and level of evidence C.

In 2014, for the first time, a soluble guanylate-cyclase stimulator (riociguat, a pulmonary vasodilator) received approval for insurance reimbursement in the context of inoperable or persistent/recurrent CTEPH. This was based on the findings of a multicenter randomized clinical trial (CHEST-1)⁸ and its extension study (CHEST-2)⁹ which highlighted the efficacy of riociguat for patients with inoperable CTEPH. Balloon pulmonary angioplasty (BPA) is a catheter-based treatment which has also been reported to be effective for inoperable CTEPH¹⁰⁻²². Riociguat and BPA are recommended for patients with inoperable CTEPH in the case of recommendation class I and level of evidence B, or recommendation class IIb and level of evidence C, respectively, in the 2015 ESC/ESR guidelines⁶, and in the case of recommendation class I and level of evidence B, and recommendation class I and level of evidence C, respectively, in the 2017 JCS/JPCPHS guidelines⁷. Although BPA is associated with the risk of complications such as procedure-related pulmonary artery injury, it can result in marked improvement of CTEPH. Riociguat is an effective pulmonary vasodilator and is associated with a low risk of serious adverse events. It has been reported that sequential

1
2
3 treatment with riociguat and BPA results in significant improvements in terms of mean
4
5 pulmonary arterial pressure and pulmonary vascular resistance among patients with
6
7 inoperable CTEPH²³, no reports to date have directly compared the treatment outcomes of
8
9 these two treatment methods. A randomized controlled trial comparing riociguat and BPA
10
11 (the RACE study) is conducted in France²⁴, aligning with the start of the present study²⁵. The
12
13 aim of the present study is to compare the efficacy and safety of riociguat and BPA for
14
15 inoperable CTEPH over the course of 12 months. The results of this study may aid in
16
17 optimizing treatment selection and improving patient outcomes.
18
19
20
21
22
23

24 **Methods and Analysis**

25
26 **Study design and setting:** This Multicenter Randomized controlled trial based on Balloon
27
28 Pulmonary Angioplasty for chronic thromboembolic pulmonary hypertension (MR BPA)
29
30 study will recruit subjects from January 15, 2016 to October, 31, 2019. The study is a
31
32 multicenter, prospective, randomized controlled trial. As shown in Figure 1, subjects will
33
34 undergo right-heart catheterization and pulmonary angiography before provisional
35
36 enrollment. An independent experienced PEA surgeon will determine if subjects are eligible
37
38 for PEA. Those who are judged to have inoperable CTEPH will be assigned into either a
39
40 BPA or riociguat group via an online assignment system, and will be observed for 12 months.
41
42 In the BPA group, the severity of pulmonary hypertension and morphology of the pulmonary
43
44 lesion will be evaluated by preoperative right-heart catheterization and pulmonary
45
46 angiography. Then, BPA will be conducted depending on the lesion type. If lesions of
47
48 pulmonary artery are not suitable for BPA, the procedure will not be performed even if the
49
50 patient is assigned to the BPA group. However, at least among the collaborative institutions
51
52 included in this study, PEA-inoperable patients are very rarely considered unsuitable for BPA,
53
54 because these institutes are expert BPA centers in Japan. In general, BPA will be completed
55
56
57
58
59
60

1
2
3 within 4 months of the first BPA procedure. In the riociguat group, 1.0 mg riociguat will be
4 administered three times per day. When systolic blood pressure is 95 mmHg or higher, the
5 dose will be increased by 0.5 mg every two weeks up to a maximum dosage of 2.5 mg thrice
6 daily. Dosage adjustment will be completed within 4 months of the first administration of
7 riociguat, and administration will be continued for a total of 12 months. Observations will be
8 made at the time of screening; baseline; and at 0–4, 6, and 12 months after initial treatment.
9
10 Table 1 shows the schedule of assessments performed at each visit for each treatment group,
11 including mandatory and optional assessments.
12
13
14
15
16
17
18
19
20
21
22
23
24

25 **Sample size calculation:** Previously, BPA has been shown to result in reduced mean
26 pulmonary arterial pressure from 45.4 ± 9.6 to 24.0 ± 6.4 mmHg (mean \pm standard deviation)
27 within 24 months¹¹, while riociguat has been reported to decrease pulmonary arterial pressure
28 by 4 ± 7 mmHg⁹. Based on these studies, it was assumed that the change in mean pulmonary
29 arterial pressure from the start of treatment to 12 months after treatment would be -15 mmHg
30 for the BPA group and -4 mmHg for the riociguat group, with standard deviation of 14 and
31 10, respectively. The minimum sample size required to achieve a significance of 0.05 from a
32 two-sided test with a statistical power of 90% was determined to be 27 subjects for both
33 groups; a total of 54 subjects. We estimated the dropout rate to be 10%; thus, the planned
34 enrollment was set at 60 subjects, with 30 in each group.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 **Eligibility criteria:** *Inclusion criteria:* (a) Diagnosis with CTEPH with a World Health
52 Organization (WHO) functional class II or III based on the diagnostic criteria of the 2012
53 Japanese Circulation Society guidelines²⁴, (b) age ≥ 20 years or < 80 years, (c) mean
54 pulmonary arterial pressure of ≥ 25 to < 60 mmHg and pulmonary artery wedge pressure of
55 ≤ 15 mmHg, (d) administration of appropriate anticoagulant therapy for at least 3 months
56
57
58
59
60

1
2
3 prior to study enrollment (in the case of warfarin, the prothrombin time-international
4 normalized ratio should be 1.5–3.0), and (e) provision of written informed consent to
5 participate after full explanation of the study.
6
7
8

9
10
11 *Exclusion criteria:* (a) History of BPA, (b) PEA within six months prior to study enrollment,
12 (c) use of unapproved pharmaceutical products, (d) use of a pulmonary vasodilator within 4
13 weeks prior to right-heart catheterization, (e) co-existing etiology of pulmonary hypertension
14 (except for that classified as Group 4 in the Nice Pulmonary Hypertension Classification
15 System), (f) pregnancy or breastfeeding, (g) contraindicated for riociguat, (h) life expectancy
16 of less than two years, and (i) deemed to be unsuitable for participation by the investigators.
17
18
19
20
21
22
23
24
25
26

27 **Recruitment and consent:** The informed consent document is presented to potentially
28 eligible subjects to provide a comprehensive explanation of this study. Written consent is
29 then obtained.
30
31
32

33
34 As a general rule, right-heart catheterization and pulmonary angiography are performed after
35 acquiring consent and the possibility of definitive diagnosis of CTEPH is determined by the
36 investigators. However, to reduce the burden on the subjects, data from within three months
37 prior to consent acquisition for pulmonary angiography, right-heart catheterization, and CT
38 scan, as well as pulmonary ventilation-perfusion scintigraphy obtained in general practice
39 within 3 months prior to the time of consent, can also be utilized. This is explained to
40 subjects by investigators at the time of obtaining consent.
41
42
43
44
45
46
47
48

49
50 Once consent is obtained, an independent experienced PEA surgeon who is not involved in
51 this study will determine operability (whether subjects are eligible for PEA) based on
52 imaging data according to the Guidelines for Treatment of Pulmonary Hypertension (2012
53 revised version)²⁶.
54
55
56
57
58
59
60

1
2
3 **Random allocation:** Random assignment will be performed centrally with stratification by
4 mean pulmonary arterial pressure (<40 mmHg and \geq 40 mmHg), and research institutions
5 (Keio University, Okayama Medical Center, Kyusyu University, and Kobe University) by
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

biased-coin minimization.

Endpoints: The primary endpoint will be the change in mean pulmonary arterial pressure between baseline and 12 months. Secondary endpoints will include several clinical and quality-of-life parameters (detailed in Table 2).

Data collection: An electronic, clinical-test data collection system—electric data capture system (EDC) —will be used for data collection. In cases when the system is unavailable, a case report form—a specialized data collection form—will be used, and the data later entered into the EDC. The investigators who will enter information into the EDC system will be responsible for ensuring accuracy and completeness of information.

Data management and monitoring: Data collection and management will be carried out by third-party entities to avoid bias. Data management will be performed by Soiken Inc. Data Management Group (the Data Center). The Data Center will prepare a “Procedure Manual for Data Management”. The Data Center’s approval is required prior to sending any data related to the subjects in electronic format. If data is transmitted over an unsecured electronic network, the data must be encoded at the source. Linkable anonymization by central registration number will be used to identify the subjects. The investigators will be responsible for appropriate storage of the correspondence table prepared by them to identify subjects, in accordance with the procedures at the particular research institution. This correspondence table must be retained for five years after completion of the study or three years after final

1
2
3 publication, whichever is later. Appropriate measures, such as encoding or deletion, will be
4
5 taken to ensure that the subjects cannot be identified in any display or public disclosure of
6
7 information related to the study, in accordance with applicable laws and regulations.
8
9

10 The Soiken Inc. Data Management Group will monitor the present study to manage and
11
12 ensure quality. The monitoring manager will monitor subjects in accordance with the manual
13
14 on monitoring procedure. For data quality management, the principal investigator and Central
15
16 Committee will confirm the progress of the study as necessary through the Soiken Inc. Data
17
18 Management Group to ensure conformance with the protocol and the Ethical Guidelines for
19
20 Medical and Health Research Involving Human Subjects (Dec. 22, 2014; Ministry of
21
22 Education, Culture, Sports, Science and Technology/Ministry of Health, Labour and
23
24 Welfare).
25
26
27
28
29
30

31 **Adverse events:** The occurrence of any untoward medical events, including complications or
32
33 the worsening of pre-existing underlying diseases, will be defined as adverse events.

34
35 Worsening of efficacy evaluation indices will not be defined as adverse events. Any
36
37 concomitant symptoms or clinically significant abnormal fluctuations in test results will be
38
39 investigated to determine whether there is a cause-and-effect relationship with BPA or
40
41 riociguat, and findings will be documented in the EDC system. Adverse events will be
42
43 followed up until normalization or recovery to a level not considered to be an adverse event;
44
45 or, in the case of an irreversible adverse event (cerebral infarction, myocardial infarction,
46
47 etc.), until symptoms stabilize.
48
49
50

51
52
53 **Statistical analysis:** Primary and secondary efficacy endpoints will be analyzed using the full
54
55 study population, which will include all patients who were randomized into one of the
56
57 intervention groups. However, patients who withdraw their consent, patients with severe
58
59
60

1
2
3 protocol violation, such as registration without consenting, or registration out of the
4
5 enrollment period, or patients without any data related to the primary endpoint after the
6
7 randomization, were excluded from the full study population. Safety analysis will be
8
9 conducted in the safety analysis population, which will include all patients who were
10
11 randomized into one of the intervention groups and either received at least one dose of
12
13 riociguat or attended at least one BPA procedure (regardless of whether BPA was carried out
14
15 or not).

16
17
18
19 Baseline variables are presented as frequencies and proportions for categorical data, and
20
21 means and standard deviations for continuous data. Patient characteristics will be compared
22
23 using Pearson's chi-square test or Fisher's exact test for categorical endpoints, and the
24
25 Student's t-test for continuous variables.

26
27
28 For primary analysis, the least square-means difference and 95% confidence interval for
29
30 change of pulmonary arterial pressure between groups at 12 months will be estimated using
31
32 analysis of covariance (ANCOVA) adjusted for allocation factors. Secondary analysis will be
33
34 performed in the same manner as primary analysis. Adverse events will be evaluated during
35
36 safety analysis. The frequencies of adverse events will be compared using Fisher's exact test.

37
38 All comparisons are planned, and all *p*-values will be two sided. We consider *p*-values of
39
40 <0.05 to be statistically significant. All statistical analyses will be performed using SAS
41
42 software version 9.4 (SAS Institute, Cary, NC, USA). Statistical analysis plan will be
43
44 developed by the principal investigator and biostatistician before completion of patient
45
46 recruitment and data fixation.
47
48
49
50

51
52
53
54 **Patient and public involvement:** There is no patient involvement.
55
56
57

58 59 Discussion 60

1
2
3 Guidelines for the diagnosis and treatment for CTEPH in Western countries^{5, 6} and Japan^{7, 26}
4
5 recommend riociguat and BPA for patients with inoperable CTEPH. However, there are no
6
7 reports directly comparing treatment outcomes of these two approaches. The primary
8
9 endpoint of this study will be the change in mean pulmonary arterial pressure from baseline
10
11 to 12 months, as this is an important prognostic factor of CTEPH. Other outcomes often used
12
13 in studies on CTEPH, such as the 6-minute walk distance and pulmonary vascular resistance,
14
15 are secondary endpoints in the present study. Sequential treatment with riociguat and BPA for
16
17 patients with inoperable CTEPH has been shown to significantly improve mean pulmonary
18
19 arterial pressure and pulmonary vascular resistance, highlighting the benefits of BPA²³. A
20
21 randomized controlled trial directly comparing riociguat and BPA is conducted in France²⁴;
22
23 the present study was therefore planned to compare the efficacy and safety of riociguat and
24
25 BPA for treatment of inoperable CTEPH. The present study and the RACE study both began
26
27 in January 2016²⁵. Results from randomized trials such as these will be critical for optimizing
28
29 treatment selection and improving outcomes of inoperable CTEPH.
30
31
32
33
34

35 In the present study, BPA treatment will be completed in 4 months, which is equivalent as
36
37 real-world conditions in Japan. This study will also evaluate the long-term efficacy and safety
38
39 of riociguat and BPA by continuing evaluations for 12 months after initiation of treatment. A
40
41 recent systematic review has shown that treatment outcomes of BPA are better in Japan than
42
43 in Western countries^{4, 27}. The present study will be conducted in expert CTEPH centers in
44
45 Japan, and will therefore compare the treatment efficacy and safety of riociguat and the
46
47 highest-quality BPA in Japan. In addition, the operability of PEA will be determined by an
48
49 independent experienced PEA surgeon who belongs to independent institute and is the most
50
51 experienced PEA surgeon in Japan, having performed 49 PEAs in the last 3 years (320 PEAs
52
53 in total). This will avoid recruitment bias and guarantee reliability in the present study.
54
55
56
57

58 Furthermore, this study will compare the costs to health insurance resources and patient-
59
60

1
2
3 reported quality-of-life parameters for each therapy. These factors may contribute to
4
5 optimizing treatment strategies or amending treatment guidelines for inoperable CTEPH.
6
7 While these are the strengths of this study, there are several limitations which should be
8
9 acknowledged. One limitation is that this is an open-label trial. Because there is no distinct
10
11 criterion for BPA in each lesion, surgeons are aware of the mean pulmonary arterial pressure
12
13 (the primary endpoint in this study), and they might be incentivized to continue BPA. Thus,
14
15 bias for the BPA surgeons cannot be completely avoided. However, since this study will
16
17 compare medical and surgical treatment, it is difficult to use a placebo or mask patients
18
19 and/or physicians. Another limitation is that a relatively small number of patients will be
20
21 enrolled (30 subjects per group, a total of 60 subjects).
22
23
24
25
26
27

28 **Ethics and dissemination:** This study and its protocols were approved by the institutional
29
30 review board of the Keio University School of Medicine, and by each participating
31
32 institution. The study will be conducted in accordance with the Declaration of Helsinki,
33
34 Ethical Guidelines for Medical and Health Research Involving Human Subjects issued by the
35
36 Ministry of Health, Labour and Welfare in Japan, and other current legal regulations in Japan.
37
38 Written informed consent will be obtained from all participants after full explanation of this
39
40 study. Results of the study will be disseminated at medical conferences and in journal
41
42 publications.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

- 1) Memon HA, Lin CH, Guha A (2016) Chronic thromboembolic pulmonary hypertension: Pearls and pitfalls of diagnosis. *Methodist Debaquey Cardiovasc J.* 12:199-204
- 2) Nishimura R, Tanabe N, Sugiura T, Shigeta A, Jujo T, Sekine A, Sakao S, Kasahara Y, Tatsumi K (2013) Improved survival in medically treated chronic thromboembolic pulmonary hypertension. *Circ J.* 77:2110-2117
- 3) Madani MM (2016) Surgical treatment of chronic thromboembolic pulmonary hypertension: Pulmonary thromboendarterectomy. *Methodist Debaquey Cardiovasc J.* 12:213-218
- 4) Kim NH, Delcroix M, Jais X, Madani MM, Matsubara H, Mayer E, Ogo T, Tapson VF, Ghofrani HA, Jenkins DP (2019) Chronic thromboembolic pulmonary hypertension. *Eur Respir J.* 53:1801915
- 5) McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, Moliterno DJ, Mukherjee D, Pohost GM, Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. *Circulation.* 119:2250-2294

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 6) Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M (2016) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J.* 37:67-119
 - 7) Fukuda K, Date H, Doi S, Fukumoto Y, Fukushima N, Hatano M, Ito H, Kuwana M, Matsubara H, Momomura SI, Nishimura M, Ogino H, Satoh T, Shimokawa H, Yamauchi-Takahara K, Tatsumi K, Ishibashi-Ueda H, Yamada N, Yoshida S, Abe K, Ogawa A, Ogo T, Kasai T, Kataoka M, Kawakami T, Kogaki S, Nakamura M, Nakayama T, Nishizaki M, Sugimura K, Tanabe N, Tsujino I, Yao A, Akasaka T, Ando M, Kimura T, Kuriyama T, Nakanishi N, Nakanishi T, Tsutsui H (2019) Guidelines for the treatment of pulmonary hypertension (JCS 2017/JPCPHS 2017). *Circ J.* 83:842-945
 - 8) Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C; CHEST-1 Study Group (2013) Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. *N Engl J Med.* 369:319-329
 - 9) Simonneau G, D'Armini AM, Ghofrani HA, Grimminger F, Hoeper MM, Jansa P, Kim NH, Wang C, Wilkins MR, Fritsch A, Davie N, Colorado P, Mayer E (2015) Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: A long-term extension study (CHEST-2). *Eur Respir J.* 45:1293-1302

- 1
2
3 10) Kataoka M, Inami T, Hayashida K, Shimura N, Ishiguro H, Abe T, Tamura Y, Ando M,
4
5 Fukuda K, Yoshino H, Satoh T (2012) Percutaneous transluminal pulmonary
6
7 angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. *Circ*
8
9 *Cardiovasc Interv.* 5:756-762
10
11
- 12
13 11) Mizoguchi H, Ogawa A, Munemasa M, Mikouchi H, Ito H, Matsubara H (2012)
14
15 Refined balloon pulmonary angioplasty for inoperable patients with chronic
16
17 thromboembolic pulmonary hypertension. *Circ Cardiovasc Interv.* 5:748-755
18
19
- 20
21 12) Andreassen AK, Ragnarsson A, Gude E, Geiran O, Andersen R (2013) Balloon
22
23 pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary
24
25 hypertension. *Heart.* 99:1415-1420
26
27
- 28
29 13) Fukui S, Ogo T, Morita Y, Tsuji A, Tateishi E, Ozaki K, Sanda Y, Fukuda T, Yasuda S,
30
31 Ogawa H, Nakanishi N (2014) Right ventricular reverse remodelling after balloon
32
33 pulmonary angioplasty. *Eur Respir J.* 43:1394-1402
34
35
- 36
37 14) Taniguchi Y, Miyagawa K, Nakayama K, Kinutani H, Shinke T, Okada K, Okita Y,
38
39 Hirata KI, Emoto N (2014) Balloon pulmonary angioplasty: an additional treatment
40
41 option to improve the prognosis of patients with chronic thromboembolic pulmonary
42
43 hypertension. *EuroIntervention.* 10:518-525
44
45
- 46
47 15) Tsugu T, Murata M, Kawakami T, Yasuda R, Tokuda H, Minakata Y, Tamura Y,
48
49 Kataoka M, Hayashida K, Tsuruta H, Maekawa Y, Inoue S, Fukuda K (2015)
50
51 Significance of echocardiographic assessment for right ventricular function after
52
53 balloon pulmonary angioplasty in patients with chronic thromboembolic induced
54
55 pulmonary hypertension. *Am J Cardiol.* 115:256-261
56
57
- 58
59 16) Dimopoulos K, Kempny A, Alonso-Gonzalez R, Wort SJ (2015) Percutaneous
60
transluminal pulmonary angioplasty for the treatment of chronic thromboembolic
pulmonary hypertension: Challenges and future directions. *Int J Cardiol.* 187:401-403

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 17) Ogawa A, Satoh T, Fukuda T, Sugimura K, Fukumoto Y, Emoto N, Yamada N, Yao A, Ando M, Ogino H, Tanabe N, Tsujino I, Hanaoka M, Minatoya K, Ito H, Matsubara H (2017) Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: Results of a multicenter registry. *Circ Cardiovasc Qual Outcomes*. 10:e004029
 - 18) Kimura M, Kohno T, Kawakami T, Kataoka M, Tsugu T, Akita K, Isobe S, Itabashi Y, Maekawa Y, Murata M, Fukuda K (2017) Midterm effect of balloon pulmonary angioplasty on hemodynamics and subclinical myocardial damage in chronic thromboembolic pulmonary hypertension. *Can J Cardiol*. 33:463-470
 - 19) Aoki T, Sugimura K, Tatebe S, Miura M, Yamamoto S, Yaoita N, Suzuki H, Sato H, Kozu K, Konno R, Miyata S, Nochioka K, Satoh K, Shimokawa H (2017) Comprehensive evaluation of the effectiveness and safety of balloon pulmonary angioplasty for inoperable chronic thrombo-embolic pulmonary hypertension: long-term effects and procedure-related complications. *Eur Heart J*. 38:3152-3159
 - 20) Olsson KM, Wiedenroth CB, Kamp JC, Breithecker A, Fuge J, Krombach GA, Haas M, Hamm C, Kramm T, Guth S, Ghofrani HA, Hinrichs JB, Cebotari S, Meyer K, Hoepfer MM, Mayer E, Liebetrau C, Meyer BC (2017) Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: The initial German experience. *Eur Respir J*. 49:1602409
 - 21) Kawakami T, Ogawa A, Miyaji K, Mizoguchi H, Shimokawahara H, Naito T, Oka T, Yunoki K, Munemasa M, Matsubara H (2016) Novel angiographic classification of each vascular lesion in chronic thromboembolic pulmonary hypertension based on selective angiogram and results of balloon pulmonary angioplasty. *Circ Cardiovasc Interv*. 9:e003318

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 22) Ogo T, Fukuda T, Tsuji A, Fukui S, Ueda J, Sanda Y, Morita Y, Asano R, Konagai N, Yasuda S (2017) Efficacy and safety of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension guided by cone-beam computed tomography and electrocardiogram-gated area detector computed tomography. *Eur J Radiol.* 89:270-276
- 23) Wiedenroth CB, Ghofrani HA, Adameit MSD, Breihecker A, Haas M, Kriechbaum S, Rieth A, Hamm CW, Mayer E, Guth S, Liebetau C (2018) Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. *Pulm Circ.* 8:2045894018783996
- 24) Riociguat versus balloon pulmonary Angioplasty in non-operable Chronic thromboEmbolic pulmonary hypertension (RACE). ClinicalTrials.gov identifier NCT02634203. available at <https://clinicaltrials.gov/ct2/show/NCT02634203>. last accessed May 21st, 2019
- 25) Multicenter Randomized controlled trial based on Balloon Pulmonary Angioplasty for chronic thromboembolic pulmonary hypertension (MR BPA study). UMIN-CTR ID: UMIN000019549. available at https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022608. last accessed May 21st, 2019
- 26) Nakanishi N, Ando M, Ueda H, Ogino H, Saji T, Shiomi T, Tatsumi K, Date H, Nishimura M, Fukushima N, Fukumoto Y, Momomura S, Yamada N, Yoshida S (2012) Guidelines for Treatment of Pulmonary Hypertension (JCS2012). available at http://www.j-circ.or.jp/guideline/pdf/JCS2012_nakanishi_h.pdf. last accessed September 5th, 2018 (in Japanese)
- 27) Tanabe N, Kawakami T, Satoh T, Matsubara H, Nakanishi N, Ogino H, Tamura Y, Tsujino I, Ogawa A, Sakao S, Nishizaki M, Ishida K, Ichimura Y, Yoshida M, Tatsumi

1
2
3 K (2018) Balloon pulmonary angioplasty for chronic thromboembolic pulmonary
4
5 hypertension: A systematic review. *Respir Investig*. 56:332-341
6
7
8
9

10 **Author contributions:**

11
12 TK and HM contributed to the conception and design of the study, drafted the protocol, and
13 supervised the revision. MK, KA, SK, YS and TS provided intellectual input to improve the
14 study design and revise the protocol. KF contributed to and supervised the conception and
15 design of the study. All authors read and approved the final manuscript.
16
17
18
19
20
21
22
23

24 **Funding statement:**

25
26
27 This study was financially supported by Bayer Yakuhin, Ltd.
28
29
30
31
32

33 **Competing interests statement:**

34
35
36 SK received honoraria for scientific lectures from Bayer Yakuhin, Ltd. KF received
37 scholarship grants from Bayer Yakuhin, Ltd. and MSD K.K. The other authors declare no
38 conflict of interest.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure and table legends

Figure 1. Flow diagram of study recruitment and randomization. After obtaining consent and diagnosis of chronic thromboembolic pulmonary hypertension is confirmed, subjects will be randomized into either the balloon-pulmonary-angioplasty or riociguat group, to receive treatment for 12 months. Observations will be recorded at the time of screening; baseline; and at 0–4, 6, and 12 months after the initiation of treatment. Abbreviations: BPA, balloon pulmonary angioplasty; CTEPH, chronic thromboembolic pulmonary hypertension.

Table 1. Schedule of assessments for enrolled subjects.

Table 2. Secondary endpoints that will be measured and/or compared at baseline and at 12 months after initiation of treatment.

Table 1: Schedule of assessments for enrolled subjects.

Observation items	Screening	Baseline	Observation period		
	~0M	0M	0–4M	6M + 1M	12M + 2M
Subjects' attributes	○	○	—	—	—
6-minute walk distance	—	○	—	○	○
Borg dyspnea index	—	○	—	○	○
WHO functional class	—	○	—	○	○
Right-heart catheterization	○	—	—	○	○
Pulmonary angiography	○	—	—	—	—
Pulmonary function	—	○	—	○	○
Blood gas test ^(a)	—	○	—	○	○
Vital signs ^(a)	—	○	—	○	○
Echocardiography (cardiac ultrasound)	—	○	—	○	○
Chest X-ray	—	○	○ ^(b)	○	○
Chest CT scan	○	—	○ ^(b)	○	○
Oxygen therapy usage status	—	○	—	○	○
Adverse event onset ^(c)	—	—	—	← ○ →	
Clinical worsening and time to clinical	—	—	—	← ○ →	

1	worsening ^(c)					
2						
3						
4						
5						
6	Quality-of-life parameters (EQ5D)	—	○	—	○	○
7						
8						
9	Health insurance	—	—		← ○ →	
10						
11						
12	BPA status ^(d)	—	—	○	—	—
13						
14						
15						
16	Medication adherence ^(e)	—	—		← ○ →	
17						

Notes: (a) Recommended during right-heart catheterization, (b) required if balloon pulmonary angioplasty is performed, (c) onset of adverse events and indices related to clinical worsening will be observed as necessary throughout the clinical study period, (d) observational items for the balloon-pulmonary-angioplasty group, (e) observational items for the riociguat group. Abbreviations: BPA, balloon pulmonary angioplasty; CT, computed tomography; WHO, World Health Organization.

Table 2: Secondary endpoints that will be measured and/or compared at baseline and at 12 months after initiation of treatment.

Endpoint	
Change in 6-minute walk distance	
Change in Borg dyspnea index	
Change in hemodynamic variables	Including pulmonary vascular resistance, mean right arterial pressure, cardiac output, etc.
Change in WHO functional class	
Change in plasma brain natriuretic peptide levels	
Change in SaO ₂ and PaO ₂	
Change in usage volume of oxygen therapy	Including commencing oxygen therapy due to exacerbation of primary disease or dosage change.
Change in pulmonary function	
Change in echocardiography parameter	
Frequency and severity of pulmonary artery injury	Assessed by chest X-ray and chest CT scan.
Frequency of adverse events	Bloody sputum/hemoptysis/pulmonary hemorrhage (vascular perforation, vascular dissection, vascular rupture, etc.), pneumothorax, hypotension, pulmonary congestion/pulmonary edema, late-onset lung disturbance, heart failure, pneumonia, headache, dizziness, peripheral edema, nausea/vomiting, retching, diarrhea, nasopharyngitis, upper respiratory

1
2
3
4 inflammation, respiratory distress, coughing, fainting.
5
6 Clinical worsening during the All-cause mortality, heart/lung transplant, salvage
7 observation period and time to clinical PEA due to worsening of primary disease, new or
8 worsening repeated implementation of BPA due to the
9
10 worsening of a primary disease, hospitalization, new
11
12 initiation of pulmonary vasodilators, worsening of
13
14 30% or greater from baseline in the 6-minute walk
15
16 distance, persistent worsening in the WHO functional
17
18 class from baseline due to the worsening of a primary
19
20 disease.
21
22
23
24
25

26 Change in quality-of-life parameters
27
28 (EQ5D)
29

30 Health insurance resource costs
31
32

33 Abbreviations: BPA, balloon pulmonary angioplasty; CT, computed tomography; PaO₂,
34 partial pressure of oxygen; PEA, pulmonary endarterectomy; SaO₂, saturation of arterial
35
36 blood; WHO, World Health Organization.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Study outline and randomization schematic. After consent, and CTEPH diagnosis is confirmed, subjects will be randomized into either BPA or riociguat group for 12 months, and observation measurements taken at screening, baseline, 0-4, 6 and 12 months.



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/Item	Item No.	Description	Page in protocol	Page in protocol paper
Administrative information				
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1, 5	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	42	3
	2b	All items from the World Health Organization Trial Registration Data Set	42	3
Protocol version	3	Date and version identifier	1	
Funding	4	Sources and types of financial, material, and other support	43	2, 17
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1, 43-47	1
	5b	Name and contact information for the trial sponsor	1	2
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	43	
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	44-47	
Introduction				
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	11	3, 5
	6b	Explanation for choice of comparators	11	3, 5
Objectives	7	Specific objectives or hypotheses	5, 11-12	3, 5-6
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	5, 12	6
Methods: Participants, interventions, and outcomes				
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	45	1
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	5-6, 13-14	7
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	12, 16-24	6
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	28-29, 36	
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	23-24	20
	11d	Relevant concomitant care and interventions that are permitted	17	

1					
2					
3			or prohibited during the trial		
4	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	6-7, 14-16	8, 21-22
5					
6					
7					
8					
9					
10	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	16-24	6-8, 19-20
11					
12					
13	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	31	6-7
14					
15	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	17-20	7-8
16					
17					
18	Methods: Assignment of interventions (for controlled trials)				
19	Allocation:				
20	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	19-20	6-8
21					
22					
23					
24					
25	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	16, 19-20	8
26					
27					
28	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	16, 19-20	8
29					
30	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	18-19	6
31					
32					
33					
34		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	18-19	6
35					
36					
37	Methods: Data collection, management, and analysis				
38	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	20-24	6-8, 19-20
39					
40					
41					
42					
43					
44		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	28-29	
45					
46					
47					
48	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	29-31	9
49					
50					
51					
52					
53	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	32-34	10-11
54					
55		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	32-34	10-11
56					
57		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple	30-31	10-11
58					
59					
60					

1				
2				
3			imputation)	
4	Methods: Monitoring			
5	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	46
6				
7				
8				
9				
10				
11		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	34
12				
13	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	25-28
14				10
15				
16	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	N/A
17				N/A
18				
19	Ethics and dissemination			
20	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	34-35
21				11-12
22	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	35
23				
24				
25	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	36-39
26				7-8
27		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
28				N/A
29				
30	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	38-39
31				
32				
33	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	43
34				17
35	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	29-31
36				9
37				
38	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	40
39				
40	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	42
41				11-12
42				
43				
44				
45		31b	Authorship eligibility guidelines and any intended use of professional writers	N/A
46				N/A
47		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	N/A
48				N/A
49	Appendices			
50	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	37-38
51				
52	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A
53				N/A
54				
55				

56 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation &
 57 Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated.
 58 The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons
 59 "Attribution-NonCommercial-NoDerivs 3.0 Unported" license.
 60

BMJ Open

Multicenter randomized controlled trial of balloon pulmonary angioplasty and riociguat in patients with chronic thromboembolic pulmonary hypertension: Protocol for the MR BPA study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028831.R3
Article Type:	Protocol
Date Submitted by the Author:	20-Dec-2019
Complete List of Authors:	Kawakami, Takashi; Keio University, School of Medicine, Cardiology Matsubara, Hiromi; Okayama Medical Center Abe, Kohtaro; Kyushu University Kataoka, Masaharu ; Keio University, School of Medicine Kohsaka, Shun; Keio University, School of Medicine Sato, Yasunori ; Department of Preventive Medicine and Public Health, Keio University School of Medicine, Shinke, Toshiro; Showa University Fukuda, Keiichi; Keio University, School of Medicine
Primary Subject Heading:	Surgery
Secondary Subject Heading:	Cardiovascular medicine, Surgery
Keywords:	chronic thromboembolic pulmonary hypertension, balloon pulmonary angioplasty, riociguat

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 Multicenter randomized controlled trial of balloon pulmonary angioplasty and riociguat in
4 patients with chronic thromboembolic pulmonary hypertension: Protocol for the MR BPA
5 study
6
7
8
9

10
11
12
13
14 **Authors:**
15

16
17 Takashi Kawakami^{1*}, Hiromi Matsubara^{2*}, Kohtaro Abe³, Masaharu Kataoka¹, Shun
18 Kohsaka¹, Yasunori Sato⁴, Toshiro Shinke⁵, Keiichi Fukuda¹
19
20
21

22
23 *These authors contribute equally to the study.
24
25
26
27
28

29 ¹Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi,
30 Shinjuku-ku, Tokyo, 160-8582, Japan
31
32

33
34 ²Department of Cardiology, Okayama Medical Center, 1711-1, Tamasu, Kita-ku, Okayama,
35 Okayama, 701-1192, Japan
36
37
38

39
40 ³Department of Cardiovascular Medicine, Kyushu University, 3-1-1 Maidashi, Higashi-ku,
41 Fukuoka 812-8582, Japan
42
43
44

45
46 ⁴Department of Preventive Medicine and Public Health, Keio University School of Medicine,
47 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
48
49

50
51 ⁵Division of Cardiovascular Medicine, Department of Internal Medicine, Showa University
52 School of Medicine, 1-5-8 Hatanaodai, Shinagawa-ku, Tokyo, 142-8666 Japan
53
54
55
56
57
58

59 **Corresponding Author:**
60

1
2
3 Takashi Kawakami, MD
4

5
6 Department of Cardiology, Keio University School of Medicine, Tokyo, Japan
7

8
9 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
10

11
12 Tel: + 81-3-5843-6702, Fax: + 81-3-5363-3875
13

14
15 E-mail: kawakami.1650@gmail.com
16
17

18
19
20
21
22 **Acknowledgements:** The study was funded by Bayer Yakuhin Ltd.
23
24

25
26
27
28 **Keywords:** Chronic thromboembolic pulmonary hypertension, balloon pulmonary
29
30 angioplasty, riociguat
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction: Management of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) remains a clinical challenge. Currently, medical treatment involving pulmonary vasodilators (such as soluble guanylate-cyclase stimulators) is recommended, primarily for ameliorating symptoms. More recently, balloon pulmonary angioplasty (BPA) has been developed as alternative treatment for inoperable CTEPH. The present study aimed to compare the efficacy and safety of BPA and riociguat (a soluble guanylate-cyclase stimulator) as treatments for inoperable CTEPH.

Methods and analysis: The present study is a multicenter randomized controlled trial. Subjects with inoperable CTEPH were randomized (1:1) into either a BPA or riociguat group, and observed for 12 months after initiation of treatment. The primary endpoint will be the change in mean pulmonary arterial pressure from baseline to 12 months after initiation of treatment. For primary analysis, we will estimate the least square-means difference and 95% confidential interval for the change of pulmonary arterial pressure between the groups at 12 months using analysis of covariance adjusted for allocation factors.

Ethics and dissemination: This study and its protocols were approved by the institutional review board of Keio University School of Medicine and each participating institution. Written informed consent was obtained from all participants. Results will be disseminated at medical conferences and in journal publications.

Registration: This study is registered at the University Hospital Medical Information Network Clinical Trial Registry (UMIN-CTR) (UMIN000019549).

Strengths and limitations of the study:

- This is a randomized controlled trial comparing the efficacy and safety of BPA and riociguat in patients with inoperable CTEPH.
- This study evaluates the efficacy and safety of BPA and riociguat over a relatively long period (12 months).
- This is the first study to compare health insurance resource costs between BPA and riociguat.
- A limitation of this study is the open-label trial design.
- Another limitation of is that this study recruited a relatively small number of subjects.

Introduction

Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by stenosis and/or occlusion of pulmonary arteries caused by organized thrombi¹. Early diagnosis and appropriate treatment are critical, as the condition is associated with a high rate of mortality due to right-sided heart failure². Pulmonary endarterectomy (PEA) is an established curative treatment for operable CTEPH^{3,4}. According to the American Heart Association/American College of Cardiology (AHA/ACC)⁵, European Society of Cardiology/European Respiratory Society (ESC/ERS)⁶, and Japanese Circulation Society/the Japanese Pulmonary Circulation and Pulmonary Hypertension Society (JCS/JPCPHS)⁷ guidelines, PEA is recommended for patients with operable CTEPH as the first-line therapy in the case of recommendation class I and level of evidence C.

In 2014, for the first time, a soluble guanylate-cyclase stimulator (riociguat, a pulmonary vasodilator) received approval for insurance reimbursement in the context of inoperable or persistent/recurrent CTEPH. This was based on the findings of a multicenter randomized clinical trial (CHEST-1)⁸ and its extension study (CHEST-2)⁹ which highlighted the efficacy of riociguat for patients with inoperable CTEPH. Balloon pulmonary angioplasty (BPA) is a catheter-based treatment which has also been reported to be effective for inoperable CTEPH¹⁰⁻²². Riociguat and BPA are recommended for patients with inoperable CTEPH in the case of recommendation class I and level of evidence B, or recommendation class IIb and level of evidence C, respectively, in the 2015 ESC/ESR guidelines⁶, and in the case of recommendation class I and level of evidence B, and recommendation class I and level of evidence C, respectively, in the 2017 JCS/JPCPHS guidelines⁷. Although BPA is associated with the risk of complications such as procedure-related pulmonary artery injury, it can result in marked improvement of CTEPH. Riociguat is an effective pulmonary vasodilator and is associated with a low risk of serious adverse events. It has been reported that sequential

1
2
3 treatment with riociguat and BPA results in significant improvements in terms of mean
4 pulmonary arterial pressure and pulmonary vascular resistance among patients with
5 inoperable CTEPH²³, no reports to date have directly compared the treatment outcomes of
6 these two treatment methods. A randomized controlled trial comparing riociguat and BPA
7 (the RACE study) is conducted in France²⁴, aligning with the start of the present study²⁵. The
8 aim of the present study is to compare the efficacy and safety of riociguat and BPA for
9 inoperable CTEPH over the course of 12 months. The results of this study may aid in
10 optimizing treatment selection and improving patient outcomes.
11
12
13
14
15
16
17
18
19
20
21
22
23

24 **Methods and Analysis**

25
26 **Study design and setting:** This Multicenter Randomized controlled trial based on Balloon
27 Pulmonary Angioplasty for chronic thromboembolic pulmonary hypertension (MR BPA)
28 study recruited subjects from January 15, 2016 to October, 31, 2019. The study is a
29 multicenter, prospective, randomized controlled trial. As shown in Figure 1, subjects willing
30 to consider enrolment were consented prior to invasive evaluation. Subjects underwent right-
31 heart catheterization and pulmonary angiography for definitive diagnosis of CTEPH by the
32 standard practice in Japan. The identified CTEPH patients were provisionally enrolled in the
33 study. An independent experienced PEA surgeon determined if subjects were eligible for
34 PEA. If the subjects were deemed technically operable, they were excluded from the study.
35 Those who were judged to have inoperable CTEPH were assigned into either a BPA or
36 riociguat group via an online assignment system, and will be observed for 12 months. In the
37 BPA group, the severity of pulmonary hypertension and morphology of the pulmonary lesion
38 were evaluated by preoperative right-heart catheterization and pulmonary angiography. Then,
39 BPA will be conducted depending on the lesion type. If lesions of pulmonary artery are not
40 suitable for BPA, the procedure will not be performed even if the patient is assigned to the
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 BPA group. However, at least among the collaborative institutions included in this study,
4
5 PEA-inoperable patients are very rarely considered unsuitable for BPA, because these
6
7 institutes are expert BPA centers in Japan. In general, BPA will be completed within 4
8
9 months of the first BPA procedure. In the riociguat group, 1.0 mg riociguat will be
10
11 administered three times per day. When systolic blood pressure is 95 mmHg or higher, the
12
13 dose will be increased by 0.5 mg every two weeks up to a maximum dosage of 2.5 mg thrice
14
15 daily. Dosage adjustment will be completed within 4 months of the first administration of
16
17 riociguat, and administration will be continued for a total of 12 months. Observations will be
18
19 made at the time of screening; baseline; and at 0–4, 6, and 12 months after initial treatment.
20
21 Table 1 shows the schedule of assessments performed at each visit for each treatment group,
22
23 including mandatory and optional assessments.
24
25
26
27
28
29
30
31

32 **Sample size calculation:** Previously, BPA has been shown to result in reduced mean
33
34 pulmonary arterial pressure from 45.4 ± 9.6 to 24.0 ± 6.4 mmHg (mean \pm standard deviation)
35
36 within 24 months¹¹, while riociguat has been reported to decrease pulmonary arterial pressure
37
38 by 4 ± 7 mmHg⁹. Based on these studies, it was assumed that the change in mean pulmonary
39
40 arterial pressure from the start of treatment to 12 months after treatment would be -15 mmHg
41
42 for the BPA group and -4 mmHg for the riociguat group, with standard deviation of 14 and
43
44 10, respectively. The minimum sample size required to achieve a significance of 0.05 from a
45
46 two-sided test with a statistical power of 90% was determined to be 27 subjects for both
47
48 groups; a total of 54 subjects. We estimated the dropout rate to be 10%; thus, the planned
49
50 enrollment was set at 60 subjects, with 30 in each group.
51
52
53
54
55
56
57

58 **Eligibility criteria:** *Inclusion criteria:* (a) Diagnosis with CTEPH with a World Health
59
60 Organization (WHO) functional class II or III based on the diagnostic criteria of the 2012

1
2
3 Japanese Circulation Society guidelines²⁴, (b) age ≥ 20 years or < 80 years, (c) mean
4 pulmonary arterial pressure of ≥ 25 to < 60 mmHg and pulmonary artery wedge pressure of
5 ≤ 15 mmHg, (d) administration of appropriate anticoagulant therapy for at least 3 months
6 prior to study enrollment (in the case of warfarin, the prothrombin time-international
7 normalized ratio should be 1.5–3.0), and (e) provision of written informed consent to
8 participate after full explanation of the study.
9

10
11
12
13
14
15
16
17
18 *Exclusion criteria:* (a) History of BPA, (b) PEA within six months prior to study enrollment,
19 (c) use of unapproved pharmaceutical products, (d) use of a pulmonary vasodilator within 4
20 weeks prior to right-heart catheterization, (e) co-existing etiology of pulmonary hypertension,
21 (f) pregnancy or breastfeeding, (g) contraindicated for riociguat, (h) life expectancy of less
22 than two years, and (i) deemed to be unsuitable for participation by the investigators.
23
24
25
26
27
28
29
30

31 **Recruitment and consent:** The informed consent document was presented to potentially
32 eligible subjects to provide a comprehensive explanation of this study. Written consent was
33 then obtained.
34
35
36
37

38 As a general rule, subjects willing to consider enrolment were consented prior to right-heart
39 catheterization and pulmonary angiography for definitive diagnosis of CTEPH by the
40 standard practice in Japan. However, to reduce the burden on the subjects, suitable patients
41 that had undergone comprehensive evaluation including right-heart catheterization and
42 pulmonary angiography within 3 months prior to the consenting could also be enrolled to the
43 study. This was explained to subjects by investigators at the time of obtaining consent.
44
45
46
47
48
49
50

51 Once consent was obtained, an independent experienced PEA surgeon who is not involved in
52 this study determined operability (whether subjects were eligible for PEA) based on imaging
53 data according to the Guidelines for Treatment of Pulmonary Hypertension (2012 revised
54 version)²⁶.
55
56
57
58
59
60

1
2
3
4
5
6 **Random allocation:** Random assignment were performed centrally with stratification by
7 mean pulmonary arterial pressure (<40 mmHg and \geq 40 mmHg), and research institutions
8 (Keio University, Okayama Medical Center, Kyusyu University, and Kobe University) by
9 biased-coin minimization.
10
11
12
13
14
15
16
17

18 **Endpoints:** The primary endpoint will be the change in mean pulmonary arterial pressure
19 between baseline and 12 months. Secondary endpoints will include several clinical and
20 quality-of-life parameters (detailed in Table 2).
21
22
23
24
25
26

27 **Data collection:** An electronic, clinical-test data collection system—electric data capture
28 system (EDC) —is used for data collection. In cases when the system is unavailable, a case
29 report form—a specialized data collection form—is used, and the data later entered into the
30 EDC. The investigators who enter information into the EDC system are responsible for
31 ensuring accuracy and completeness of information. The information of the health insurance
32 resource costs are collected from Diagnosis Procedure Combination/Pre-Diem Payment
33 system.
34
35
36
37
38
39
40
41
42
43
44

45 **Data management and monitoring:** Data collection and management is carried out by third-
46 party entities to avoid bias. Data management is performed by Soiken Inc. Data Management
47 Group (the Data Center). The Data Center prepared a “Procedure Manual for Data
48 Management”. The Data Center’s approval is required prior to sending any data related to the
49 subjects in electronic format. If data is transmitted over an unsecured electronic network, the
50 data must be encoded at the source. Linkable anonymization by central registration number is
51 used to identify the subjects. The investigators are responsible for appropriate storage of the
52
53
54
55
56
57
58
59
60

1
2
3 correspondence table prepared by them to identify subjects, in accordance with the
4
5 procedures at the particular research institution. This correspondence table must be retained
6
7 for five years after completion of the study. Appropriate measures, such as encoding or
8
9 deletion, are taken to ensure that the subjects cannot be identified in any display or public
10
11 disclosure of information related to the study, in accordance with applicable laws and
12
13 regulations.
14
15

16
17 The Soiken Inc. Data Management Group monitors the present study to manage and ensure
18
19 quality. The monitoring manager monitors subjects in accordance with the manual on
20
21 monitoring procedure. For data quality management, the principal investigator and Central
22
23 Committee confirms the progress of the study as necessary through the Soiken Inc. Data
24
25 Management Group to ensure conformance with the protocol and the Ethical Guidelines for
26
27 Medical and Health Research Involving Human Subjects (Dec. 22, 2014; Ministry of
28
29 Education, Culture, Sports, Science and Technology/Ministry of Health, Labour and Welfare)
30
31 and the Clinical Trials Act (April. 14, 2017; Ministry of Education, Culture, Sports, Science
32
33 and Technology/Ministry of Health, Labour and Welfare).
34
35
36
37
38
39

40 **Adverse events:** The occurrence of any untoward medical events, including complications or
41
42 the worsening of pre-existing underlying diseases, is defined as adverse events. Worsening of
43
44 efficacy evaluation indices are be defined as adverse events. Any concomitant symptoms or
45
46 clinically significant abnormal fluctuations in test results are investigated to determine
47
48 whether there is a cause-and-effect relationship with BPA or riociguat, and findings will be
49
50 documented in the EDC system. Adverse events are followed up until normalization or
51
52 recovery to a level not considered to be an adverse event; or, in the case of an irreversible
53
54 adverse event (cerebral infarction, myocardial infarction, etc.), until symptoms stabilize.
55
56
57
58
59
60

1
2
3 **Statistical analysis:** Primary and secondary efficacy endpoints will be analyzed using the full
4 study population, which will include all patients who were randomized into one of the
5 intervention groups. However, patients who withdraw their consent, patients with severe
6 protocol violation, such as registration without consenting, or registration out of the
7 enrollment period, or patients without any data related to the primary endpoint after the
8 randomization, were excluded from the full study population. Safety analysis will be
9 conducted in the safety analysis population, which will include all patients who were
10 randomized into one of the intervention groups and either received at least one dose of
11 riociguat or attended at least one BPA procedure (regardless of whether BPA was carried out
12 or not).

13
14
15
16
17
18
19
20
21
22
23
24
25
26 Baseline variables are presented as frequencies and proportions for categorical data, and
27 means and standard deviations for continuous data. Patient characteristics will be compared
28 using Pearson's chi-square test or Fisher's exact test for categorical endpoints, and the
29 Student's t-test for continuous variables.

30
31
32
33
34
35 For primary analysis, the least square-means difference and 95% confidence interval for
36 change of pulmonary arterial pressure between groups at 12 months will be estimated using
37 analysis of covariance (ANCOVA) adjusted for allocation factors. Secondary analysis will be
38 performed in the same manner as primary analysis. Adverse events will be evaluated during
39 safety analysis. The frequencies of adverse events will be compared using Fisher's exact test.

40
41
42
43
44
45
46 All comparisons are planned, and all p -values will be two sided. We consider p -values of
47 <0.05 to be statistically significant. All statistical analyses will be performed using SAS
48 software version 9.4 (SAS Institute, Cary, NC, USA). Statistical analysis plan will be
49 developed by the principal investigator and biostatistician before completion of patient
50 recruitment and data fixation.
51
52
53
54
55
56
57
58
59
60

1
2
3 **Patient and public involvement:** Patients nor public are not involved in the study, including
4 the planning, execution, analysis and evaluation..
5
6
7
8

9 10 **Discussion**

11
12 Guidelines for the diagnosis and treatment for CTEPH in Western countries^{5, 6} and Japan^{7, 26}
13 recommend riociguat and BPA for patients with inoperable CTEPH. However, there are no
14 reports directly comparing treatment outcomes of these two approaches. The primary
15 endpoint of this study will be the change in mean pulmonary arterial pressure from baseline
16 to 12 months, as this is an important prognostic factor of CTEPH. Other outcomes often used
17 in studies on CTEPH, such as the 6-minute walk distance and pulmonary vascular resistance,
18 are secondary endpoints in the present study. Sequential treatment with riociguat and BPA for
19 patients with inoperable CTEPH has been shown to significantly improve mean pulmonary
20 arterial pressure and pulmonary vascular resistance, highlighting the benefits of BPA²³. A
21 randomized controlled trial directly comparing riociguat and BPA is conducted in France²⁴;
22 the present study was therefore planned to compare the efficacy and safety of riociguat and
23 BPA for treatment of inoperable CTEPH. The present study and the RACE study both began
24 in January 2016²⁵. Results from randomized trials such as these will be critical for optimizing
25 treatment selection and improving outcomes of inoperable CTEPH.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 In the present study, BPA treatment will be completed in 4 months, which is equivalent as
46 real-world conditions in Japan. This study will also evaluate the long-term efficacy and safety
47 of riociguat and BPA by continuing evaluations for 12 months after initiation of treatment. A
48 recent systematic review has shown that treatment outcomes of BPA are better in Japan than
49 in Western countries^{4, 27}. The present study is conducted in expert CTEPH centers in Japan,
50 and will therefore compare the treatment efficacy and safety of riociguat and the highest-
51 quality BPA in Japan. In addition, the operability of PEA were determined by an independent
52
53
54
55
56
57
58
59
60

1
2
3 experienced PEA surgeon who belongs to independent institute and is the most experienced
4
5 PEA surgeon in Japan, having performed 49 PEAs in the last 3 years (320 PEAs in total).
6
7 This avoided recruitment bias and guarantee reliability in the present study. Furthermore, this
8
9 study will compare the costs to health insurance resources and patient-reported quality-of-life
10
11 parameters for each therapy. These factors may contribute to optimizing treatment strategies
12
13 or amending treatment guidelines for inoperable CTEPH. While these are the strengths of this
14
15 study, there are several limitations which should be acknowledged. One limitation is that this
16
17 is an open-label trial. Because there is no distinct criterion for BPA in each lesion, operators
18
19 are aware of the mean pulmonary arterial pressure (the primary endpoint in this study), and
20
21 they might be incentivized to continue BPA. Thus, bias for the BPA operators cannot be
22
23 completely avoided. However, since this study will compare medical and surgical treatment,
24
25 it is difficult to use a placebo or mask patients and/or physicians. Another limitation is that a
26
27 relatively small number of patients will be enrolled (30 subjects per group, a total of 60
28
29 subjects).
30
31
32
33
34
35
36
37

38 **Ethics and dissemination:** This study and its protocols were firstly approved by the
39
40 institutional review board of each participating institution; Keio University School of
41
42 Medicine an Ethical Committee, Ethics Committee of Okayama Medical Center, Clinical trial
43
44 ethical review committee of Kyusyu University Graduated School of Medicine, and Medical
45
46 Ethical committee of Kobe University Graduated School of Medicine, according to the
47
48 Ethical Guidelines for Medical and Health Research Involving Human Subjects issued by the
49
50 Ministry of Health, Labour and Welfare in Japan. Because of the dispense of the Clinical
51
52 Trials Act in April, 2017, this study and its protocols were again inspected and approved by
53
54 the Certified Review Board of Keio, which had obtained certification from the Minister of
55
56 Health, Labour and Welfare in Japan. The study is conducted in accordance with the
57
58
59
60

1
2
3 Declaration of Helsinki, Ethical Guidelines for Medical and Health Research Involving
4
5 Human Subjects issued by the Ministry of Health, Labour and Welfare in Japan, the Clinical
6
7 Trials Act, and other current legal regulations in Japan. Written informed consent was
8
9 obtained from all participants after full explanation of this study. Results of the study will be
10
11 disseminated at medical conferences and in journal publications.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

References

- 1) Memon HA, Lin CH, Guha A (2016) Chronic thromboembolic pulmonary hypertension: Pearls and pitfalls of diagnosis. *Methodist Debaquey Cardiovasc J.* 12:199-204
- 2) Nishimura R, Tanabe N, Sugiura T, Shigeta A, Jujo T, Sekine A, Sakao S, Kasahara Y, Tatsumi K (2013) Improved survival in medically treated chronic thromboembolic pulmonary hypertension. *Circ J.* 77:2110-2117
- 3) Madani MM (2016) Surgical treatment of chronic thromboembolic pulmonary hypertension: Pulmonary thromboendarterectomy. *Methodist Debaquey Cardiovasc J.* 12:213-218
- 4) Kim NH, Delcroix M, Jais X, Madani MM, Matsubara H, Mayer E, Ogo T, Tapson VF, Ghofrani HA, Jenkins DP (2019) Chronic thromboembolic pulmonary hypertension. *Eur Respir J.* 53:1801915
- 5) McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, Moliterno DJ, Mukherjee D, Pohost GM, Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. *Circulation.* 119:2250-2294

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 6) Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M (2016) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J.* 37:67-119
 - 7) Fukuda K, Date H, Doi S, Fukumoto Y, Fukushima N, Hatano M, Ito H, Kuwana M, Matsubara H, Momomura SI, Nishimura M, Ogino H, Satoh T, Shimokawa H, Yamauchi-Takahara K, Tatsumi K, Ishibashi-Ueda H, Yamada N, Yoshida S, Abe K, Ogawa A, Ogo T, Kasai T, Kataoka M, Kawakami T, Kogaki S, Nakamura M, Nakayama T, Nishizaki M, Sugimura K, Tanabe N, Tsujino I, Yao A, Akasaka T, Ando M, Kimura T, Kuriyama T, Nakanishi N, Nakanishi T, Tsutsui H (2019) Guidelines for the treatment of pulmonary hypertension (JCS 2017/JPCPHS 2017). *Circ J.* 83:842-945
 - 8) Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C; CHEST-1 Study Group (2013) Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. *N Engl J Med.* 369:319-329
 - 9) Simonneau G, D'Armini AM, Ghofrani HA, Grimminger F, Hoeper MM, Jansa P, Kim NH, Wang C, Wilkins MR, Fritsch A, Davie N, Colorado P, Mayer E (2015) Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: A long-term extension study (CHEST-2). *Eur Respir J.* 45:1293-1302

- 10) Kataoka M, Inami T, Hayashida K, Shimura N, Ishiguro H, Abe T, Tamura Y, Ando M, Fukuda K, Yoshino H, Satoh T (2012) Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. *Circ Cardiovasc Interv.* 5:756-762
- 11) Mizoguchi H, Ogawa A, Munemasa M, Mikouchi H, Ito H, Matsubara H (2012) Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. *Circ Cardiovasc Interv.* 5:748-755
- 12) Andreassen AK, Ragnarsson A, Gude E, Geiran O, Andersen R (2013) Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. *Heart.* 99:1415-1420
- 13) Fukui S, Ogo T, Morita Y, Tsuji A, Tateishi E, Ozaki K, Sanda Y, Fukuda T, Yasuda S, Ogawa H, Nakanishi N (2014) Right ventricular reverse remodelling after balloon pulmonary angioplasty. *Eur Respir J.* 43:1394-1402
- 14) Taniguchi Y, Miyagawa K, Nakayama K, Kinutani H, Shinke T, Okada K, Okita Y, Hirata KI, Emoto N (2014) Balloon pulmonary angioplasty: an additional treatment option to improve the prognosis of patients with chronic thromboembolic pulmonary hypertension. *EuroIntervention.* 10:518-525
- 15) Tsugu T, Murata M, Kawakami T, Yasuda R, Tokuda H, Minakata Y, Tamura Y, Kataoka M, Hayashida K, Tsuruta H, Maekawa Y, Inoue S, Fukuda K (2015) Significance of echocardiographic assessment for right ventricular function after balloon pulmonary angioplasty in patients with chronic thromboembolic induced pulmonary hypertension. *Am J Cardiol.* 115:256-261
- 16) Dimopoulos K, Kempny A, Alonso-Gonzalez R, Wort SJ (2015) Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension: Challenges and future directions. *Int J Cardiol.* 187:401-403

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 17) Ogawa A, Satoh T, Fukuda T, Sugimura K, Fukumoto Y, Emoto N, Yamada N, Yao A, Ando M, Ogino H, Tanabe N, Tsujino I, Hanaoka M, Minatoya K, Ito H, Matsubara H (2017) Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: Results of a multicenter registry. *Circ Cardiovasc Qual Outcomes*. 10:e004029
- 18) Kimura M, Kohno T, Kawakami T, Kataoka M, Tsugu T, Akita K, Isobe S, Itabashi Y, Maekawa Y, Murata M, Fukuda K (2017) Midterm effect of balloon pulmonary angioplasty on hemodynamics and subclinical myocardial damage in chronic thromboembolic pulmonary hypertension. *Can J Cardiol*. 33:463-470
- 19) Aoki T, Sugimura K, Tatebe S, Miura M, Yamamoto S, Yaoita N, Suzuki H, Sato H, Kozu K, Konno R, Miyata S, Nochioka K, Satoh K, Shimokawa H (2017) Comprehensive evaluation of the effectiveness and safety of balloon pulmonary angioplasty for inoperable chronic thrombo-embolic pulmonary hypertension: long-term effects and procedure-related complications. *Eur Heart J*. 38:3152-3159
- 20) Olsson KM, Wiedenroth CB, Kamp JC, Breithecker A, Fuge J, Krombach GA, Haas M, Hamm C, Kramm T, Guth S, Ghofrani HA, Hinrichs JB, Cebotari S, Meyer K, Hoepfer MM, Mayer E, Liebetrau C, Meyer BC (2017) Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: The initial German experience. *Eur Respir J*. 49:1602409
- 21) Kawakami T, Ogawa A, Miyaji K, Mizoguchi H, Shimokawahara H, Naito T, Oka T, Yunoki K, Munemasa M, Matsubara H (2016) Novel angiographic classification of each vascular lesion in chronic thromboembolic pulmonary hypertension based on selective angiogram and results of balloon pulmonary angioplasty. *Circ Cardiovasc Interv*. 9:e003318

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 22) Ogo T, Fukuda T, Tsuji A, Fukui S, Ueda J, Sanda Y, Morita Y, Asano R, Konagai N, Yasuda S (2017) Efficacy and safety of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension guided by cone-beam computed tomography and electrocardiogram-gated area detector computed tomography. *Eur J Radiol.* 89:270-276
- 23) Wiedenroth CB, Ghofrani HA, Adameit MSD, Breithecker A, Haas M, Kriechbaum S, Rieth A, Hamm CW, Mayer E, Guth S, Liebetrau C (2018) Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. *Pulm Circ.* 8:2045894018783996
- 24) Riociguat versus balloon pulmonary Angioplasty in non-operable Chronic thromboEmbolic pulmonary hypertension (RACE). ClinicalTrials.gov identifier NCT02634203. available at <https://clinicaltrials.gov/ct2/show/NCT02634203>. last accessed May 21st, 2019
- 25) Multicenter Randomized controlled trial based on Balloon Pulmonary Angioplasty for chronic thromboembolic pulmonary hypertension (MR BPA study). UMIN-CTR ID: UMIN000019549. available at https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022608. last accessed May 21st, 2019
- 26) Nakanishi N, Ando M, Ueda H, Ogino H, Saji T, Shiomi T, Tatsumi K, Date H, Nishimura M, Fukushima N, Fukumoto Y, Momomura S, Yamada N, Yoshida S (2012) Guidelines for Treatment of Pulmonary Hypertension (JCS2012). available at http://www.j-circ.or.jp/guideline/pdf/JCS2012_nakanishi_h.pdf. last accessed September 5th, 2018 (in Japanese)
- 27) Tanabe N, Kawakami T, Satoh T, Matsubara H, Nakanishi N, Ogino H, Tamura Y, Tsujino I, Ogawa A, Sakao S, Nishizaki M, Ishida K, Ichimura Y, Yoshida M, Tatsumi

1
2
3 K (2018) Balloon pulmonary angioplasty for chronic thromboembolic pulmonary
4
5 hypertension: A systematic review. *Respir Investig*. 56:332-341
6
7
8
9

10 **Author contributions:**

11
12 TK and HM contributed to the conception and design of the study, drafted the protocol, and
13 supervised the revision. MK, KA, SK, YS and TS provided intellectual input to improve the
14 study design and revise the protocol. KF contributed to and supervised the conception and
15 design of the study. All authors read and approved the final manuscript.
16
17
18
19
20
21
22
23

24 **Funding statement:**

25
26 This study was financially supported by Bayer Yakuhin, Ltd. Bayer Yakuhin, Ltd. is not
27 involved in this study, including the planning, execution, data management, statistical
28 analysis, evaluation, or write-up.
29
30
31
32
33
34
35
36
37

38 **Competing interests statement:**

39
40 SK received honoraria for scientific lectures from Bayer Yakuhin, Ltd. KF received
41 scholarship grants from Bayer Yakuhin, Ltd. and MSD K.K. The other authors declare no
42 conflict of interest.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure and table legends

Figure 1. Flow diagram of study recruitment and randomization. After obtaining consent and diagnosis of chronic thromboembolic pulmonary hypertension is confirmed, subjects will be randomized into either the balloon-pulmonary-angioplasty or riociguat group, to receive treatment for 12 months. Observations will be recorded at the time of screening; baseline; and at 0–4, 6, and 12 months after the initiation of treatment. Abbreviations: BPA, balloon pulmonary angioplasty; CTEPH, chronic thromboembolic pulmonary hypertension.

Table 1. Schedule of assessments for enrolled subjects.

Table 2. Secondary endpoints that will be measured and/or compared at baseline and at 12 months after initiation of treatment.

Table 1: Schedule of assessments for enrolled subjects.

Observation items	Screening	Baseline	Observation period		
	~0M	0M	0–4M	6M + 1M	12M + 2M
Subjects' attributes	○	○	—	—	—
6-minute walk distance	—	○	—	○	○
Borg dyspnea index	—	○	—	○	○
WHO functional class	—	○	—	○	○
Right-heart catheterization	○	—	—	○	○
Pulmonary angiography	○	—	—	—	—
Pulmonary function	—	○	—	○	○
Blood gas test ^(a)	—	○	—	○	○
Vital signs ^(a)	—	○	—	○	○
Echocardiography (cardiac ultrasound)	—	○	—	○	○
Chest X-ray	—	○	○ ^(b)	○	○
Chest CT scan	○	—	○ ^(b)	○	○
Oxygen therapy usage status	—	○	—	○	○
Adverse event onset ^(c)	—	—	—	← ○ →	
Clinical worsening and time to clinical	—	—	—	← ○ →	

worsening ^(c)					
Quality-of-life parameters (EQ5D)	—	○	—	○	○
Health insurance	—	—		← ○ →	
BPA status ^(d)	—	—	○	—	—
Medication adherence ^(e)	—	—		← ○ →	

Notes: (a) Recommended during right-heart catheterization, (b) required if balloon pulmonary angioplasty is performed, (c) onset of adverse events and indices related to clinical worsening will be observed as necessary throughout the clinical study period, (d) observational items for the balloon-pulmonary-angioplasty group, (e) observational items for the riociguat group. Abbreviations: BPA, balloon pulmonary angioplasty; CT, computed tomography; WHO, World Health Organization.

Table 2: Secondary endpoints that will be measured and/or compared at baseline and at 12 months after initiation of treatment.

Endpoint	
Change in 6-minute walk distance	
Change in Borg dyspnea index	
Change in hemodynamic variables	Including pulmonary vascular resistance, mean right arterial pressure, cardiac output, etc.
Change in WHO functional class	
Change in plasma brain natriuretic peptide levels	
Change in SaO ₂ and PaO ₂	
Change in usage volume of oxygen therapy	Including commencing oxygen therapy due to exacerbation of primary disease or dosage change.
Change in pulmonary function	
Change in echocardiography parameter	
Frequency and severity of pulmonary artery injury	Assessed by chest X-ray and chest CT scan.
Frequency of adverse events	Bloody sputum/hemoptysis/pulmonary hemorrhage (vascular perforation, vascular dissection, vascular rupture, etc.), pneumothorax, hypotension, pulmonary congestion/pulmonary edema, late-onset lung disturbance, heart failure, pneumonia, headache, dizziness, peripheral edema, nausea/vomiting, retching, diarrhea, nasopharyngitis, upper respiratory

1
2
3
4 inflammation, respiratory distress, coughing, fainting.
5
6 Clinical worsening during the All-cause mortality, heart/lung transplant, salvage
7 observation period and time to clinical PEA due to worsening of primary disease, new or
8 worsening repeated implementation of BPA due to the
9
10 worsening of a primary disease, hospitalization, new
11
12 initiation of pulmonary vasodilators, worsening of
13
14 30% or greater from baseline in the 6-minute walk
15
16 distance, persistent worsening in the WHO functional
17
18 class from baseline due to the worsening of a primary
19
20 disease.
21
22
23
24
25

26 Change in quality-of-life parameters
27
28 (EQ5D)
29

30 Health insurance resource costs
31
32

33 Abbreviations: BPA, balloon pulmonary angioplasty; CT, computed tomography; PaO₂,
34 partial pressure of oxygen; PEA, pulmonary endarterectomy; SaO₂, saturation of arterial
35
36 blood; WHO, World Health Organization.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Study outline and randomization schematic. After consent, and CTEPH diagnosis is confirmed, subjects will be randomized into either BPA or riociguat group for 12 months, and observation measurements taken at screening, baseline, 0-4, 6 and 12 months.



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/Item	Item No.	Description	Page in protocol	Page in protocol paper
Administrative information				
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1, 5	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	42	3
	2b	All items from the World Health Organization Trial Registration Data Set	42	3
Protocol version	3	Date and version identifier	1	
Funding	4	Sources and types of financial, material, and other support	43	2, 17
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1, 43-47	1
	5b	Name and contact information for the trial sponsor	1	2
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	43	
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	44-47	
Introduction				
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	11	3, 5
	6b	Explanation for choice of comparators	11	3, 5
Objectives	7	Specific objectives or hypotheses	5, 11-12	3, 5-6
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	5, 12	6
Methods: Participants, interventions, and outcomes				
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	45	1
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	5-6, 13-14	7
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	12, 16-24	6
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	28-29, 36	
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	23-24	20
	11d	Relevant concomitant care and interventions that are permitted	17	

1					
2					
3			or prohibited during the trial		
4	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	6-7, 14-16	8, 21-22
5					
6					
7					
8					
9					
10	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	16-24	6-8, 19-20
11					
12					
13	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	31	6-7
14					
15	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	17-20	7-8
16					
17					
18	Methods: Assignment of interventions (for controlled trials)				
19	Allocation:				
20	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	19-20	6-8
21					
22					
23					
24					
25	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	16, 19-20	8
26					
27					
28	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	16, 19-20	8
29					
30	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	18-19	6
31					
32					
33					
34		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	18-19	6
35					
36					
37	Methods: Data collection, management, and analysis				
38	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	20-24	6-8, 19-20
39					
40					
41					
42					
43					
44		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	28-29	
45					
46					
47					
48	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	29-31	9
49					
50					
51					
52					
53	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	32-34	10-11
54					
55		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	32-34	10-11
56					
57		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple	30-31	10-11
58					
59					
60					

		imputation)		
Methods: Monitoring				
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	46	
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	34	
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	25-28	10
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	N/A	N/A
Ethics and dissemination				
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	34-35	11-12
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	35	
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	36-39	7-8
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A	N/A
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	38-39	
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	43	17
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	29-31	9
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	40	
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	42	11-12
	31b	Authorship eligibility guidelines and any intended use of professional writers	N/A	N/A
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	N/A	N/A
Appendices				
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	37-38	
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A	N/A

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "Attribution-NonCommercial-NoDerivs 3.0 Unported" license.